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Abstract 
Chronic kidney disease (CKD) occurs as a result of declining renal function for 3 or more 
months. CKD effects 1 in 10 Canadians and is associated with a number of co-morbidities 
including diabetes and cardiovascular disease. To manage CKD and associated co-
morbidities, patients take an average of 12 medications with a median pill burden of 19. 
Indeed, renal drug elimination is compromised in CKD, as declining glomerular filtration 
reduces drug excretion into urine. More recently, studies have provided evidence of altered 
non-renal drug clearance in CKD.  The majority of drug clearance occurs in the liver by 
CYP2C and CYP3A drug metabolizing enzymes. Hepatic CYP2C and CYP3A drug 
metabolizing enzymes are tightly regulated by nuclear receptors. The majority of CKD 
patients have mild to moderate degrees of CKD and the potential for altered hepatic drug 
metabolism at these earlier stages is unknown. As renal function declines, patients begin to 
experience the uremic condition, which consists of metabolic waste product accumulation in 
the blood. A number of studies suggest that these uremic toxins may mediate the 
downregulation of hepatic CYP2C and CYP3A; however, the mechanism by which this 
occurs remains to be determined. My overall hypothesis is that hepatic drug metabolism is 
altered in CKD. 
Herein, we evaluate the effects of moderate CKD on hepatic drug metabolism and determine 
a possible mechanism of CYP2C and CYP3A downregulation in rats with CKD. In a rat 
model of moderate CKD, hepatic CYP2C and CYP3A function and expression were 
significantly decreased demonstrating a negative exponential correlation with kidney 
function. Transcriptional activation in both the CYP2C and CYP3A promoters was reduced 
as a result of decreased nuclear receptor binding and histone acetylation. Untargeted 
metabolomics was utilized to identify potential uremic mediators of hepatic CYP2C and 
CYP3A altered expression and function. Gut-derived uremic toxins accounted for the most 
significant metabolic signatures defining plasma and liver tissue in CKD, leading to the 
evaluation of these toxin effects on hepatic CYP2C and CYP3A. Reduction of gut-derived 
uremic toxins did not recover CYP2C and CYP3A function and expression in CKD. In 
conclusion, these studies further our understanding of hepatic drug metabolizing enzyme 
downregulation in the setting of CKD. 
 iii 
 
 
Keywords 
Drug metabolism, Pharmacokinetics, Cytochrome P450, Chronic Kidney Disease, End-stage 
renal disease, Uremia, AST-120, Indoxyl Sulfate, Chromatin Immunoprecipitation, 
Metabolomics. 
 
 iv 
 
Co-Authorship Statement 
Chapter 1: 
A portion of the introduction was reproduced from a review article: 
Velenosi TJ and Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney 
disease and patients requiring dialysis. Expert opinion on drug metabolism & 
toxicology 10:1131-1143. 
TJV and BLU wrote and revised the manuscript and approved of the final version of this 
review article. 
Chapter 3: 
Velenosi TJ, Fu AY, Luo S, Wang H, and Urquhart BL (2012) Down-Regulation of Hepatic 
CYP3A and CYP2C Mediated Metabolism in Rats with Moderate Chronic Kidney 
Disease. Drug Metab Dispos 40:1508-1514. 
TJV and BLU designed the experiments. TJV, AF and SL conducted experiments. TJV and 
BLU analyzed and interpreted data. TJV and BLU wrote the manuscript and all authors  
approved of the final version. 
Chapter 4: 
Velenosi TJ, Feere DA, Sohi G, Hardy DB, and Urquhart BL (2014) Decreased nuclear 
receptor activity and epigenetic modulation associates with down-regulation of 
hepatic drug-metabolizing enzymes in chronic kidney disease. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 
28:5388-5397. 
TJV and BLU designed the experiments. TJV, DAF and GS conducted experiments. TJV, 
DBH and BLU analyzed and interpreted data. TJV and BLU wrote the manuscript and all 
authors  approved of the final version. 
Chapter 5: 
 
Velenosi TJ, Hennop A, Feere DA, Tieu A, Kucey A, Kyriacou P, McCuaig LE, Nevison SE, Kerr 
MA, Urquhart BL (2015) Untargeted plasma and tissue metabolomics in rats with chronic 
kidney disease given AST-120. Submitted to Scientific Reports. Manuscript number: SREP-
15-27972 
 
TJV and BLU contributed to the experimental design. Animal experiments and procedures 
were conducted by TJV, AH, DAF and AT. UPLC-QToFMS experiments were conducted by 
TJV, AH, DAF, AT, ASK and BLU. Compound standards were synthesized by PK and 
MAK. Data and statistical analysis were performed by TJV, AH, DAF, AT, ASK, LEM, 
SEN and BLU. Reagents and analytical tools were contributed by BLU. The manuscript was 
drafted by TJV, with additions and revisions by all authors. 
 
 v 
 
 
 
 
Chapter 6: 
Velenosi TJ, Tieu A, Kucey A, Urquhart BL (2015) The Effects of Gut-Derived Uremic 
Toxins on Hepatic Drug Metabolism in Chronic Kidney Disease. In preparation. 
 
TJV and BLU designed the experiments. Animal experiments and procedures were 
conducted by TJV, AT and AK. All other experiments were conducted by TJV. TJV and 
BLU analyzed and interpreted data. TJV and BLU wrote the manuscript. 
 vi 
 
Dedication 
 
 
 
 
 
 
 
To Nonno and Nonna 
 vii 
 
Acknowledgments 
I would first like to express my deepest thanks to Dr. Brad Urquhart, who guided me into 
research as an undergraduate student and has been an amazing mentor throughout graduate 
school. From the day I began in his lab, Brad has created a positive environment that is 
conducive to learning and has always been available to give advice. I am incredibly 
privileged to be his first graduate student and be involved in establishing his research 
program. Throughout the 5 years I have spent in his lab, doing research has been more fun 
than work and has motivated me to pursue a career in science. His great vision and approach 
to research has left a tremendous impression on me and, for that, I am most grateful.  
Dr. David Freeman, imparting your expertise in liquid chromatography and analytical 
pharmacology has provided me with a strong basis for my graduate studies. Dr. Murray 
Cutler, teaching me to design and develop my own experiments has been a great asset in grad 
school. Thank you for your mentorship as an undergraduate supervisor, and as a friend. 
Thank you to the past and present members of the Urquhart Lab. Dave Feere, your assistance 
in the lab and your invaluable friendship has made my time as a graduate student an 
enjoyable experience. May your handicap never go above 10 and your “hot hands” keep your 
dentistry skills up to par. I am also grateful for the teamwork and contributions provided by 
Alvin Tieu and Andrew Kucey. Alvin, I hope that you continue to put the same effort into 
research as you do into fashion and always be the best dressed. Andrew Kucey, may you 
continue to work as hard at achieving your career goals as you do at scoring in the top corner 
in hockey, and settle for nothing but the best. I have no doubt that you will both succeed in 
your future endeavors. This work could not have been made possible without other previous 
members of the Urquhart Lab, including Angel Fu and Anzel Hennop.  
I would also like to thank Dr. Nica Borradaile for her mentorship as well as the past and 
current members of her lab. To Alex Stoianov, I appreciate our life discussions both during 
and after your time at Western. Your ability to give good advice will be an asset to your 
career as a physician. Alex Hetherington, your generous baking and positive attitude have 
always been uplifting in the lab. You’re always the most organized and helpful to everyone 
in the lab. I wish you both the best of luck. 
 viii 
 
To the members of my advisory committee, Drs. Dan Hardy, Wei-Yang Lu and Ruud 
Veldhuizen for your discussion about my project and guidance throughout graduate school. 
I am also grateful for the advice I have received from the many faculty members, staff and 
students in the department of Physiology and Pharmacology including Dr. Peter Chidiac, Dr. 
Rommel Tirona, Dr. Angela Nissen, Dr. Christopher Pin, Dr. John DiGuglielmo, Buon Thai, 
Dr. Moshi Bhattacharya, Dr. Timothy Regnault, Dr. Dean Betts, Dr. Gurjeev Sohi and many 
others. 
I would like to thank the Schulich School of Medicine and Dentistry and the Natural 
Sciences and Engineering Research Council of Canada for the financial support of this thesis. 
Last but not least, I would like to thank my family including my parents and brother who 
have encouraged and supported me throughout the hardships of graduate school. To my 
grandparents, who have inspired me to pursue higher education and my aunts, uncles and 
cousins who have always been highly supportive of my career goals. 
 ix 
 
Table of Contents 
Abstract ............................................................................................................................... ii	
Co-Authorship Statement ................................................................................................... iv	
Dedication .......................................................................................................................... vi	
Acknowledgments ............................................................................................................. vii	
Table of Contents ............................................................................................................... ix	
List of Tables .................................................................................................................... xv	
List of Figures .................................................................................................................. xvi	
List of Appendices ......................................................................................................... xviii	
Abbreviations ................................................................................................................... xix	
1	 INTRODUCTION1 ........................................................................................................ 1	
1.1	 Overview of Chronic Kidney Disease .................................................................... 2	
1.1.1	 Prevalence and Stages ................................................................................. 2	
1.1.2	 Causes, Comorbidities, Signs and Symptoms ............................................ 4	
1.2	 Renal Replacement Therapy for ESRD Treatment ................................................. 7	
1.3	 Uremia ..................................................................................................................... 8	
1.3.1	 Free water-soluble uremic toxins ................................................................ 9	
1.3.2	 Middle Molecules ....................................................................................... 9	
1.3.3	 Protein-bound and gut-derived uremic toxins ........................................... 10	
1.4	 Removal of gut-derived uremic toxins in uremia ................................................. 14	
1.4.1	 Probiotics, Prebiotics, and dietary fibre .................................................... 14	
1.4.2	 AST-120 .................................................................................................... 15	
1.5	 Metabolomics ........................................................................................................ 16	
1.5.1	 Metabolomics Methods ............................................................................. 17	
1.5.2	 Data Processing and Analysis ................................................................... 18	
 x 
 
1.5.3	 Metabolite Identification ........................................................................... 19	
1.6	 Drug Therapy for CKD Management ................................................................... 20	
1.7	 Drug Metabolism and Disposition ........................................................................ 21	
1.7.1	 P450 Enzyme Function and Regulation .................................................... 21	
1.7.2	 Nuclear Receptor Regulation of CYP2C and CYP3A .............................. 22	
1.7.3	 Epigenetic Regulation of CYP2C and CYP3A ......................................... 24	
1.8	 Pharmacokinetic Changes in CKD ....................................................................... 25	
1.8.1	 Drug Absorption and Bioavailability ........................................................ 25	
1.8.2	 Distribution ............................................................................................... 28	
1.8.3	 Drug Metabolism ...................................................................................... 29	
1.8.4	 Other Routes of Elimination ..................................................................... 31	
1.8.5	 Altered Non-Renal Drug Clearance in Dialysis Patients .......................... 33	
1.9	 Animal Models of CKD ........................................................................................ 36	
1.10	References ............................................................................................................. 38	
2	 HYPOTHESES AND SPECIFIC AIMS ..................................................................... 58	
2.1	 Focus of the thesis ................................................................................................. 59	
2.2	 Specific Aim 1 ...................................................................................................... 60	
2.3	 Specific Aim 2 ...................................................................................................... 60	
2.4	 Specific Aim 3 ...................................................................................................... 61	
2.5	 Specific Aim 4 ...................................................................................................... 62	
2.6	 References ............................................................................................................. 63	
3	 Down-Regulation of Hepatic CYP3A and CYP2C Mediated Metabolism in Rats with 
Moderate Chronic Kidney Disease2 ............................................................................. 65	
3.1	 Introduction ........................................................................................................... 66	
3.2	 Methods................................................................................................................. 68	
3.2.1	 Chemical Reagents and Drugs .................................................................. 68	
 xi 
 
3.2.2	 Experimental Model .................................................................................. 68	
3.2.3	 Surgical Induction of Kidney Disease ...................................................... 68	
3.2.4	 Real-time PCR Analysis ........................................................................... 69	
3.2.5	 Hepatic Microsome Isolation .................................................................... 69	
3.2.6	 Western Blot Analysis .............................................................................. 70	
3.2.7	 Hepatic Metabolism of CYP3A and CYP2C substrates ........................... 70	
3.2.8	 Metabolite Analysis by UPLC-PDA ......................................................... 71	
3.2.9	 Data Analysis and Statistical Procedures .................................................. 72	
3.3	 Results ................................................................................................................... 73	
3.3.1	 Serum Biochemistry .................................................................................. 73	
3.3.2	 CYP3A2 and CYP2C11 mRNA and Protein Expression ......................... 73	
3.3.3	 Hepatic CYP3A and CYP2C Mediated Drug Metabolism ....................... 77	
3.4	 Discussion ............................................................................................................. 83	
3.5	 References ............................................................................................................. 87	
4	 DECREASED NUCLEAR RECEPTOR ACTIVITY AND EPIGENETIC 
MODULATION ASSOCIATES WITH DOWNREGULATION OF HEPATIC 
DRUG METABOLIZING ENZYMES IN CHRONIC KIDNEY DISEASE.3 ........... 91	
4.1	 Introduction ........................................................................................................... 92	
4.2	 Methods................................................................................................................. 95	
4.2.1	 Experimental Rat Model ........................................................................... 95	
4.2.2	 Testosterone Metabolism and Analyte Quantification ............................. 95	
4.2.3	 RNA Extraction and Real-time PCR Analysis ......................................... 95	
4.2.4	 Western Blot Analysis .............................................................................. 97	
4.2.5	 Chromatin Immunoprecipitation ............................................................... 97	
4.2.6	 Statistical Analysis .................................................................................... 98	
4.3	 Results ................................................................................................................... 99	
4.3.1	 Serum Biochemistry and Body Weight .................................................... 99	
 xii 
 
4.3.2	 Hepatic CYP3A and CYP2C Mediated Drug Metabolism ....................... 99	
4.3.3	 Protein and mRNA expression of Drug Metabolizing Enzymes .............. 99	
4.3.4	 RNA Pol II Recruitment to the CYP3A2 and CYP2C11 Promoters ........ 99	
4.3.5	 Hepatic Nuclear Receptor Expression and Recruitment to the CYP2C11 
and CYP3A2 Promoters in CKD ............................................................ 103	
4.3.6	 Decreased Histone Acetylation in the CYP2C11 and CYP3A2 Promoters 
of Rats with CKD. .................................................................................. 103	
4.4	 Discussion ........................................................................................................... 110	
4.5	 References ........................................................................................................... 115	
5	 UNTARGETED PLASMA AND TISSUE METABOLOMICS IN RATS WITH 
CHRONIC KIDNEY DISEASE GIVEN AST-120.3 ................................................ 119	
5.1	 Introduction ......................................................................................................... 120	
5.2	 Methods............................................................................................................... 123	
5.2.1	 Chemicals and Reagents ......................................................................... 123	
5.2.2	 Animal Models ........................................................................................ 123	
5.2.3	 Sample Preparation ................................................................................. 124	
5.2.4	 Chromatographic Separation and Mass Spectrometry ............................ 124	
5.2.5	 Data Analysis .......................................................................................... 125	
5.2.6	 Metabolite Identification ......................................................................... 126	
5.3	 Results ................................................................................................................. 127	
5.3.1	 Validation of Experimental Model ......................................................... 127	
5.3.2	 Principal Component Analysis and the Removal of Metabolites by AST-
120 in Biological Matrices ...................................................................... 127	
5.3.3	 Orthogonal Partial Least Squares Discriminant Analysis of Control and 
CKD Biological Matrices. ...................................................................... 133	
5.3.4	 Common Significant Metabolites ........................................................... 137	
5.4	 Discussion ........................................................................................................... 141	
5.5	 References ........................................................................................................... 146	
 xiii 
 
6	 THE EFFECT OF GUT-DERIVED UREMIC TOXINS ON THE EXPRESSION OF 
HEPATIC DRUG METABOLIZING ENZYMES IN CHRONIC KIDNEY 
DISEASE4 .................................................................................................................. 151	
6.1	 Introduction ......................................................................................................... 152	
6.2	 Methods............................................................................................................... 155	
6.2.1	 In vitro Assessment of Uremic Toxins on CYP3A4 Expression ............ 155	
6.2.2	 Animal Model ......................................................................................... 155	
6.2.3	 Plasma Quantification of Gut-derived Uremic Toxins ........................... 156	
6.2.4	 RNA Extraction and Real-time PCR Analysis ....................................... 156	
6.2.5	 Western Blot Analysis ............................................................................ 158	
6.2.6	 Hepatic CYP3A and CYP2C Microsomal Metabolism .......................... 158	
6.2.7	 Data and Statistical Analysis .................................................................. 159	
6.3	 Results ................................................................................................................. 160	
6.3.1	 Indoxyl Sulfate Downregulates Hepatic CYP3A4 Expression in vitro .. 160	
6.3.2	 Plasma Biochemistry and Body Weight ................................................. 160	
6.3.3	 Hepatic CYP2C and CYP3A Enzyme Function ..................................... 166	
6.3.4	 Hepatic CYP2C11 and CYP3A2 Protein and mRNA Expression .......... 166	
6.4	 Discussion ........................................................................................................... 171	
6.5	 References ........................................................................................................... 176	
7	 DISCUSSION AND CONCLUSIONS ..................................................................... 182	
7.1	 Summary and Discussion .................................................................................... 183	
7.1.1	 Chapter 3 ................................................................................................. 183	
7.1.2	 Chapter 4 ................................................................................................. 184	
7.1.3	 Chapter 5 ................................................................................................. 185	
7.1.4	 Chapter 6 ................................................................................................. 186	
7.2	 Models of CKD ................................................................................................... 187	
7.3	 Therapeutic Implications .................................................................................... 189	
 xiv 
 
7.4	 Future Directions ................................................................................................ 190	
7.5	 Conclusions ......................................................................................................... 191	
7.6	 References ........................................................................................................... 193	
Appendices ...................................................................................................................... 195	
Curriculum Vitae ............................................................................................................ 210	
 xv 
 
List of Tables 
Table 1.1 Risk of progression as determined by eGFR and albuminuria at various stages of 
CKD. ......................................................................................................................................... 3	
Table 3.1 Physical and biochemical characteristics of control, moderate and severe kidney 
disease rats. ............................................................................................................................. 74	
Table 3.2 Michaelis-Menten kinetic values for CYP3A probe substrates in control, moderate 
and severe kidney disease rat liver microsomes. .................................................................... 80	
Table 3.3 Michaelis-Menten kinetic values for CYP2C probe substrates in control, moderate 
and severe kidney disease rat liver microsomes. .................................................................... 82	
Table 4.1 Real-time PCR Primers ........................................................................................... 96	
Table 4.2 Characteristics of control and CKD rats. .............................................................. 100	
Table 5.1. Physical and biochemical characteristics of control, CKD and CKD+AST-120 
rats. ........................................................................................................................................ 128	
Table 5.2 Summary of metabolites altered in plasma, liver, heart and kidney tissue in rats 
with CKD compared to control and CKD+AST-120. .......................................................... 136	
Table 6.1 Normal and uremic serum concentrations of selected uremic toxins. .................. 161	
Table 6.2 Rat body weight and plasma biochemistry of 8 weeks after study initiation. ...... 164	
Table 6.3 Michaelis-Menten kinetic values for P450 probe substrates in control, 
control+AST-120, CKD and CKD+AST-120 rat liver microsomes. ................................... 168	
Table 7.1 Hepatic CYP2C11 and CYP3A2 enzyme function and expression in rats with CKD 
using various experimental models. ...................................................................................... 188	
 
 xvi 
 
List of Figures 
Figure 1.1 Generation of indoxyl sulfate, p-cresyl sulfate and hippuric acid from gut-derived 
aromatic amino acid putrefaction. ........................................................................................... 11	
Figure 3.1 mRNA expression of hepatic P450s in control, moderate and severe kidney 
disease rats. ............................................................................................................................. 75	
Figure 3.2 Protein expression of hepatic P450s in control, moderate and severe kidney 
disease rats. ............................................................................................................................. 76	
Figure 3.3 Michaelis-Menten kinetics of CYP3A enzyme function in rat liver microsomes 
from control, moderate and severe kidney disease groups. .................................................... 79	
Figure 3.4 Michaelis-Menten kinetics of CYP2C enzyme function in rat liver microsomes 
from control, moderate and severe kidney disease groups. .................................................... 81	
Figure 4.1 Hepatic P450 enzyme function and expression in control and chronic kidney 
disease (CKD) rats. ............................................................................................................... 101	
Figure 4.2 RNA Pol II chromatin immunoprecipitation ....................................................... 102	
Figure 4.3 Nuclear receptor expression in control and chronic kidney disease (CKD) rats. 104	
Figure 4.4 Nuclear receptor binding to the CYP2C11 and CYP3A2 promoter in control and 
chronic kidney disease (CKD) rats. ...................................................................................... 105	
Figure 4.5 Histone acetylation at the initiation site of hepatic CYP2C11 and CYP3A2. ..... 106	
Figure 4.6 Histone methylation at the initiation site of hepatic CYP2C11 and CYP3A2. ... 108	
Figure 4.7 Schematic of mechanistic hypothesis describing the downregulation of drug 
metabolizing enzymes in chronic kidney disease (CKD). .................................................... 114	
Figure 5.1 Plasma and liver tissue principal component analysis and metabolites increased in 
CKD and decreased by AST-120 in negative ESI mode. ..................................................... 130	
 xvii 
 
Figure 5.2 Heart and kidney tissue principal component analysis and metabolites increased in 
CKD and decreased by AST-120 in negative ESI mode. ..................................................... 132	
Figure 5.3 Principal component analysis and metabolites increased in CKD and decreased by 
AST-120 in positive ESI mode. ............................................................................................ 134	
Figure 5.4 Orthogonal partial least squares discriminant analysis (OPLS-DA) and S-plots of 
control and CKD biological matrices in negative ESI mode. ............................................... 135	
Figure 5.5 Orthogonal partial least squares discriminant analysis (OPLS-DA) and S-plots of 
control and CKD biological matrices in positive ESI mode. ................................................ 138	
Figure 5.6 Meta-analysis of significantly different metabolites between control and CKD in 
biological matrices. ............................................................................................................... 139	
 Figure 5.7 Common significantly different metabolites found in all biological matrices. .. 140	
Figure 6.1 Study diet schedule for rats with CKD given AST-120, n = 10. ......................... 157	
Figure 6.2 CYP3A4 mRNA expression in Huh7 cells treated with uremic toxins. .............. 162	
Figure 6.3 Huh7 CYP3A4 mRNA expression and cell viability in the presence of increasing 
indoxyl sulfate (IS) concentrations. ...................................................................................... 163	
Figure 6.4. Plasma indoxyl sulfate (A), p-cresyl sulfate (B), and hippuric acid (C) levels in 
control, control +AST-120, CKD, and CKD+AST-120 groups. .......................................... 165	
Figure 6.5 Michaelis-Menten kinetics of hepatic CYP3A and CYP2C drug metabolizing 
enzymes in control, control +AST-120, CKD and CKD+AST-120 rats. ............................. 167	
Figure 6.6 Protein expression of hepatic CYP2C11 (A) and CYP3A2 (B) in control, control 
+AST-120, CKD and CKD+AST-120 rats. .......................................................................... 169	
Figure 6.7 mRNA expression of hepatic CYP2C11 (A) and CYP3A2 (B) in control, control 
+AST-120, CKD and CKD+AST-120 rats. .......................................................................... 170	
 
 xviii 
 
List of Appendices 
Appendix A: Ethics Approval ............................................................................................ 196	
Appendix B: Copyright Approval ...................................................................................... 197	
Appendix C: Supplementary Information ........................................................................ 200	
 
 xix 
 
Abbreviations 
AAG Alpha 1 acidic glycoprotein  
ABC ATP-Binding Cassette 
ADR Adverse drug reaction 
AcH3 Acetylated histone 3 
AcH4 Acetylated histone 4 
ACR Albumin to creatinine ratio 
AhR Aryl hydrocarbon receptor 
ANOVA Analysis of variance 
AUC Area under the curve 
BCRP Breast cancer resistance protein 
CAR Constitutive androstane receptor 
ChIP Chromatin Immunoprecipitation 
CKD Chronic Kidney Disease 
Cmax Maximum serum concentration 
CMPF 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid 
CRP C-reactive protein 
DHA Docosahexaenoic acid 
DMSO Dimethyl sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
EPA Eicosapentaenoic acid 
eGFR Estimated glomerular filtration rate 
EPPIC Evaluating Prevention of Progression in CKD  
ESRD End stage renal disease 
EuTox European Uremic Toxin Work Group 
FDA Food and Drug Administration 
GFR Glomerular filtration rate 
HDAC Histone deacetylase 
H3K27me3 Histone 3 Lysine 27 tri-methylation 
H3K4me2 Histone 3 Lysine 4 dimethylation 
H3K9me3 Histone 3 Lysine 9 tri-methylation 
H4R3me2a Histone 4 arginine 3 asymmetric dimethylation 
HD Hemodialysis 
HMDB Human Metabolome Database 
HNF Hepatocyte nuclear factor 
hPCFT Human proton coupled folate transporter 
HRP Horseradish peroxidase 
HSA Human serum albumin 
Huh7 Human hepatoma 7 cells 
IC50 Half maximal inhibitory concentration 
 xx 
 
IgG Immunoglobulin G 
IL Interleukin 
Km Michaelis constant 
MAPK Mitogen-activated protein kinases 
miR Micro RNAs 
MS Mass spectrometer 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced) 
NAT2 N-acetyltransferease 2  
NF-κB Nuclear factor kappa B 
NHANES National Health and Nutrition Examination Survey 
NMR Nuclear magnetic resonance 
OAT Organic anion transporter 
OPLS-DA Orthogonal partial least squares discriminate analysis 
P-gp P-glycoprotein 
P450 Cytochrome P450 
PCA Principal component analysis 
PD Peritoneal dialysis 
PDA Photodiode array detection 
PRMT1 Protein arginine methyltransferase 1 
PXR Pregnane X receptor 
QToF Quantitative time of flight 
ROS Reactive oxygen species 
rs Spearman's rank correlation coefficient  
RNA Pol II RNA polymerase II 
RXR Retinoid X receptor 
SEM Standard error of the mean 
SLC Solute carrier 
STAT5b Signal transducer and activator of transcription-5b 
T1/2 Half-life 
TGF Transforming growth factor 
TMAO Trimethylamine N-oxide 
TNF-α Tumour necrosis factor α 
UPLC Ultra performance liquid chromatography 
VIP Variable importance in projection 
Vmax Maximum enzyme velocity 
1 
1Portions of this chapter are reproduced with permission from: Velenosi TJ and 
Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney disease and 
patients requiring dialysis. Expert Opin Drug Metab Toxicol 10:1131-1143. 
 
 
 
 
 
 
 
 
1 INTRODUCTION1
 
 
2 
 
1.1 Overview of Chronic Kidney Disease 
1.1.1 Prevalence and Stages 
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function 
present for over three months that have implications for health (Stevens et al., 2013). 
Approximately 1 in 10 Canadians have CKD, which is similar to other countries 
including the USA (10-14%) and China (11%) (Coresh et al., 2007; Zhang et al., 2012a; 
Arora et al., 2013; Saran et al., 2015). The majority of patients with CKD are over 60, 
where prevalence of the disease is approximately 25% (Saran et al., 2015).  
CKD is divided into 5 stages and classified based on estimated glomerular filtration rate 
(eGFR). There are several equations used to estimate GFR; however, the current method 
recommended by the National Kidney Foundation is the CKD Epidemiology 
Collaboration (CKD-EPI) (Stevens et al., 2011). This equation uses serum creatinine as a 
biomarker as well as age, gender and race to estimate GFR. In early stages of CKD, 
patients may not present with altered GFR and therefore, an albumin to creatinine ratio 
(ACR) in urine is used to assess the initial stages of kidney damage. Glomerular filtration 
of albumin is restricted due to its large size (68 kDa) so its presence in the urine is 
suggestive of kidney damage. In CKD, albumin is the most abundant protein found in 
urine (National Kidney Foundation, 2002). The amount of albumin in urine is measured 
as a ratio to creatinine with micro- (3-30 mg/g creatinine) and macroalbuminuria (≥ 30 
mg/g creatinine) levels defining individual risk for CKD progression along with eGFR 
(Table 1.1). Stages 1 and 2 of CKD are defined by kidney damage (including elevated 
ACR) with normal eGFR (stage 1, ≥ 90 ml/min/1.73 m2) or slightly decreased eGFR 
(stage 2, 60 – 89 ml/min/1.73 m2). Complications generally begin when eGFR is 30 – 59 
ml/min/1.73 m2 in stage 3, which contains more than half of all CKD patients (Arora et 
al., 2013). CKD progresses when eGFR continues to decline until stage 5 (< 15 
ml/min/1.73 m2) or end-stage renal disease (ESRD). Patients with ESRD require renal 
replacement therapy such as hemodialysis (HD) or transplant to support life. In Canada, 
the risk of death during the first year of ESRD is 16.4% (Quinn et al., 2011). Other 
markers of kidney damage, if present for > 3 months, can also be considered CKD  
3 
 
Table 1.1 Risk of progression as determined by eGFR and albuminuria at various stages 
of CKD. 
   Albuminuria Categories 
Stages 
eGFR 
(ml/min/1.73 
m2) 
Description 
Normal to 
mildly 
increased 
(< 30 mg/g) 
Moderately 
Increased 
(30-300 
mg/g) 
Severely 
Increased 
(≥300 mg/g) 
1 ≥ 90 Normal Low  Moderate  High  
2 60–89 Mild ↓GFR Moderate  Moderate  High  
3 30–59 Moderate ↓GFR Moderate  High  Very high  
4 15–29 Severe decreased 
Very high  
5 <15 or anuric Kidney failure 
Adapted from: (National Kidney Foundation, 2002; KDIGO, 2013) 
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including structural abnormalities detected by histology or imaging, tubular disorders, 
and urinary sediment aberrations (KDIGO, 2013).   
1.1.2 Causes, Comorbidities, Signs and Symptoms 
1.1.2.1 Diabetes in CKD 
Diabetes is the primary cause of CKD and ESRD diagnosis, accounting for the largest 
proportion of ESRD patients at 36% (CIHI, 2015). When patients are diagnosed with 
type II diabetes, 7.3% have microalbuminuria, which progresses at a rate of 2% per year 
(Adler et al., 2003). Microalbuminuria in diabetic patients also progresses to 
macroalbuminuria at a rate of 2.8% per year. Hyperglycemia is thought to be a major 
cause of diabetic nephropathy and a number of clinical trials have suggested glycemic 
control as an important factor in delaying the progression of CKD in diabetic patients 
(KDIGO, 2013). Glycated hemoglobin (HbA1c) is the standard measure for 
hyperglycemia over long periods. The National Kidney Foundation guidelines 
recommend HbA1c < 7.0% for CKD patients, which is consistent with recommendations 
for the general population (KDOQI, 2007). In the US, approximately 35% of ESRD 
patients are above this value (Williams et al., 2006). It is difficult to maintain glycemic 
control in CKD patients with diabetes. These patients have insulin resistance, impaired 
insulin secretion as well as decreased insulin degradation (Williams and Garg, 2014). 
When eGFR decreases below 20 mL/min/1.73 m2, renal insulin clearance also decreases, 
prolonging its activity. The liver and kidney are major sites of insulin degradation, which 
also declines in CKD due to kidney damage (Williams and Garg, 2014).  
1.1.2.2 Cardiovascular Disease in CKD 
Renal vascular disease, including high blood pressure, causes ESRD in 23% of new cases 
and is the second leading cause of CKD (CIHI, 2015). Progression of CKD can occur as a 
result of poorly controlled hypertension. Over 70% of patients with stage 3-5 CKD have 
hypertension and patients who have a baseline blood pressure of 180/100 mmHg or 
higher are 15 times more likely to develop ESRD than those with a baseline blood 
pressure of 110/50 mmHg (Tozawa et al., 2003; Inker et al., 2011). The interaction 
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between CKD and cardiovascular disease is complex. These patients experience the 
traditional cardiovascular risk factors including hypertension, advanced age and 
dyslipidemia as well as CKD-specific cardiovascular risk factors such as volume 
overload, malnutrition, anemia, oxidative stress and inflammation (Segall et al., 2014). 
As a result, the standard treatment of cardiovascular disease in the general population can 
be ineffective in patients with CKD (Segall et al., 2014). Vascular calcification and 
thickening are also CKD-specific risk factors that contribute to cardiovascular disease. 
Left ventricular hypertrophy is the predominant clinical indicator of cardiovascular 
disease when ESRD patients begin dialysis (Foley et al., 1995). Cardiac fibrosis is also a 
common cardiovascular complication that occurs in patients with CKD. Inter-
myocardiocyte fibrosis occurs in hypertensive CKD patients, which is not seen in 
hypertensive patients that have normal renal function (Aoki et al., 2005). The 
combination of left ventricular hypertrophy and cardiac fibrosis can be detrimental to 
both CKD and ESRD patients. These clinical manifestations are considered the highest 
priority for treatment in ESRD patients to prevent sudden cardiac death and congestive 
heart failure (Glassock et al., 2009). 
Other major causes of ESRD include polycystic kidney disease (5%), pyelonephritis 
(2%), and drug induced CKD (2%) (CIHI, 2015).  
1.1.2.3 Other Co-morbidities and Treating CKD 
The majority of complications in CKD begin to arise in stage 3. Screening for anemia, 
bone abnormalities and metabolic acidosis is recommended at this stage of the disease 
(National Kidney Foundation, 2002). Bone abnormalities can occur as a result of 
secondary hyperparathyroidism. As renal function declines, vitamin D levels decrease 
leading to less calcium absorption (de Francisco, 2004). Phosphate clearance is also 
compromised, resulting in hyperphosphatemia. High serum phosphate causes depletion of 
serum calcium stores through the formation of insoluble calcium phosphate. When this 
occurs, serum calcium stores deplete, causing increased production of parathyroid 
hormone and the development of secondary hyperparathyroidism (de Francisco, 2004). 
Patients generally begin to develop secondary hyperparathyroidism when parathyroid 
hormone blood levels increase during stage 3 of CKD (National Kidney Foundation, 
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2003). Increases in parathyroid hormone cause increased bone resorption and can lead to 
various types of bone disease. Anemia occurs in CKD as a result of decreased 
erythropoietin production in the kidney and the pro-inflammatory condition associated 
with CKD. Anemia can develop in the early stages of CKD, but is most common in 
ESRD (Iseki and Kohagura, 2007).  Inflammation is also highly prevalent in CKD and is 
measured using serum c-reactive protein (CRP). CRP levels are increased in a large 
percentage of CKD patients and, once increased, remain consistently high (Ortega et al., 
2002). A number of non-specific signs and symptoms can also develop as early as stage 3 
of CKD including nausea and vomiting, loss of appetite, weight loss, confusion, lethargy, 
gastrointestinal ulcers and impaired homeostasis (Depner, 2001). Although present in 
many patients, it is difficult to attribute these non-specific signs and symptoms as CKD 
without prior knowledge of serum and/or urine biochemistry changes. In the 1999 to 
2006 National Health and Nutrition Examination Survey (NHANES), approximately 40% 
of subjects with undiagnosed diabetes or prediabetes had CKD (Plantinga et al., 2010). It 
is estimated that the majority of patients with CKD are undiagnosed, which may be a 
result of under-diagnosed co-morbidities that contribute to CKD as well as the many 
nonspecific signs and symptoms of the disease (Coresh et al., 2005). 
The National Kidney Foundation recommends CKD testing for all patients with diabetes, 
hypertension, family history of CKD and age > 60. This includes assessing proteinuria as 
well as eGFR. In the Modified Diet in Renal Disease Study, CKD progressed in 85% of 
patients at a rate of 4 mL/min annually for all stages (Hunsicker et al., 1997; Murphree 
and Thelen, 2010). There are modifiable and non-modifiable risk factors that contribute 
to the decline in renal function. Treatment is aimed to reduce modifiable risk factors such 
as proteinuria, low levels of serum albumin, high glycemic index and blood pressure 
(Murphree and Thelen, 2010). Non-modifiable risk factors include male gender, 
increasing age and African-American race (Murphree and Thelen, 2010).  
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1.2 Renal Replacement Therapy for ESRD Treatment 
If a patient progresses to ESRD, renal replacement therapy is required in order to sustain 
life and can include HD, peritoneal dialysis (PD) or kidney transplantation. The time to 
initiate dialysis is controversial and dependent on many factors. Currently, there are no 
laboratory values that dictate the requirement to begin dialysis, although two approaches 
are typically used which include “early-start” or “late-start”. In early start, patients begin 
on renal replacement therapy once their eGFR is reduced to less than 15 mL/min/1.73 m2. 
In contrast, late start dialysis is initiated once the patient begins to experience signs of 
uremia or their eGFR drops to less than 7 mL/min/1.73 m2. A recent randomized 
controlled trial found no difference in survival or clinical outcomes when comparing 
early start and late start dialysis (Cooper et al., 2010).  Accordingly, nephrologists in 
some countries are now recommending an intent-to-defer approach to starting dialysis 
(Nesrallah et al., 2014).  Over one million patients worldwide now receive renal 
replacement therapy to treat kidney failure (Coresh et al., 2007).  Institutional HD is the 
most commonly used method of renal replacement therapy and has consistently 
accounted for 77% of all new patients initiating dialysis in Canada over the last 10 years 
(CIHI, 2015). This method involves the removal of solutes and excess water from the 
blood using a semi-permeable dialysis membrane and dialysate solution. Blood travels 
out of the body, generally through a catheter or fistula, and into a dialysis machine where 
liquid, solutes and ions are exchanged across a synthetic membrane using a counter-
current flow of dialysate. Dialysate is a physiological salt solution containing a number of 
components such as potassium, sodium and calcium as well as bicarbonate and glucose 
(Locatelli et al., 2015). The composition of dialysate is prescribed to an individual patient 
to optimize the amount of fluid removal during a dialysis session. The filtered blood then 
travels back into the patient. The extracorporeal filtration of solutes is dependent on pore 
size, surface area and material of the dialysis membrane as well as blood and dialysate 
flow rate. Low-flux dialysis membranes with small pore sizes were used for conventional 
dialysis; however, they have recently been replaced by larger pore size high-flux dialysis 
membranes. The advantages of high-flux dialysis include clearance of larger solutes 
(called middle molecules) including β-2 microglobulin (11, 800 Da) and shorter duration 
of dialysis session (Schneider and Streicher, 1985). Continuous ambulatory and 
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automated PD account for approximately 20% of the initial renal replacement treatment 
for patients diagnosed with ESRD (CIHI, 2015). PD involves the surgical insertion of a 
catheter into the peritoneal cavity. For continuous ambulatory PD, peritoneal cavity is 
filled via catheter allowing solutes to diffuse through the catheter membrane into a 
hypertonic dialysis solution prior to emptying, which must occur multiple times per day. 
Automated PD uses a machine to exchange fluid at night while the patient sleeps. 
Dialysis is the most frequently used renal replacement modality; however, in Canada, 
42.5% of ESRD patients have a functioning kidney transplant (CIHI, 2015). Transplant 
patients no longer require dialysis once the kidney allograft begins to function and their 
risk of cardiovascular events are significantly decreased (Zolty et al., 2008). 
Erythropoietin levels increase in the first few days after kidney transplant and 
hemoglobin can reach target levels (11 to 12 g/dL) around 3 months after transplant (Joist 
et al., 2006). Quality of life is also greatly improved in transplant patients; however these 
patients must take immunosuppressants to inhibit rejection of the transplanted kidney 
(Laupacis et al., 1996). 
 
1.3 Uremia 
The definition of uremia has evolved in the literature over many years. A condition 
originally defined by its literal meaning of “urine in the blood”, has been used as an 
umbrella term to encompass all signs and symptoms of advanced CKD. More recently, 
anemia, hypocalcemic tetany and hypertension due to volume overload have been 
removed from the definition of uremia, which is now described as the illness associated 
with the accumulation of organic waste products that are normally cleared by the kidney 
(Meyer and Hostetter, 2007). If untreated, uremia can lead to death; however, the advent 
of renal replacement therapy has prolonged life expectancy in ESRD patients. As a result, 
a number of the small molecular weight compounds cleared in dialysis have been 
implicated in uremic toxicity (Meyer and Hostetter, 2007). Despite the intermittent 
removal of organic waste products by dialysis, patients continue to suffer from a number 
of uremic symptoms known as the “residual syndrome” (Depner, 2001). Possible causes 
of the residual syndrome include hormone imbalances, incomplete removal of dialyzable 
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solutes as well as the accumulation of protein-bound metabolic waste products that are 
poorly cleared in dialysis (Depner, 2001). In this section, uremic toxins will be described 
and characterized according to the European Uremic Toxin Work Group (EUTox). This 
collaborative research effort focuses on the deleterious effects of solute retention on 
biological systems in CKD as well as effective removal of these toxins (Vanholder et al., 
2009). The EUTox has identified over 90 uremic toxins, which are classified based on 
size and protein binding properties (Duranton et al., 2012). 
1.3.1 Free water-soluble uremic toxins 
Free water-soluble low molecular weight compounds (< 500 Da) account for 46% of 
identified uremic toxins in patients with CKD (Duranton et al., 2012). These compounds 
include reactive carbonyl compounds such as alkanals, alkenals, and 4-OH-alkenals, 
which are produced as a result of the increased oxidative state in uremia (Alhamdani et 
al., 2006). Guanidine based molecules such as guanidinosuccinic acid and 
methylguanidine are generated from arginine metabolism and are among the uremic 
toxins with the highest fold change in CKD in relation to patients with normal kidney 
function (Duranton et al., 2012). Asymmetric dimethyl arginine also accumulates in CKD 
and these toxins have been implicated in cardiovascular morbidity and mortality (Taes et 
al., 2008; Sibal et al., 2010). Trimethylamine N-oxide (TMAO) is another free water-
soluble uremic toxin derived from choline and trimethylamine. A recent study discovered 
a novel pathway linking TMAO to cardiovascular disease and atherosclerosis (Wang et 
al., 2011).  
1.3.2 Middle Molecules 
Uremic toxins > 500 Da are classified as middle molecules. These account for 28% of 
identified uremic toxins and mostly include proteins and cytokines (Duranton et al., 
2012). As described above, parathyroid hormone accumulates in CKD and is considered 
a middle molecule. Implementation of high-flux dialyzers from conventional have 
allowed for the removal of other large proteins including β-2 microglobulin, which can 
cause amyloidosis and has been associated with increased mortality in long-term dialysis 
patients (Cheung et al., 2006). Cytokines are also a fairly large class of middle molecules 
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that accumulate in plasma of patients with CKD. These include interleukin (IL)-6, IL-8, 
and IL-10 as well as tumour necrosis factor α (TNF-α)(Duranton et al., 2012). High 
cytokine levels increase the risk of cardiovascular complications and mortality in CKD 
patients and can be elevated in the absence of clinically apparent inflammation (Zoccali 
et al., 2006). 
1.3.3 Protein-bound and gut-derived uremic toxins 
Solutes classified as protein-bound uremic toxins represent 25% of all identified uremic 
toxins (Duranton et al., 2012). These solutes are highly bound to plasma protein and 
therefore, poorly cleared in dialysis (Lesaffer et al., 2000). Unlike many free water-
soluble toxins, the plasma concentration of protein bound uremic toxins increases as 
CKD progresses and are highest in ESRD (Vanholder et al., 2003a). The majority of 
protein-bound uremic toxins are also derived from aromatic amino acid putrefaction, 
involving bacterial decomposition in the colon. These protein-bound gut-derived 
metabolic products are further classified into indole, phenol and hippurate groups. 
1.3.3.1 Indoles  
Indole is produced from tryptophan metabolism by bacterial tryptophanase. The majority 
of bacteria-produced indole is absorbed and hydroxylated in the liver by cytochrome 
P450 2E1 to form 3-hydroxy indole (Banoglu et al., 2001). 3-Hydroxy indole undergoes 
sulfation by sulfotransferase 1A1 to form indoxyl sulfate (Banoglu and King, 2002) (Fig. 
1.1). Plasma levels of indoxyl sulfate are reduced in ESRD patients, similar to levels in 
normal renal function, when these patients undergo partial colectomies (Aronov et al., 
2011). This indicates that the colon is the major site of indole generation and is required 
for the production of indoxyl sulfate (Aronov et al., 2011). A number of intestinal 
bacteria contain tryptophanase, which is inducible in the presence of tryptophan. In 
ESRD, Clostridiaceae, Enterobacteriaceae, and Verrucomicrobiaceae tryptophanase 
containing bacterial families are found in higher abundance than in patients with normal 
kidney function, which can contribute to elevated levels of indoxyl sulfate in these 
patients (Wong et al., 2014).  
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Figure 1.1 Generation of indoxyl sulfate, p-cresyl sulfate and hippuric acid from gut-
derived aromatic amino acid putrefaction. 
Fig. 1.1 images were modified from Servier Medical Art 
(http://www.servier.co.uk/medical-art-gallery). 
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Once in circulation, approximately 93% of indoxyl sulfate is protein-bound to albumin 
(Devine et al., 2014). Indoxyl sulfate has been shown to have a number of deleterious 
effects in CKD, contributing to nephrotoxicity and cardiovascular disease. In proximal 
tubule cells, indoxyl sulfate has been shown to induce reactive oxygen species (ROS) and 
cause renal fibrosis in CKD (Saito et al., 2014). Indoxyl sulfate increases the p53-
transforming growth factor (TGF) β1-Smad3 pro-fibrotic pathway through p53 activation 
in the proximal tubule (Shimizu et al., 2013). ROS production by indoxyl sulfate in both 
renal tubular cells and glomerular mesangial cells activates nuclear factor (NF)-κB, 
enhancing infiltration of monocytes into uremic kidneys (Miyazaki et al., 1997).  
In the clinic, indoxyl sulfate has been correlated with cardiovascular events in ESRD 
patients (Cao et al., 2015). Aortic calcification and left ventricle systolic dysfunction are 
also associated with high levels of indoxyl sulfate in patients with CKD (Barreto et al., 
2009; Sato et al., 2013). Indoxyl sulfate plays a role in cardiovascular remodeling of 
cardiac myocytes and cardiac fibroblasts. This occurs through activation of pro-fibrotic, 
pro-hypertrophic and pro-inflammatory pathways including the NF-κB pathway 
(Lekawanvijit et al., 2010; Niwa, 2013). Indoxyl sulfate has a strong association of 
cardiovascular mortality in ESRD and therefore, plays a significant role in cardiovascular 
disease (Barreto et al., 2009).  
Due to its strong protein binding, indoxyl sulfate does not undergo significant glomerular 
filtration. Instead, organic anion transporters (OAT) 1 and 3 on the basolateral membrane 
of the proximal tubule mediate indoxyl sulfate transcellular transport.  On the apical 
membrane, OAT4 is responsible for secretion into urine (Enomoto and Niwa, 2007). It is 
estimated that 3% of tryptophan is excreted by the kidney as indoxyl sulfate (Bender, 
1983; Keszthelyi et al., 2009). Therefore, although production of indoxyl sulfate is 
increased in ESRD, as mentioned above, elevated plasma levels are mainly a result of 
decreased clearance. 
Indole that is not absorbed can also be converted into indole acid derivatives, which are 
generated by gut bacteria and found in smaller quantities in plasma than indoxyl sulfate. 
13 
 
These include indole-3-acetic acid, indolyl-acetyl-glutamine and indolyl-propionic acid 
(Keszthelyi et al., 2009).  
1.3.3.2 Phenols 
Gut bacterial metabolism of tyrosine produces a number of phenol derivatives that 
accumulate in patients with CKD. Similar to indoxyl sulfate, Clostridiaceae and 
Enterobacteriaceae bacteria are more abundant in the colon of patients with ESRD and 
produce p-cresol (Wong et al., 2014). In these bacteria, p-hydroxyphenylacetate is 
generated from hydroxyphenylacetate decarboxylase mediated metabolism of tyrosine, 
which can be further metabolized to p-cresol (Smith and Macfarlane, 1997). The majority 
of p-cresol is subsequently absorbed and sulfated in the liver (Fig. 1.1). ESRD patients 
with partial colectomies have reduced plasma levels of p-cresyl sulfate suggesting that 
the colon is the major site of p-cresol formation (Aronov et al., 2011). P-cresyl sulfate is 
also 90% protein bound to albumin in circulation and therefore, poorly removed by 
dialysis (De Smet et al., 1998; Martinez et al., 2005). Clearance of p-cresyl sulfate mainly 
occurs in the kidneys via OATs (Miyamoto et al., 2011).  
Indeed, elevated plasma levels of p-cresyl sulfate in ESRD have been shown to cause 
many of the same toxic effects as indoxyl sulfate. Interestingly, in patients with ESRD, 
high levels of unbound plasma p-cresyl sulfate increase the risk of all cause mortality and 
cardiovascular mortality beyond the traditional risk in uremia (Wu et al., 2012). Unbound 
p-cresyl sulfate is also a predictor of mortality in earlier stages of CKD (Liabeuf et al., 
2010). P-cresyl sulfate can induce pro-fibrotic TGF-β1 in human proximal tubule cells 
and ROS production via NADPH oxidase 4 activation. Kidney damage is also 
exacerbated in animals with CKD supplemented with p-cresyl sulfate (Watanabe et al., 
2013). 
P-cresol can also be glucuronidated to form p-cresyl glucuronide; however, research on 
p-cresyl glucuronide is limited mostly to its identification in urine or plasma (Lesaffer et 
al., 2003; Aronov et al., 2011). Therefore, there is insufficient evidence for 
pathophysiologic effects of p-cresyl glucuronide, although one study suggested that it 
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might be an indicator of altered gut microbiota during inflammation (Zhang et al., 
2012b).  
The majority of studies assessing the accumulation of tyrosine derivatives in CKD have 
focused on p-cresyl sulfate. However, phenol is another gut-derived tyrosine metabolite 
that accumulates in CKD, detected in plasma and urine as phenyl sulfate (Kikuchi et al., 
2010; Akiyama et al., 2012). Like the other sulfated uremic toxins, phenyl sulfate is 
highly protein bound (90.7%), and transported by OATs (Wikoff et al., 2011; Itoh et al., 
2012). Conversely, phenyl sulfate is more efficiently removed by HD, possibly due to a 
weak interaction with albumin (Itoh et al., 2012). 
1.3.3.3 Hippurate 
Phenylalanine is converted to benzoic acid by intestinal bacteria and subsequently 
combined with glycine to form hippuric acid in the intestine or the liver (Fig. 1.1)(Chiba 
et al., 1994; Mulder et al., 2005). Hippuric acid is also strongly bound to albumin and 
plasma levels of this uremic toxin are highly elevated in CKD. Elevated levels of 
hippuric acid have been shown to cause insulin resistance and glucose intolerance, 
possibly contributing to diabetic complications (Spustova et al., 1989). Endothelial cell 
dysfunction has also been attributed to increased plasma levels of hippuric acid, which 
may promote cardiovascular disease prior to the development of uremia (Addabbo et al., 
2013). 
 
1.4 Removal of gut-derived uremic toxins in uremia 
1.4.1 Probiotics, Prebiotics, and dietary fibre 
As described above, not only is the clearance of gut-derived uremic toxins decreased in 
CKD, but indole and p-cresol producing bacteria are also more abundant in the colon 
microbiota for these patients. Therefore, a therapeutic strategy to reduce plasma levels of 
these uremic toxins is to manipulate the colon microbiota in patients with CKD. This can 
be accomplished by improving gut dysbiosis in CKD using probiotics, prebiotics or the 
combination of both, known as symbiotics. Probiotics are defined as microorganisms that 
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express exogenous enzymes and increase the colon concentrations of symbiotons to 
provide a health benefit (Food and Agriculture Organization, 2002). Administration of 
non-indole producing bacteria including Lactobacillus and Bifidobacillus have 
demonstrated decreased level of plasma indoxyl sulfate and p-cresyl sulfate in CKD and 
ESRD (Hida et al., 1996; Guida et al., 2014). However, there are concerns of increased 
inflammation due to urease hydrolysis of urea in these probiotics (Koppe et al., 2015). 
The use of probiotics can also be supplemented with prebiotics. Prebiotics are 
carbohydrates that are not digested or absorbed in the gut but can be used by intestinal 
bacteria. Lactulose is a common example of a prebiotic and has been shown to lower 
indoxyl sulfate and p-cresyl sulfate levels in healthy patients (Terada et al., 1992). 
Finally, increasing dietary fibre can also reduce plasma indoxyl sulfate and p-cresyl 
sulfate levels in ESRD patients (Sirich et al., 2014). In CKD, lower dietary protein to 
fibre ratios have been shown to associate with decreased plasma levels of both indoxyl 
sulfate and p-cresyl sulfate (Rossi et al., 2015). 
1.4.2 AST-120 
Another method used to remove gut-derived uremic toxins is to prescribe AST-120 to 
patients with CKD. AST-120 is a compound that began development for the treatment of 
uremia in 1975 and was approved in Japan in 1991 (Niwa et al., 1991; Schulman et al., 
2015). It is also approved in both Korea (2005) and the Philippines (2010). AST-120 is a 
spherical carbon adsorbent, 0.2-0.4 mm in diameter, composed of carbon with a surface 
oxide. Unlike activated charcoal, AST-120 is capable of binding small molecules (100-
10,000 Da) with negligible effects on amylase, pepsin, lipase, and chymotrypsin enzymes 
(Niwa et al., 1991). It has also been reported to have limited adsorption to fat-soluble 
vitamins (Schulman et al., 2006). AST-120 is indicated in Japan for delaying the onset of 
dialysis and mitigating symptoms of progressive CKD. It has minimal adverse effects, 
which can include constipation, nausea and diarrhea; however, the frequency of these 
adverse events is similar in placebo treated patients (Schulman et al., 2015). AST-120 
acts by adsorbing gut-derived uremic toxin precursors in the colon, thereby inhibiting 
their absorption. A number of studies have demonstrated reduced plasma concentration of 
indoxyl sulfate, p-cresyl sulfate, indole-3-acetic acid, phenyl sulfate and hippuric acid 
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following administration of AST-120 in CKD (Kikuchi et al., 2010; Akiyama et al., 
2012; Wu et al., 2014). In the colon, AST-120 administration to rats mitigated the 
depletion of epithelial tight-junction proteins (Vaziri et al., 2013). AST-120 has also been 
shown to ameliorate a number of effects caused by gut-derived uremic toxins described 
above including endothelial dysfunction, CKD progression, serum cytokine 
accumulation, and inflammation (Iida et al., 2006; Ito et al., 2013; Inami et al., 2014).  
There is conflicting evidence for the beneficial use of AST-120 in clinical trials for 
patients with CKD. AST-120 has been shown to slow the decline in renal function for 
patients with CKD over a 12 month and 56 week period in Japanese patients (Konishi et 
al., 2008; Nakamura et al., 2011). However, these data are not consistent with other 
clinical trials. In a Phase II clinical trial, AST-120 was given at doses of 2.7, 6.3 and 9 
g/d resulting in a dose-dependent decrease in serum indoxyl sulfate with no effect on 
serum creatinine levels for patients with CKD (Schulman et al., 2006). The largest 
clinical trials for AST-120 were the Evaluating Prevention of Progression in CKD 
(EPPIC) trials -1 and -2, which were separate trials conducted simultaneously with a total 
5840 patients (Schulman et al., 2006). The primary endpoint for these trials was a triple 
composite and included dialysis initiation, serum creatinine doubling and kidney 
transplantation.  EPPIC-1, EPPIC-2 and a pooled analysis of both studies showed that 
AST-120 did not delay the primary endpoints and therefore, did not support its use as 
therapy for moderate and severe CKD (Schulman et al., 2015). 
 
1.5 Metabolomics 
There are a number of methods to measure small molecules in biological matrices using 
known standards; however, recent advances in technology have allowed for the 
identification of unknown metabolites. Metabolomics is the study of all metabolites 
generated in a biological system and currently the newest of the “-omic” technologies. 
Metabolites are the final product in response to genetic and environmental changes and 
can provide signatures for genotype-phenotype and genotype-environmental relationships 
(Corona et al., 2012). Metabolomics is also a powerful technique for identifying altered 
17 
 
metabolic pathways that are affected by chronic disease. Prior to the advent of 
metabolomics, hypothesis driven studies were required to measure known biomarkers 
and assess their potential to cause complications in disease.  However, untargeted 
metabolomics allows for the measurement of unknown small molecules. In the context of 
uremia, metabolomics is ideal for the measurement and identification of small molecules 
that accumulate as a result of declining renal function (Rhee, 2015). 
1.5.1 Metabolomics Methods 
Strategies to assess metabolomics are divided into targeted and untargeted approaches. 
Targeted analysis characterizes known groups of metabolites and can be quantitative with 
the use of internal standards. Metabolites measured using this approach are predefined, 
which allows for a refined sample preparation to enrich a targeted group of metabolites 
and reduce analytical artifacts (Roberts et al., 2012).  In contrast, untargeted 
metabolomics allows for the discovery of novel metabolites. The comprehensive 
identification of metabolites by this method is determined by sample preparation and 
analytical instrumentation, which can limit the overall coverage of metabolites measured 
in a sample. Untargeted metabolomics requires either nuclear magnetic resonance (NMR) 
or mass spectrometry (MS) to identify compounds. NMR is highly quantitative and 
reproducible but has low-sensitivity. MS is highly sensitive and reliable for metabolite 
identification; however, metabolites must be separated using either liquid or gas 
chromatography prior to detection and matrix effects can influence signal intensities (Pan 
and Raftery, 2007). The majority of recent studies are employing the use of quantitative 
time-of-flight (QToF) mass spectrometry coupled to ultra performance liquid 
chromatography (UPLC) or gas chromatography.  Electrospray ionization (ESI) probes 
are commonly used to ionize metabolites by adding or removing a proton using a positive 
or negative voltage, respectively. Ions are then accelerated and their accurate mass is 
detected based on the time between acceleration and detection. During a metabolomics 
method, new QToF mass spectrometers, such as Waters XevoTM G2S-QToFMS, can 
simultaneously acquire both MS and MSE data. In the MS function, data is acquired by 
scanning for a range of masses to detect small molecules. In the MSE function, the same 
range is scanned; however, argon and collision energy are used to fragment ions and 
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detect the resulting daughter ions. Acquiring simultaneous MS and MSE data for a 
metabolite allows for the determination of elemental composition and structural 
information, respectively. 
1.5.2 Data Processing and Analysis 
Metabolomics using UPLC-QToFMS generates an enormous amount of data that must be 
processed prior to analysis. The first step is peak-picking, which integrates the area of 
chromatographic peaks based on a minimum threshold. This results in a list of ion 
masses, retention times and peak areas for each sample. Peaks with similar retention time 
and ion mass are then aligned for each sample. For a given ion mass and retention time, 
some samples will have a peak area below the minimum threshold set in the peak-picking 
step and contain a value of zero. To avoid problems during statistical analysis, the area 
below the peak-picking threshold is calculated. Each ion with the same mass and 
retention time is called a feature. The data are then normalized across samples prior to 
statistical analysis.  
A number of proprietary and open software packages are available for processing and 
data analysis including Markerlynx (with EZinfo) (Umetrics, Umea, Sweden) and XCMS 
Online (Tautenhahn et al., 2012). Markerlynx with EZinfo is Waters and Umetrics 
proprietary software package that can be used for multivariate statistical analysis. It 
allows for data scaling using unit variance or pareto scaling to reduce noise and analysis 
by principal component analysis (PCA) as well as orthogonal partial least squares 
discriminant analysis (OPLS-DA). PCA allows for visualization of the largest variation in 
the data set and OPLS-DA demonstrates the variation between experimental groups 
separate from variation within experimental groups. Finally, EZinfo can be used to 
construct S-plot projections, which show features with the largest difference in magnitude 
between two experimental groups combined with the least variation within groups 
(Wiklund et al., 2008). The XCMS Online open software package allows for univariate 
statistical analysis (Tautenhahn et al., 2012). After uploading and processing data using 
the XCMS Online site, statistical analysis by ANOVA can be performed to determine 
significantly different peaks across multiple experimental groups. This analysis not only 
reports p-values for each feature, but also reports q-values as a measure of false discovery 
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rate (Benjamini and Hochberg, 1995). Features can be filtered for isotopes and p-value 
and q-value thresholds are set to determine highly significant features. Further analysis of 
significant features is necessary to identify them as metabolites.  
1.5.3 Metabolite Identification 
Metabolites can be identified using the accurate ion mass to determine elemental 
composition as well as fragmentation pattern to confirm molecular structure. A number 
of databases exist with metabolite spectral libraries including, METLIN (Smith et al., 
2005), the Human Metabolome Database (HMDB) (Wishart et al., 2013) and MassBank 
(Horai et al., 2010); however, the spectral information is fairly limited and relative 
fragment intensity can vary between mass spectrometers. Therefore, for unknown 
compounds with missing published spectral information, putative fragmentation in silico 
is used to aid in identification. The potential elemental composition is first determined 
from accurate mass, which can be used to query biological compounds. The 
fragmentation pattern of the unknown metabolite is then compared to the putative 
fragmentation of biological compounds based on structural information. Putative 
fragmentation can be done using Waters MassFragment® or online using MetFrag and 
MetFusion (Wolf et al., 2010; Gerlich and Neumann, 2013). Finally, fragmentation 
pattern and retention time of a purchased compound standard is compared to the 
unknown sample to confirm its identity.  
There are four levels of metabolite identification found in published metabolomics 
literature (Sumner et al., 2007). Level 1 completes all of the above steps to the gold 
standard of comparing unknown metabolites to authentic standards using a minimum of 
two independent methods including retention time, fragmentation spectrum and accurate 
mass. Level 2 putatively annotates metabolites by comparing the unknown metabolite 
fragmentation pattern to in silico fragmentation of a biological compound or using 
spectral libraries. Level 3 also putatively annotates a compound but can only identify the 
class of compound and not the specific identity. This commonly occurs when identifying 
unsaturated fatty acids, as fragmentation pattern rarely provides information for the 
location of alkene or alkyne functional groups. Metabolites that remain unknown despite 
the use of in silico fragmentation and database queries are classified as level 4. 
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1.6 Drug Therapy for CKD Management  
Patients with CKD and ESRD have several co-morbidities, as discussed above, that 
require pharmacological management including diabetes, hypertension, bone disease and 
anemia. In early stages of CKD, the strongest evidence exists for treatment benefits using 
angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, which are 
supported by multiple randomized controlled trials (Ruggenenti et al., 1998; Rodby et al., 
2000; Brenner et al., 2001). Lipid lowering drugs may also reduce the risk of 
cardiovascular events in CKD; however, the association between LDL cholesterol and 
myocardial infarction in stages 3-5 of CKD is weaker than the general population 
(Tonelli et al., 2013). As patients progress to later stages of CKD, they require 
medications to treat bone disease and anemia (Wouters et al., 2015). Drug therapy 
intensifies for ESRD patients that require renal replacement therapy, as more 
complications arise in this final stage of kidney disease. It is estimated that ESRD 
patients take an average of 12 different medications (Manley et al., 2004) with a median 
daily pill burden of 19 (Chiu et al., 2009). Many prescribed medications are required for 
these patients to manage an average of 6 comorbidities along with ESRD (Manley et al., 
2005). Common medications to treat CKD can be classified into a number of categories 
(Manley et al., 2003). Bone disease medications include vitamin D analogues, phosphate 
binders, calcium salts. Iron and erythropoietin are used to treat anemia, and cardiac 
medications include drugs to treat hypertension, arrhythmia, coronary artery disease and 
congestive heart failure. Endocrine medications comprise agents for diabetes and thyroid 
disorders, and anti-infective drugs are used for bacteria and viral infections (Manley et 
al., 2003).  
A consequence of the polypharmacy experienced by ESRD patients is heightened risk for 
medication related problems. It has been reported that one medication related problem 
occurs for every 2.7 medication exposures in dialysis patients (Manley et al., 2005). 
Despite widespread evidence in the literature, dosing errors in patients with CKD still 
occur at an alarming rate (Farag et al., 2014).   
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1.7 Drug Metabolism and Disposition 
In order for a drug to be effective, it must reach the site of action at an appropriate 
concentration. This can depend on a number of factors associated with drug 
administration including the route, dose, and formulation. Once inside the body, drug 
concentration at the site of action depends on absorption, distribution, metabolism and 
excretion. The majority of drug elimination occurs through hepatic drug metabolism but 
can also occur in the intestines and kidney (Wienkers and Heath, 2005). Drugs can enter 
cells by traversing the plasma membrane either directly through the lipid bilayer or via 
uptake transporters. This depends on the physicochemical characteristics of the drug, as 
large hydrophilic drugs are more likely to require transport. Once inside the cell, drugs 
can undergo biotransformation by phase I and/or phase II drug metabolizing enzymes. 
Phase I drug metabolism generally results in oxidation through cytochrome P450 
enzymes (P450s). Phase II drug metabolism involves the conjugation of drugs by adding 
large hydrophilic functional groups including glutathione, glucuronic acid and sulfate. 
Conjugation can occur directly with the parent drug or may require initial phase I 
metabolism. Efflux transporters also exist to excrete parent drugs or drug metabolites, 
which requires active transport. Therefore, drug concentrations at the site of action 
depend on the interplay between drug metabolizing enzymes and transporters. 
1.7.1 P450 Enzyme Function and Regulation 
1.7.1.1 P450 Enzyme Function 
P450 enzymes are a large group of major drug metabolizing enzymes. In humans, 18 
families and 44 subfamilies exist; however only P450 families 1, 2 and 3 are involved in 
the biotransformation of drugs. These enzymes contain a heme functional group, which is 
an iron-containing protoporphyrin IX molecule. Monooxygenation reactions account for 
the majority of P450 function, which occurs in a number of steps using the heme 
functional group and oxygen as well as an electron and proton source (Zhu and 
Silverman, 2008). P450 enzymes are embedded in the smooth endoplasmic reticulum 
membrane along with NAPDH-cytochrome P450 oxidoreductase, which is required for 
enzymatic function. NADPH-cytochrome P450 oxidoreductase transfers electrons from 
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NADPH to the P450 heme group, reducing the iron to its ferrous state. The reduced iron 
can bind O2 and transfer one oxygen atom to a substrate, releasing the other oxygen after 
protonation as water (Denisov et al., 2005). Oxidation of drugs by P450 enzymes 
generally reduces activity. Substrates for P450 enzymes are mostly hydrophobic and 
poorly soluble; therefore, oxidation of these substrates increases hydrophilicity to 
promote excretion from the body (Denisov et al., 2005). In vitro P450-mediated 
metabolism can be assessed using Michaelis-Menten kinetics. This requires an 
experimental set-up in which the substrate concentration is much greater than the enzyme 
concentration allowing for a steady state of enzyme-substrate complex formation to 
enzyme-product decay. If this occurs, then the enzyme kinetics can be modeled to this 
simplified equation: 
𝑣 = 𝑉!"# 1+ 𝐾!𝑆  
Where Vmax is the maximum enzyme velocity and Km is defined as the substrate 
concentration at half of the Vmax, obtained under saturating conditions. The Km is also 
known as the Michaelis constant and varies between enzymes and between substrates. 
The above equation creates a hyperbolic curve, which approaches an asymptote defining 
the Vmax (Shou et al., 2001). 
1.7.2 Nuclear Receptor Regulation of CYP2C and CYP3A 
Transcription of hepatic drug metabolizing enzymes and transporters is highly regulated 
by nuclear receptors. These transcription factors contain three protein domains. 
Interaction with co-activators and other nuclear receptors occurs at the n-terminus, which 
is the ligand independent activating domain (Urquhart et al., 2007). A central DNA 
binding domain can interact directly with a recognition sequence in the DNA to regulate 
transcription.  A c-terminus ligand-binding domain associates with a number of ligands 
including drugs, bile acids, hormones, and lipids (Urquhart et al., 2007). There are six 
evolutionary groups of nuclear receptors, the largest of which are type I nuclear receptors 
(Germain et al., 2006). Localization of type I nuclear receptors begins in the cytosol, 
where these proteins are bound to chaperones. Upon ligand activation, these nuclear 
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receptors translocate to the nucleus. This group includes the pregnane X receptor (PXR) 
and constitutive androstane receptor (CAR). Conversely, type II nuclear receptors are 
bound to co-repressors in the nucleus when inactive and include the retinoid X receptor 
(RXR) and hepatocyte nuclear factor (HNF)-4α. RXR forms heterodimers with PXR and 
CAR in the nucleus prior to DNA binding. HNF-4α forms a homodimer when activated 
(Urquhart et al., 2007). Once active, these nuclear receptors bind to specific motifs in the 
DNA. 
In humans, hepatic CYP3A4 is regulated by a number of nuclear receptors including 
PXR, CAR, RXR, glucocorticoid receptor and HNF-4α (Urquhart et al., 2007). PXR is a 
major regulator of CYP3A4 and can bind to two separate sites in the CYP3A4 promoter. 
A proximal PXR response element exists at -160 bp and a distal binding site is located 
between -7800 and -7200 bp. The most frequent PXR binding motif is AG(G/T)TCA, 
which is connected by a spacer to a similar sequence. The CYP3A4 proximal PXR 
binding site is an everted repeat with a 6 bp spacer (ER6) of AGGTCA. The distal 
promoter contains an ER6 site flanked by two direct repeats linked with a 3 base pair 
spacer (DR3) (Goodwin et al., 1999).  Binding of PXR to these regions of the CYP3A4 
promoter induces transcription. CAR can also bind to the proximal ER6 motif in the 
CYP3A4 promoter to activate transcription (Sueyoshi et al., 1999). The glucocorticoid 
receptor can increase PXR mRNA, which has been linked to increases in CYP3A4 
expression but can also activate CYP3A4 expression through a PXR-independent 
pathway (Pascussi et al., 2000; El-Sankary et al., 2002). HNF-4α is critically involved in 
PXR and CAR activation of CYP3A4. HNF-4α binds upstream of the distal PXR/CAR 
binding site to a response element containing a DR1 repeat and regulates both induction 
and basal transcription of CYP3A4 (Tirona, 2010). 
Regulation of rat CYP3A2 is slightly different than human CYP3A4. CYP3A2 contains 
only a proximal PXR binding site, which exists as a DR3 of AGTTCA instead of an ER6 
motif. In rats, HNF-4α binds Site A in the proximal promoter of CYP3A2, which 
regulates both basal and induced transcriptional activity (Huss and Kasper, 2000).  
Similar to CYP3A4 regulation, the glucocorticoid receptor activation also increases PXR 
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and RXR expression and can activate CYP3A2 expression through a PXR-dependent 
pathway (Miyata et al., 1995). 
Human CYP2C9 is regulated by PXR, CAR and HNF-4α. The CYP2C9 promoter 
contains a proximal HNF-4α binding site and is thought to bind to an HPF-1 motif 
(Ibeanu and Goldstein, 1995). A PXR response element is located between -1839 and -
1824 bp in the CYP2C9 promoter. Induction of CYP2C9 has been shown to occur 
through this increased binding of PXR to this response element (Chen et al., 2004). 
Phenobarbital, a stereotypical CAR inducer, has also been shown to increase CYP2C9 
mRNA expression. However, phenobarbital is not a potent inducer of CYP2C9 as large 
concentrations are required for induction. At high concentrations, phenobarbital has been 
shown to activate PXR and therefore, it is unknown whether PXR or CAR is responsible 
for phenobarbital-mediated induction of CYP2C9 (Gerbal-Chaloin et al., 2001; Chen et 
al., 2004). CYP2C9 is also regulated by the glucocorticoid receptor and the CYP2C9 
promoter contains two glucocorticoid receptor elements between -1684 and -1654 bp. 
Conversely, a major physiological regulator of the sexually dimorphic pattern of hepatic 
CYP2C11 expression in rats is growth hormone (Wauthier and Waxman, 2008). This 
occurs as a result of the differences between male and female pituitary release of growth 
hormone. A continuous release of growth hormone in female rats suppresses CYP2C11 
expression and activates the female specific CYP2C12. The male rat pituitary has a 
pulsatile release of growth hormone, which stimulates CYP2C11 expression (Wauthier 
and Waxman, 2008). CYP2C11 is also regulated by a number of transcription factors 
including: HNF-1α, HNF-3β, HNF-4α, and HNF-6 (Park and Waxman, 2001).   
1.7.3 Epigenetic Regulation of CYP2C and CYP3A 
Epigenetic regulation of hepatic drug metabolizing enzymes has been shown to occur 
through histone post-translational modifications, DNA methylation and micro RNAs 
(miR). CpG islands exist in the HNF-4α and distal PXR binding site regions of the 
CYP3A4 promoter (Kacevska et al., 2012). PXR and HNF-4α can also be inhibited by 
micro RNAs. Overexpression of miR-148a decreases protein levels of PXR (Takagi et 
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al., 2008). Similarly, overexpression of miR-24 and miR-34a downregulate HNF-4α and 
target genes including CYP3A4.  
Post-translational modifications of histones also regulate CYP3A4. Protein arginine 
methyltransferase 1 (PRMT1) is involved in PXR-mediated transcriptional activation of 
CYP3A4 (Tian, 2013). PRMT1 functions by asymmetrically dimethylating histone 4 
arginine 3 (H4R3) using s-adenosyl methionine as a methyl donor. H4R3 asymmetric 
dimethylation (H4R3me2) facilitates H4 acetylation by p300 and transcriptional 
activation of CYP3A4 (Xie et al., 2009). The process of H4R3me2 and subsequent H4 
acetylation is suggested to be unidirectional (Tian, 2009). PRMT1 also facilitates HNF-
4α dependent transcriptional activation (Barrero and Malik, 2006).  
Epigenetic modifications associated with PXR have not been studied in rats; however, in 
mice, PXR binding overlaps with histone 3 lysine 4 dimethylation (H3K4me2) (Cui et al., 
2010). This study also found that PXR binding did not associate with the histone 3 lysine 
27 tri-methylation (H3K27me3) epigenetic signature. H3K4me2 is a signature of 
transcriptional activation and H3K27me3 is a marker of gene silencing (Lorincz et al., 
2004; Shilatifard, 2006). 
There is minimal information in the literature specifically identifying epigenetic 
modifications in the human CYP2C9, rat CYP2C11 and CYP3A2 promoters. 
 
1.8 Pharmacokinetic Changes in CKD 
1.8.1 Drug Absorption and Bioavailability 
Drug absorption following oral dosing is primarily mediated by the physicochemical 
characteristics of the drug.  Bioavailability can be further impacted by the balance 
between uptake and efflux drug transporter activity as well as pre-systemic metabolism 
mediated by intestinal and hepatic P450s or gut bacteria. Paracellular intestinal drug 
absorption is usually minimal due to tight junctions in the intestinal epithelium 
(Groschwitz and Hogan, 2009) and the fact that the surface area for paracellular transport 
26 
 
represents only approximately 0.01% of the intestinal surface area (Pappenheimer and 
Reiss, 1987).  
The absorption and bioavailability of drugs is highly variable in patients with ESRD. The 
mechanism for variable absorption and bioavailability is multifactorial and begins with 
the intestinal pH. Urea retention in ESRD results in a high influx of urea into the gut, 
which can be hydrolyzed by bacterial urease into ammonia (Ramezani and Raj, 2014). 
According to the FDA, the target pH range for a drug to be considered highly soluble 
drug is 1 to 7.5 (CDER/FDA, 2000); therefore, an increase in pH due to high 
concentrations of ammonia may alter the absorption of weakly basic drugs. Studies by 
Magnusson et al. assessed the integrity of the intestinal barrier in uremic rats (Magnusson 
et al., 1990) and human patients with CKD (Magnusson et al., 1991) by using 
polyethylene glycols that ranged in size from 326 – 1162 Da. They found increased 
polyethylene glycol leakage in both uremic rats and human patients with CKD and 
conclude that these relatively large molecules are able to undergo paracellular transport 
across the intestinal epithelium in kidney disease. To evaluate the impact of CKD on 
intestinal barrier function mechanistically, Vaziri et al. evaluated the expression of 
proteins that make up the intestinal tight junction complex in a rodent model of CKD. 
They found a greater than 50% decrease in the expression of the tight junction complex 
proteins claudin-1, occludin and zonula occludens-1 (Vaziri et al., 2012). This was 
further confirmed using T84 tight junction forming enterocytes. Similar to the studies in 
uremic rats, treatment of T84 cells with uremic serum impaired intestinal barrier function 
secondary to decreases in claudin-1, occludin and zonula occludens-1 expression. It has 
been proposed that uremic toxins and inflammation mediate the decreased intestinal 
barrier function in renal failure. This was evaluated by treating CKD rats with AST-120 
and assessing intestinal barrier function (Vaziri et al., 2013). Treatment of CKD rats with 
AST-120 partially restored the protein expression of claudin-1, zonula occludens-1 and 
occludin demonstrating that uremic toxins are at least partially responsible for the 
disruption in intestinal barrier function.  
Data from studies in rodents and human patients with CKD suggest that intestinal barrier 
function is reduced in CKD. Given that the absorption of polyethylene glycols are 
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increased in CKD, it is likely that increased paracellular absorption of drugs partially 
accounts for the increased and variable drug absorption observed in dialysis. 
Experimental confirmation of increased paracellular drug absorption and the impact on 
drug pharmacokinetics in patients on HD still requires validation. 
Aside from the intestinal tight junction barrier complex, transport proteins also play an 
essential role in mediating the barrier function of the intestine. The intestinal epithelium 
is lined with a multitude of uptake and efflux transporters. These transporter proteins, 
along with the physicochemical characteristics of the drug, are primary determinants of 
intestinal drug absorption. Although there are numerous transporters expressed in the 
intestine, members of the solute carrier (SLC) and ATP-binding cassette (ABC) families 
are the most important in mediating the uptake and efflux of drugs, respectively. The 
SLC transporters SLCO2B1 (OATP2B1), SLCO1A2 (OATP1A2) and SLC15A1 
(PEPT1) mediate the uptake of substrate drugs across intestinal epithelia into the 
enterocyte (Ho and Kim, 2005; Glaeser et al., 2007). In contrast, ATP binding cassette 
(ABC) efflux transporters such as ABCB1 (P-glycoprotein, P-gp), ABCG2 (Breast 
Cancer Resistance Protein, BCRP) and ABCC2 (Multidrug Resistance-Associated 
Protein 2, MRP2) restrict drug absorption by actively pumping drugs from the enterocyte 
to the intestinal lumen. Efflux transporters such as ABCC1 (MRP1) and ABCC3 (MRP3) 
mediate the efflux of drugs from the intestine into the portal circulation.  In addition, 
enterocytes express relatively large amounts of CYP3A4, which acts to metabolize 
substrate drugs thereby decreasing oral bioavailability. 
The expression and activity of intestinal drug transporters was evaluated in a rodent 
model of CKD (Naud et al., 2007). A decrease in the protein expression of P-gp, MRP2 
and MRP3 and a consistent reduction in transport activity using everted gut sacs were 
observed. In addition, intestinal CYP3A2 (rat ortholog of human CYP3A4) expression 
and activity is decreased in rats with CKD (Leblond et al., 2002). Collectively these data 
suggest that drug absorption and bioavailability are increased in CKD. It has also been 
demonstrated that the intestinal folate uptake transporter SLC46A1 (human proton 
coupled folate transporter, hPCFT) is responsible for the uptake transport of some drugs 
(Urquhart et al., 2010). Studies using the 5/6 nephrectomy model of CKD demonstrate 
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that hPCFT expression is decreased (Bukhari et al., 2011). Although no functional assays 
were conducted in this study, decreased expression of hPCFT in rats with CKD suggests 
that the absorption of drugs that are substrates for hPCFT such as methotrexate and 
pemetrexed will be decreased. 
1.8.2 Distribution  
Once absorbed, drugs are carried to target tissues and sites of elimination (e.g. liver, 
kidney) in the systemic circulation. Many drugs are extensively bound to plasma proteins 
such as albumin and alpha 1 acidic glycoprotein (AAG), which limits their extravascular 
distribution. HD is commonly associated with hypoalbuminemia. Multiple factors affect 
plasma protein levels including malnutrition and low-protein diet regimes. Albumin is the 
most abundant plasma protein and albumin levels are an indication of plasma protein 
pool size (Steinman, 2000). Albumin, which predominantly binds weakly acidic drugs, 
exhibits fluctuations in concentration due to changes in plasma volume that occur during 
the intra-dialytic period. A previous study demonstrated a 0.6 g/dL increase in plasma 
albumin concentration during 2 to 4 hour HD. The other major plasma protein AAG 
binds weakly basic drugs. In contrast to albumin, the concentration of AAG is typically 
increased in ESRD as a result of chronic inflammation experienced in this patient 
population (Vasson et al., 1991). AAG is thought to bind inflammatory mediators and 
modulate the immune response (Moore et al., 1997). Further to changes in the 
concentration of plasma proteins, accumulation of inflammatory factors and protein-
bound uremic toxins such as indoxyl sulfate, p-cresyl sulfate and hippuric acid can 
decrease plasma protein binding of drugs (Sakai et al., 2001). A combination of low 
serum albumin along with competition for plasma protein binding sites by uremic toxins 
increases the free fraction of drugs.  
One of the most highly studied drugs with regard to alteration in protein binding in 
dialysis is the anti-epileptic drug phenytoin. Phenytoin is important to study in dialysis as 
seizure disorders are relatively common in this patient population, phenytoin has a 
narrow therapeutic window, and exhibits non-linear kinetics whereby a small increase in 
dose can result in a large increase in plasma concentration. Free phenytoin concentration 
is an important determinant of both efficacy and toxicity. Multiple studies have reported 
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that the free fraction of phenytoin is greater in dialysis patients than healthy controls 
(Steele et al., 1979; Liponi et al., 1984; Dasgupta and Abu-Alfa, 1992). Phenytoin is 
weakly acidic so hypoalbuminemia may contribute to this phenomenon.  In addition, the 
uremic toxins hippuric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid 
(CMPF) inhibit the binding of phenytoin to plasma protein (Mabuchi and Nakahashi, 
1988; Vanholder et al., 1988). Changes in the protein binding of drugs like phenytoin can 
have a profound influence on dosing regimens and dialyzability.  
Another important consequence of dialysis is the fluid removal and hemoconcentration 
that can occur. In terms of pharmacokinetics of drugs, the concentration of albumin 
actually increases post-dialysis as a result of hemoconcentration. Aside from changes in 
plasma protein concentration, which may impact free drug concentration, 
hemoconcentration has also been shown to increase plasma drug concentrations in post-
dialysis plasma samples.  For example, plasma concentration of the non-dialyzed 
monoclonal antibody rituximab has been shown to increase 1.4 to 4.8-fold following a 
HD session (Jillella et al., 2002).    
1.8.3 Drug Metabolism  
While it is well appreciated that renal excretion of drugs is decreased in dialysis patients, 
73% of drugs undergo metabolism prior to excretion (Wienkers and Heath, 2005). The 
majority of drug metabolism occurs in the liver. Emerging evidence has focused on 
alterations in non-renal clearance pathways in kidney disease and their impacts on drug 
disposition. Several reviews have addressed this important issue (Nolin et al., 2003; 
Dreisbach and Lertora, 2008; Nolin et al., 2008; Naud et al., 2012; Velenosi and 
Urquhart, 2014; Yeung et al., 2014).  P450 enzymes in the small intestine and liver 
mediate the majority of drug metabolism. CYP3A4 and CYP2C9 metabolize 
approximately 43% of clinically used drugs (Zanger and Schwab, 2013). Altered function 
of these drug metabolizing enzymes has been assessed in animal studies and in patients 
with CKD. Pichette and colleagues have demonstrated that rats with severe CKD have 
decreased hepatic expression of phase I drug metabolizing enzymes CYP2C11 and 
CYP3A2 and the phase II drug metabolizing enzyme N-acetyltransferease 2 (NAT2) 
(Leblond et al., 2000; Guevin et al., 2002; Simard et al., 2008). These studies suggest 
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uremic toxins that accumulate in kidney disease downregulate the expression of 
cytochrome P450 enzymes. Studies have also demonstrated that aside from decreases in 
P450 expression, uremic solutes that accumulate in CKD may also directly inhibit P450 
mediated metabolism. For example, the uremic toxins CMPF and indoxyl sulfate inhibit 
the CYP3A mediated metabolism of erythromycin (Sun et al., 2004).    
The impact of CKD on drug metabolism in humans is not as clear as the studies in animal 
models of CKD. Early studies using non-selective P450 probe drugs lidocaine (CYP1A2 
and CYP3A4) and nifedipine (CYP3A4 and CYP2D6) revealed a decrease in hepatic 
drug metabolism for CKD patients. Interestingly, metabolism appears to be recovered in 
patients on HD (Ahmed et al., 1991; De et al., 2006). The CYP2C9 mediated metabolism 
of S-warfarin is also decreased in CKD patients. Consistent with these findings, patients 
with CKD have decreased S-warfarin clearance and require a lower warfarin dose than 
patients with normal kidney function (Dreisbach et al., 2003; Limdi et al., 2010; Gong et 
al., 2011).  Selegiline is a monoamine oxidase inhibitor that is dependent on P450 
mediated metabolism prior to excretion. Selegiline pharmacokinetics are substantially 
altered in patients with kidney disease with significant increases in Cmax and AUC 
(Anttila et al., 2005). As selegeline is metabolized by CYP2B6, CYP2C19 and CYP1A2, 
these data suggest that one or more of these enzymes is impacted by kidney disease.  
More recent clinical studies have provided conflicting results with regard to the impact of 
kidney disease on drug metabolism. The generally accepted gold standard in vivo probe 
to assess CYP3A4 activity in humans is evaluation of midazolam clearance.  Nolin et al. 
investigated the non-renal clearance of oral midazolam in HD patients and healthy 
controls (Nolin et al., 2009). In contrast to studies in animal models of CKD, midazolam 
clearance was unaltered in this study, suggesting CYP3A4 activity is unchanged in HD 
patients. A follow-up study assessing midazolam metabolism in non-dialysis dependent 
CKD, HD and PD patients, revealed significantly higher midazolam exposure for the HD 
group only, which did not support the previous study (Thomson et al., 2015). The impact 
of kidney disease on the pharmacokinetics of new drugs approved by the FDA between 
2003 and 2007 has been evaluated demonstrating similar inconsistent results (Zhang et 
al., 2009). The study identified several drugs whose clearance was predominantly 
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mediated by non-renal mechanisms such as metabolism. When assessing the specific 
contribution of individual P450s, no clear pattern could be delineated. Of the 13 drugs 
that exhibit significant non-renal clearance mediated by CYP3A4 in the study, 6 had 
altered pharmacokinetics in kidney disease and 7 had no alterations in kidney disease. 
This was evident, even in drugs within the same class.  For example, tadalafil has a 
fractional excretion of less than 0.3% and is metabolized by CYP3A4. Patients on HD 
have a 2-fold increase in Cmax and 2.7 to 4.1-fold increase in AUC compared to healthy 
controls. Accordingly, the dosage recommendation for tadalafil in HD patients is 5 mg no 
more than once every 72 hours. In contrast, vardenafil has a fractional excretion of 2-6 % 
and is also metabolized by CYP3A4 and to a minor extent by CYP2C9. Vardenafil 
exhibits only a 30% increase in AUC and therefore, no dosage adjustment is required in 
HD. It is clear that the impact of kidney disease on hepatic drug metabolism is 
complicated and addition experimental evidence is required to delineate pathways that 
are altered in patients with kidney disease.   
1.8.4 Other Routes of Elimination 
1.8.4.1 Urinary Excretion 
The most obvious consequence of ESRD is the absence of renal drug excretion. Indeed, 
the dosages of drugs that are predominantly excreted in the urine invariably require 
reduction to avoid accumulation in dialysis patients. There are many publications with 
recommendations on dosage adjustment for patients with kidney disease (Lam et al., 
1997; Gabardi and Abramson, 2005; Munar and Singh, 2007; Brater, 2009; Verbeeck and 
Musuamba, 2009; Matzke et al., 2011). Most often dosage recommendations are made 
based on the patient’s eGFR and should be based on clinical pharmacokinetic studies in 
patients with kidney disease. A notable example is the recent characterization of the 
pharmacokinetics of baclofen (Vlavonou et al., 2014). The authors evaluated baclofen’s 
pharmacokinetics in patients across the stages of CKD. As a result, they were able to 
recommend dosage reductions of 1/3, 1/2, and 2/3 for patients with mild, moderate or 
severe kidney dysfunction, respectively.  
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It is also important to consider the pharmacokinetics of metabolites that may have 
pharmacological activity. The majority of drugs undergo some degree of metabolism 
prior to renal excretion. Phase II drug metabolism typically adds a polar functional group 
to drug molecules, which promotes excretion by the kidney. Although glucuronidated 
metabolites typically have reduced pharmacological activity, there are important 
exceptions. For example, morphine-6-glucuronide is more potent than the parent drug 
morphine (Shimomura et al., 1971). Morphine pharmacokinetics are altered in patients 
with renal failure. Dialysis patients have a 2-fold increase in morphine AUC and are 
susceptible to morphine intoxication such as respiratory depression (Osborne et al., 1986; 
Osborne et al., 1993). Possibly of greater importance is the accumulation of the active 
metabolite morphine-6-glucuronide. Morphine-6-glucuronide AUC is over 4-fold greater 
in dialysis patients than patients with normal kidney function and high blood levels 
persist well beyond 24 hours (Osborne et al., 1993). 
An important consideration when contemplating dosage alteration in CKD is the method 
used to estimate GFR. It is important to note that the dosage recommendations for many 
drugs were made prior to standardization of laboratory techniques to measure serum 
creatinine. Therefore, it is possible that some recommendations may not be suitable for 
use with serum creatinine that has calibration traceable to an isotope dilution mass 
spectrometry method.  
Aside from decreases in GFR, kidney disease also impacts the expression of drug 
transporters that play a crucial role in renal drug elimination. Naud et al. determined the 
expression and activity of renal drug transporters in rats that underwent a 5/6 
nephrectomy (Naud et al., 2011). They found pronounced decreases in the expression of 
uptake transporters OAT1, OAT2, OAT3 and OATP4C1 along with a decreased 
expression of P-gp.  They also found significantly increased expression of the efflux 
transporters MRP2, MRP3 and MRP4. These data demonstrate that in addition to 
decreases in the filtration of drugs, kidney disease also changes the tubular secretion of 
drugs. The uremic toxin indoxyl sulfate has been shown to play a key role in the 
downregulation of renal OATP4C1 expression (Akiyama et al., 2013). Indoxyl sulfate 
causes increased expression of the transcription factor GATA3, which in turn 
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downregulates OATP4C1 expression. Therefore as renal disease progresses, indoxyl 
sulfate accumulates and in effect, shuts down OATP4C1 mediated renal transport. 
Human patients also appear to have decreased renal drug transporter expression. Patients 
with mild to moderate decreases in creatinine clearance have decreased OAT1 expression 
(Sakurai et al., 2004). It is currently unknown to what extent renal transporter expression 
changes in more severe kidney disease in human patients. 
1.8.4.2 Biliary Excretion 
The other major route of drug elimination is biliary excretion. Hepatic drug transporters 
predominantly mediate biliary drug excretion. Transporters such as OATP1B1, 
OATP1B3 and OATP2B1 are expressed on the sinusoidal membrane of hepatocytes and 
mediate the uptake of drugs into the hepatocyte. Multiple efflux transporters including P-
gp, BCRP and MRP2 are expressed on the canalicular membrane of hepatocytes and 
mediate the active efflux of drugs from the hepatocyte into the bile.  Rats with kidney 
disease have decreased protein expression of the uptake transporter OATP2 (Naud et al., 
2008). Similarly, there is evidence to suggest that OATP1B1 and OATP1B3 transporters 
are downregulated in humans. When normal human hepatocytes are incubated with 
uremic serum from patients, expression of OATP1B1 and OATP1B3 were decreased by 
approximately 60% (Fujita et al., 2014). These data suggest that hepatic uptake of OATP 
substrates is decreased in patients on dialysis. There is also evidence supporting the direct 
inhibition of drug transporters by uremic toxins. The protein bound uremic toxin, CMPF, 
has been shown to directly inhibit uptake of erythromycin in rat hepatocytes and SN-38, 
the active metabolite of irinotecan, in human hepatocytes (Sun et al., 2004; Fujita et al., 
2014).  Other protein bound uremic toxins including indoxyl sulfate, indole acetate and 
hippuric acid have demonstrated inhibition of OATP1B1 mediated uptake transport 
(Fujita et al., 2014). 
1.8.5 Altered Non-Renal Drug Clearance in Dialysis Patients 
Aside from dialytic clearance, prescribers must also consider that the non-renal clearance 
of several drugs is impacted by kidney disease. This is most likely a result of changes in 
the expression and activity of drug transporters and drug metabolizing enzymes and may 
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result in drug accumulation and unpredictable pharmacokinetics in HD patients. There 
are several clinical pharmacokinetic studies that have been done in HD patients. While a 
few examples are covered here, many others have been reviewed elsewhere (Nolin et al., 
2003; Dreisbach and Lertora, 2008; Nolin et al., 2008; Naud et al., 2012; Yeung et al., 
2014).   
Erythromycin is a macrolide antibiotic with minimal renal excretion. Erythromycin 
undergoes hepatic clearance and was once used as an indicator of CYP3A4 mediated 
metabolism (Watkins et al., 1989). More recent studies have identified an important role 
of the drug transporters OATP1B1 and P-gp in erythromycin clearance (Kurnik et al., 
2006; Lancaster et al., 2012). A study investigating the pharmacokinetics of erythromycin 
in anuric HD patients revealed a 31% decrease in hepatic clearance along with a 68% 
increase in the dose and weight adjusted AUC (Sun et al., 2010). Earlier studies also 
showed that HD patients had a 28% reduction in the erythromycin breath test, which was 
shown to partially recover following an HD session (Dowling et al., 2003; Nolin et al., 
2006). The data from these studies suggest that erythromycin hepatic clearance is 
decreased in HD as a result of decreased CYP3A4 mediated metabolism, OATP/P-gp 
mediated transport or a combination of both. The fact that dialysis restores the 
erythromycin breath test suggests that dialyzable uremic toxins are at least partially 
responsible for the altered hepatic clearance. Although the uremic toxin CMPF has been 
shown to decrease hepatic uptake of erythromycin (Sun et al., 2004), it is generally 
considered to be minimally dialyzed suggesting that other toxins are likely involved 
(Vanholder et al., 2003b; Neirynck et al., 2013).       
Other recent studies investigated the pharmacokinetics of fexofenadine in HD patients 
(Nolin et al., 2009; Thomson et al., 2015). Fexofenadine is widely used as a non-specific 
probe of drug transporters and exhibits negligible renal excretion. Fexofenadine 
pharmacokinetic parameters were substantially altered in HD patients compared to 
healthy controls (Nolin et al., 2009; Thomson et al., 2015).  HD patients had a 63% 
reduction in fexofenadine clearance, accompanied by significant increases in Cmax, T1/2, 
and AUC. These changes are likely mediated by a combination of increased 
bioavailability and decreased hepatic clearance.  Multiple transporters are involved in the 
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disposition of fexofenadine including OATP1B1 (Niemi et al., 2005), OATP1B3 
(Shimizu et al., 2005), P-gp (Cvetkovic et al., 1999), BSEP and MRP transporters 
(Matsushima et al., 2008). It is therefore difficult to delineate the specific transport 
pathways that are impacted in HD patients.  
Rosuvastatin is a hydroxy-methylglutaryl coenzyme A reductase inhibitor used in the 
treatment of hypercholesterolemia. Rosuvastatin is another drug that exhibits minimal 
renal excretion, is minimally metabolized, and largely undergoes transporter-mediated 
hepatic elimination into the bile. Despite not being renally eliminated, CKD patients with 
creatinine clearance less than 30 mL/min have been reported to have plasma 
concentrations 3-fold higher than healthy controls and accordingly, dose adjustments are 
recommended (Zhang et al., 2009). In contrast, studies in HD and PD patients 
demonstrate no clinically relevant changes in rosuvastatin pharmacokinetics compared to 
patients with normal kidney function (Bologa et al., 2009; Birmingham et al., 2013). 
These data highlight that the dialysis process itself impacts the interdialytic 
pharmacokinetics of drugs and the timing of the dose in relation to dialysis is likely 
important in determining the pharmacokinetics.   
It is important to note, that comorbidities associated with dialysis and non-dialysis 
dependent patients may also impact non-renal drug clearance. In addition to data 
implicating altered drug metabolism in CKD, patients with diabetes have been 
demonstrated to have decreased CYP3A4 mediated drug metabolism and increased 
CYP2E1 mediated metabolism (Dostalek et al., 2011). Accordingly, when considering 
pharmacokinetics in patients with kidney disease, it is important to consider the co-
morbidities of these patients and how they may impact drug disposition. In addition to 
pre-existing conditions, it is also possible that unintended aspects of the dialysis process 
itself may impact non-renal drug clearance. For example, there is evidence from studies 
in rodents that phthalate esters (e.g. di(2-ethylhexyl)phthalate) that leach from plastic 
tubing such as those used in dialysis can alter the expression of cytochrome P450 
enzymes (Parmar et al., 1994).  This requires confirmation in human studies with 
concentrations of phthalates found in dialysis patients.              
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1.9 Animal Models of CKD 
To understand the effects of CKD, animal models are commonly used with rapid onset 
pathogenesis. This allows for delineation of mechanisms in CKD that may take years to 
develop in patients. Ureteric obstruction of kidneys is a commonly used surgical model of 
CKD. Obstructing the ureter for greater than 72 hours results in permanent kidney 
damage and the development of CKD (Cochrane et al., 2005). A major disadvantage of 
this model is rapid and severe loss of kidney function that limits the study length. To 
extend the study length, partial ureteric obstruction has been used; however, this is 
generally performed in neonatal animals to limit complications and leads to variable and 
often mild CKD (Chevalier et al., 2009). The sub-total 5/6 nephrectomy is a well 
established model of progressive CKD (Hewitson and Becker, 2009). The 5/6 
nephrectomy is most commonly performed in rats and can be achieved using a ligation 
model or renal mass resection. The ligation model involves complete removal of one 
kidney and ligation of 2/3 of renal artery branches. The same unilateral nephrectomy is 
performed in the ablation model, along with a 2/3 nephrectomy of the other kidney for a 
5/6 total nephrectomy (Hewitson and Becker, 2009). The partially nephrectomized 
kidney keeps the animal alive while mimicking CKD. Drug induced models of kidney 
disease have also been characterized. The use of doxorubicin, a nephrotoxic 
chemotherapeutic agent, can result in interstitial fibrosis after 6 weeks of treatment in 
mice (Wang et al., 2000).  
The use of adenine-induced tubular obstruction is also a common model for the induction 
of progressive CKD. In this model, animals are orally administered up to 0.75% adenine 
supplemented into the diet. The adenine metabolite 2,8-dihydroxyadenine precipitates in 
the proximal tubule epithelia, causing tubule damage (Terai et al., 2008). Adenine 
induced CKD is reversible after 2 weeks of treatment; however 4-6 weeks of adenine 
supplemented diet results in permanent kidney damage. Rats are commonly used for this 
model and after 4-6 weeks of treatment they experience dilation of tubules, interstitial 
fibrosis and calcification of tubule basement membranes (Terai et al., 2008; Hewitson 
and Becker, 2009). The adenine-induced kidney disease model results in a more 
consistent progression of CKD with less variability than the 5/6 nephrectomy and does 
37 
 
not require the technical expertise of performing surgery (Terai et al., 2008). However, 
there are disadvantages to using the adenine model, most notably the limited food 
consumption in the first week. This results in minimal weight gain during this period and 
therefore, control animals must be pair-fed to CKD animals (Terai et al., 2008). 
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2 HYPOTHESES AND SPECIFIC AIMS 
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2.1 Focus of the thesis 
In Canada, 1 in 10 people have some form of CKD and these patients take many 
medications to manage their CKD and associated illnesses. Therefore, understanding 
altered pharmacokinetics for patients with CKD is an important health concern. 
The pharmacokinetics of many drugs are altered in CKD (Bianchetti et al., 1976; 
Osborne et al., 1993; Uehlinger et al., 1996; Marbury et al., 2000; Dowling et al., 2003; 
Dreisbach et al., 2003; De Martin et al., 2006; Periclou et al., 2006; Nolin et al., 2009; 
Zhang et al., 2009; Sun et al., 2010). The most common alteration is a decrease in drug 
elimination resulting in increased plasma concentrations and heightened risk for drug 
toxicity. For many years, it has been appreciated that drugs primarily excreted by the 
kidney require dosage adjustment in patients with ESRD. More recently, there are several 
examples of altered non-renal drug clearance in ESRD patients complicating effective 
pharmacotherapy in this highly medicated patient population (Nolin et al., 2009; Zhang et 
al., 2009; Sun et al., 2010). Highlighting the importance of altered pharmacokinetics in 
CKD, the Food and Drug Administration (FDA) published a guidance document in 1998 
in order to help direct industry to conduct appropriate pharmacokinetic studies in the 
setting of kidney disease (Food and Drug Administration, 1998). This initial document 
was updated in 2010 but currently remains as a draft and has not been formally 
implemented.  The updated draft includes the recommendation to assess drugs that are 
primarily secreted or metabolized in the liver. Therefore, research is required to provide 
information for regulatory bodies, such as the FDA and Health Canada, to implement 
appropriate drug development guidelines and ensure drug safety in patients with CKD.  
 
My overall hypothesis is that hepatic drug metabolism is altered in CKD 
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2.2 Specific Aim 1  
To determine if hepatic drug metabolism is altered in early stages of CKD 
Many of the studies assessing hepatic drug metabolism in CKD have evaluated patients 
or animals with ESRD or severe renal disease, respectively. Although this research has 
been essential in establishing a premise for the effect of CKD on hepatic drug 
metabolism, the majority of patients with CKD are in stages 1 to 3. Therefore, in Chapter 
3, we evaluate hepatic drug metabolizing enzyme function and expression using a model 
of surgically induced moderate CKD.  
I hypothesize that induction of moderate and severe CKD will produce a 
corresponding decrease in liver CYP2C11 and CYP3A2 function and expression 
using rat partial nephrectomy models. Sprague-Dawley rats were subjected to surgical 
procedures that allowed the generation of three distinct models of kidney function: 
normal kidney function, moderate and severe kidney disease. Forty-two days following 
surgery, rats were sacrificed and hepatic CYP2C11 and CYP3A expression was evaluated 
by western blot and qPCR. In addition, enzymatic activity was determined in liver 
microsomes by evaluating midazolam (CYP3A), testosterone (CYP3A and CYP2C) and 
tolbutamide (CYP2C) Michaelis-Menten kinetics in CKD. When the degree of kidney 
disease was correlated with metabolic activity, an exponential decline in CYP2C and 
CYP3A mediated metabolism was observed. Our data suggest that drug metabolism is 
significantly decreased in earlier stages of CKD and imply that patients with moderate 
CKD may be subject to unpredictable pharmacokinetics. 
  
2.3 Specific Aim 2 
To identify possible mechanisms by which hepatic drug-metabolizing enzyme 
function and expression are altered in CKD 
CYP2C and CYP3A drug-metabolizing enzymes play a critical role in determining the 
pharmacokinetics of many prescribed medications. These enzymes are transcriptionally 
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regulated by the nuclear receptors PXR and HNF4-α. Expression of CYP2C and CYP3A 
is decreased in CKD; however, the mechanism by which this occurs is unknown.  
Therefore, in Chapter 4, we investigate possible mechanisms of CYP2C and CYP3A 
downregulation in CKD. I hypothesize that altered drug metabolism in CKD is 
secondary to decreased nuclear receptor binding to the promoters of CYP2C and 
CYP3A as a result of histone modulation. We induced CKD in rats by 5/6 
nephrectomy and used chromatin immunoprecipitation (ChIP) to determine nuclear 
receptor and epigenetic alteration mediated differences in the promoter region of the 
CYP2C and CYP3A genes. This study suggests that decreased nuclear receptor binding 
and histone acetylation may contribute to the mechanism of drug-metabolizing enzyme 
down-regulation and altered pharmacokinetics in CKD. 
 
2.4 Specific Aim 3 
To determine the metabolic changes in plasma, liver, heart and kidney tissue as well 
as the metabolic axis between these biological matrices in rats with CKD. 
CKD results in the accumulation of metabolic waste products that are normally cleared 
by the kidney, known as uremia. Many of these waste products are derived from bacteria 
metabolites in the gut. Accumulation of uremic toxins in plasma and tissue, as well as the 
gut-plasma-tissue metabolic axis is important for understanding pathophysiological 
mechanisms of comorbidities and altered hepatic drug metabolism in CKD.  
I hypothesize that gut-derived uremic toxins accumulate in both plasma and tissue 
in CKD. In Chapter 5, an untargeted metabolomics approach was used to determine 
uremic toxin accumulation in plasma, liver, heart and kidney tissue in rats with adenine-
induced CKD. Rats with CKD were also given AST-120, a spherical carbon adsorbent, to 
assess metabolic changes in plasma and tissues with the removal of gut-derived uremic 
toxins. A combination of multivariate and univariate statistics was used to identify 
significant metabolic signatures in uremia. CKD was primarily defined by 8 gut-derived 
uremic toxins, which were significantly increased in plasma and all studied tissues. Our 
62 
 
results highlight the importance of diet and gut-derived metabolites in the accumulation 
of uremic toxins and define the gut-plasma-tissue metabolic axis in CKD. 
 
2.5 Specific Aim 4 
To determine which uremic toxins cause down-regulation of hepatic drug 
metabolizing enzymes in CKD. 
In Aim 3 (Chapter 5), we identify a number of gut-derived uremic toxins that accumulate 
in both plasma and liver as a result of CKD. Therefore, it is possible that these uremic 
toxins are involved in the downregulation of hepatic drug metabolizing enzymes. To 
investigate this further, the first aim of this study was to identify which uremic toxin(s) 
cause the down-regulation of hepatic CYP3A in vitro. The second aim of this study was 
to determine if gut-derived uremic toxins down regulate hepatic drug metabolizing 
enzymes in rats with CKD.  
I hypothesize that the removal of gut-derived uremic toxins, using AST-120, would 
recover expression and function of hepatic CYP2C and CYP3A in rats with CKD. 
Prior to testing this hypothesis, various uremic toxins were screened for their effects on 
CYP3A4 expression using human hepatoma (Huh7) cells. This screen provided evidence 
of indoxyl sulfate causing a concentration-dependent decrease of CYP3A4 expression. 
Subsequently, hepatic drug metabolizing enzymes were evaluated in vivo using an 
adenine-induced model of CKD followed by administration of AST-120 to remove gut-
derived uremic toxins. AST-120 did not significantly recover CYP2C and CYP3A 
function and expression in rats with CKD. Our in vitro results suggest that indoxyl sulfate 
may contribute to the downregulation of CYP3A4 in CKD; however, hepatic CYP2C and 
CYP3A function and expression were not significantly recovered in CKD by removal of 
gut-derived uremic toxins in vivo. 
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3.1 Introduction 
CKD is a progressive condition characterized by the decrease in GFR over time. The 
incidence of CKD is increasing at an alarming rate and these patients require more than 
seven medications to manage both their CKD and associated co-morbidities (Talbert, 
1994). Drug therapy in patients with CKD is complicated as these patients frequently 
experience unpredictable pharmacokinetics resulting in an increased incidence of 
medication-related adverse events (Manley et al., 2005). Although it is appreciated that 
renal clearance of drugs is compromised in CKD, recent studies have demonstrated that 
kidney failure also affects non-renal drug clearance (Leblond et al., 2001; Naud et al., 
2008; Nolin et al., 2009). The non-renal clearance of drugs is principally mediated by 
hepatic drug metabolism. CYP3A4, a member of the cytochrome P450 family of drug 
metabolizing enzymes, is involved in the oxidative metabolism of up to 50% of all drugs 
on the market (Wrighton et al., 1996). Elegant studies in experimental animal models of 
severe CKD have demonstrated a reduction in the function and expression of CYP3A and 
other members of the CYP family (Leblond et al., 2000; Leblond et al., 2002). 
The Kidney Early Evaluation Program (KEEP, 2000 to 2010) and the National Health 
and Nutritional Examination Survey (NHANES, 1996 to 2006) have estimated the 
prevalence of kidney disease to be greater than 14% in the United States (KEEP, 2011; 
McCullough et al., 2011; Stevens et al., 2011). The majority of animal and clinical 
studies investigating the effect of CKD on non-renal drug clearance have focused solely 
on severe CKD. Patients studied in the majority of these publications are on dialysis 
despite the fact that severe CKD patients comprise approximately 3% of the total number 
of patients with CKD (KEEP 2000 to 2009, NHANES 1999 to 2006). According to 
KEEP, 11%, 19% and 67% of patients with CKD are in stages 1, 2 and 3, respectively 
(KEEP, 2011). Therefore, patients with mild and moderate kidney disease comprise the 
majority (97%) of the population of patients with CKD. Few studies have evaluated 
pharmacokinetics and drug metabolism in varying degrees of kidney disease despite the 
fact that CKD is known to be a progressive disorder whereby kidney function declines 
over time. Clinical studies in patients with varying degrees of CKD have demonstrated 
altered lidocaine and nicardipine pharmacokinetics; however, these drugs are metabolized 
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by multiple P450 enzymes and are influenced by other pharmacokinetic factors in kidney 
disease, such as changes in plasma protein binding (Ahmed et al., 1991; De et al., 2006). 
Consequently, there is a lack of data investigating the effects of CKD on specific drug 
metabolizing enzymes in the majority of the patient population. This void in the literature 
has been highlighted in a recent review (Naud et al., 2012).  
The objective of this study was to determine if decreases in hepatic drug metabolizing 
enzymes observed in severe CKD are also seen at earlier stages of disease progression. 
To address this, we employed a combination of surgical kidney resection and partial renal 
artery ligation in rats to establish a novel model of CKD with two different degrees of 
kidney disease. Upon establishing this model, we assessed hepatic expression and 
function of the predominant P450 isoforms, CYP3A and CYP2C. In order to fully 
elucidate the effect of CKD progression on enzyme function, full enzyme kinetics of 
selected probe drugs was used to characterize the metabolic activity of these enzymes 
across the continuum of disease progression. 
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3.2 Methods 
3.2.1 Chemical Reagents and Drugs 
Midazolam, 1’OH-midazolam, 4’OH-midazolam, OH-tolbutamide and ketoconazole 
were purchased from Toronto Research Chemicals (Toronto, ON). Testosterone, 6βOH-
testosterone, 16αOH-testosterone were purchased from Steraloids Inc. (Newport, RI). 
Flurazepam and carbamazepine were purchased from Cerilliant (Round Rock, TX) and 
tolbutamide was purchased from Sigma (St. Louis, MO).  
3.2.2 Experimental Model 
Seventeen male Sprague-Dawley rats, weighing 150 g, were obtained from Charles River 
Laboratories, Inc. (Wilmington, MA). The animals were maintained on standard rat chow 
and water ad libitum on a 12 hour light cycle. Rats were allowed to acclimatize for at 
least 3 days before any experimental procedure was undertaken. The animal protocols 
were approved by the University of Western Ontario Animal Care Committee (Appendix 
A). 
3.2.3 Surgical Induction of Kidney Disease 
Studies were performed in three experimental groups, which simulated normal kidney 
function (n = 6) as well as moderate (n = 7) and severe (n = 4) kidney disease. Moderate 
and severe kidney disease were surgically induced by modification of a standard two-
stage partial nephrectomy. Atropine (0.04 mg/kg SC) was given prior to anaesthesia in 
addition to intramuscular xylazine (5 mg/kg) and ketamine (100 mg/kg).  Anaesthesia 
was maintained with 2% isoflurane in oxygen via facemask throughout all surgical 
procedures. On day zero, rats in the moderate kidney disease group underwent a one-third 
partial nephrectomy of the left kidney. Rats in the severe kidney disease group were 
subjected to the same procedure plus ligation of one branch of the left renal artery to 
mitigate the perfusion of blood to the remaining kidney. Seven days later, a complete 
right nephrectomy was performed on both moderate and severe kidney disease groups as 
previously reported (Leblond et al., 2000). Rats in the control group underwent sham 
laparotomies. All rats were given ketoprofen (5 mg/kg, IM) pre-operatively and every 24 
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hours post-operation for 3 days. All rats were weighed daily to monitor health. Control 
and moderate kidney disease rats were pair-fed the same amount of standard rat chow 
that was ingested by severe kidney disease rats on the previous day. Forty two days after 
the initial surgery rats were sacrificed and liver tissue was harvested, flash frozen in 
liquid nitrogen and stored at -80°C. Serum creatinine and urea concentrations were 
determined by the London Laboratory Services Group by standard methods (London, 
ON). 
3.2.4 Real-time PCR Analysis 
Total RNA was extracted using Trizol Reagent (Life Technologies Inc. Burlington, ON) 
according to the manufacturer’s instructions. RNA concentration and purity were 
measured by spectrophotometry. Total RNA was reverse transcribed using iScript RT-
qPCR Supermix (Bio-rad Hercules, CA) in a 20 µL reaction volume. Primer pairs used 
were as follows: CYP3A2 (forward) 5′-GCTCTTGATGCATGGTTAAAGATTTG-3′ 
and (reverse) 5′-ATCACAGACCTTGCCAACTCCTT-3′ (Baldwin et al., 2006), 
CYP2C11 (forward) 5′-CCCTGAGGACTTTTGGGATGGGC-3′ and (reverse) 5′-
AGGGGCACCTTTGCTCTTCCTC-3′ and β-actin (forward) 5′-
ACGAGGCCCAGAGCAAGA-3′ and (reverse) 5′-TTGGTTACAATGCCGTGTTCA-3′ 
(Sohi et al., 2011). Real-time PCR was performed using SsoFast Evagreen® (Bio-rad 
Hercules, CA) and expression was analyzed using the ΔΔCT normalized to β-actin. 
3.2.5 Hepatic Microsome Isolation 
Liver microsomes were isolated by differential centrifugation according to a slightly 
modified method by Kurosawa et al. (Kurosawa et al., 2009). Briefly, liver tissue was 
rinsed in 0.9% NaCl solution and homogenized in 1.15% KCl containing 1 mM 
ethylenediaminetetraacetic acid (EDTA) using a Potter-Elvehjem tissue grinder. The 
homogenate was centrifuged at 9000 g for 20 min at 4°C and the subsequent supernatant 
was centrifuged at 105 000 g for 60 min at 4°C. The microsomal pellet was resuspended 
in 100 mM potassium phosphate buffer containing 20% glycerol at pH 7.4 and protein 
concentration was determined by Pierce BCA protein assay (Fisher Scientific, Whitby, 
ON, Canada). Microsomal protein was stored at -80°C until analysis. 
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3.2.6 Western Blot Analysis 
Protein expression of CYP3A2 and CYP2C11 was assessed in hepatic microsomal 
fractions using Western blot analysis. Twenty five µg of microsomal protein was 
electrophoresed on a 10% polyacrylamide gel containing 0.1% sodium dodecyl sulfate. 
Proteins were transferred to nitrocellulose and immunoblots were performed according to 
antibody manufacturer’s recommendation. Immune complexes were revealed by 
horseradish peroxidase (Millipore, Billerica, MA) and band intensity was determined by 
densitometry (Quantity One 1-D Analysis Software on a VersaDoc Imaging System, Bio-
Rad, Hercules, CA). Primary antibodies for CYP3A2 (monoclonal rabbit anti-rat) were 
obtained from Millipore (Billerica, MA), CYP2C11 (monoclonal mouse anti-rat) from 
Detroit R&D Inc. (Detroit, MI) and actin (polyclonal rabbit anti-rat, chicken, mouse 
human) from Sigma (St. Louis, MO). Horseradish peroxidase (HRP)-linked secondary 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). LuminataTM 
Forte Western HRP substrate was obtained from Millipore (Billerica, MA). CYP450 
antibody specificities were determined using SupersomesTM obtained from BD 
Biosciences (Mississauga, ON) (Supplementary Fig. C1, Appendix C). 
3.2.7 Hepatic Metabolism of CYP3A and CYP2C substrates 
Metabolic activity of CYP3A and CYP2C in hepatic microsomes was determined using 
specific probe substrates.  Midazolam and testosterone were selected as probes for 
CYP3A, and testosterone and tolbutamide were selected as a probe for CYP2C enzyme 
activity. These probe substrates were selected based on their previously documented 
selective metabolism by specific rat P450 isozymes (Chovan et al., 2007). Reactions 
(final volume 250 µL) were conducted in 50 mM potassium phosphate buffer, 2 mM 
MgCl2 (pH 7.4) with 1 mg/mL of hepatic microsomal protein. Prior to experimentation, 
linear rate of production of metabolites was determined by varying time, protein and 
relevant substrate concentrations. Metabolism was determined to be linear at 10 minutes 
for formation of testosterone metabolites (6β-OH testosterone and 16α-OH testosterone) 
and 30 minutes for formation of midazolam (1’-OH midazolam, 4’-OH midazolam) and 
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tolbutamide (OH-tolbutamide) metabolites. All reactions were conducted at 37°C and 
were started by the addition of a relevant concentration of substrate drug (midazolam, 
testosterone or tolbutamide) followed by 1 mM NADPH. At the end of the incubation, 
reactions were terminated with 50 µL of ice-cold acetonitrile followed by a 15 minute 
incubation on ice and centrifugation to pellet precipitated protein (Chovan et al., 2007).  
3.2.8 Metabolite Analysis by UPLC-PDA 
Metabolite analysis was conducted by solid phase extraction followed by ultra-
performance liquid chromatography with photodiode array detection (UPLC-PDA). Solid 
phase extraction cartridges (C18, Strata-X Polymeric Reverse Phase 33 µm, 
Phenomenex, Torrance, CA) were conditioned according to manufacturer’s 
specifications. Flurazepam was used as an internal standard for midazolam and 
tolbutamide quantification and carbamazepine was used as an internal standard for 
testosterone quantification. Analytes and internal standard were passed across the 
packing by gravity after which the cartridges were washed with 1 mL of nano-pure water 
followed by 1 mL of 50/50 methanol/water (for midazolam and testosterone extraction) 
or 1 mL of 5% methanol/water (for tolbutamide extraction). Analytes were eluted into 
clean glass test tubes with 1 mL of methanol containing 0.1% triethylamine and 0.1% 
trifluoroacetic acid. The eluent was dried, reconstituted in mobile phase and injected on 
either a Waters Acquity UPLCTM BEH C18 column (1.7 µm particle size, 50 X 2.1 mm) 
for testosterone analyte separation or a Waters Acquity UPLCTM BEH Shield RP C18 
column (1.7 µm particle size, 50 X 2.1 mm) for midazolam and tolbutamide analyte 
separation. The columns were maintained at 40°C in a Waters Acquity UPLCTM H-Class 
System. The mobile phase flow was maintained at 0.8 mL/min and consisted of 10 mM 
KH2PO4 (pH = 3.0), acetonitrile and methanol. Mobile phase ratios and gradients for each 
assay are summarized in Supplementary Table C1 (Appendix C).  An ACQUITY 
UPLC® PDA detector was used to detect midazolam (254 nm), tolbutamide (230 nm) 
and testosterone (245 nm for testosterone and 290 nm for carbamazepine) for 
quantification. The inter-assay coefficients of variation for 1’OH-midazolam, 4’OH-
midazolam, 6β-OH testosterone, 16α-OH testosterone, and OH-tolbutamide were 10.7%, 
23.1%, 3.1%, 3.2%, and 5.6%, respectively. The intra-assay coefficients of variation for 
72 
 
1’OH-midazolam, 4’OH-midazolam, 6β-OH testosterone, 16α-OH testosterone and OH-
tolbutamide were 2.7%, 5.0%, 3.2%, 3.2% and 8.6%, respectively. 
3.2.9 Data Analysis and Statistical Procedures 
A Michaelis-Menten model was used to fit the formation of midazolam, testosterone and 
tolbutamide metabolites. Maximum reaction rate of enzyme (Vmax) and Michaelis 
constant (Km) were calculated using GraphPad Prism (version 5.00 for Windows, 
GraphPad Software, San Diego, CA). Correlations were performed using Spearman’s 
rank test. Statistical analysis between control, moderate and severe kidney disease groups 
was performed using one-way ANOVA followed by Tukey’s multiple comparison tests. 
Data are presented as mean ± SEM and a p-value less than 0.05 was considered 
significant. 
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3.3 Results 
3.3.1 Serum Biochemistry 
A rat 5/6 nephrectomy model has been used extensively as an animal model for severe 
CKD (Leblond et al., 2000; Michaud et al., 2006; Michaud et al., 2010). We employed 
variations of this surgical procedure to generate rats with moderate or severe CKD. Rats 
that underwent sham laparotomy (control), 2/3 nephrectomy and 2/3 nephrectomy plus 
vessel ligation surgeries resulted in three distinct degrees of kidney function (control, 
moderate CKD and severe CKD; respectively). This is represented by 1.65-fold and 4.78-
fold higher serum creatinine levels in moderate and severe CKD, respectively, compared 
to control (p < 0.05, Table 3.1). Rats in the severe CKD group also had significantly 
higher serum creatinine levels than those with moderate kidney disease (p < 0.05). Serum 
urea concentrations were higher in severe kidney disease compared to control and 
moderate CKD rats (p < 0.05). There was no difference in body weight between the 
groups (Table 3.1). One rat with severe CKD was euthanized prior to completion of the 
study. 
3.3.2 CYP3A2 and CYP2C11 mRNA and Protein Expression 
An 88% and 99.6% decrease in hepatic CYP3A2 mRNA expression was demonstrated in 
moderate and severe kidney disease rats, respectively, compared to controls (Fig. 3.1A, p 
< 0.05). Similarly, CYP2C11 mRNA expression in moderate and severe CKD was 
decreased by 77% and 95%, respectively, compared to controls (Fig. 3.1B). When 
mRNA expression was correlated with serum creatinine, there was a significant 
exponential decrease in both CYP3A and CYP2C mRNA expression as serum creatinine 
levels increased (Fig. 3.1C rs = -0.785 and Fig. 3.1D rs = -0.809, respectively; p < 0.05). 
Similar to mRNA expression, CYP3A2 and CYP2C11 protein expression were 
significantly decreased in both moderate and severe CKD. CYP3A2 protein expression 
was decreased by 75% and 91% in moderate and severe kidney disease rats, respectively, 
compared to controls (Fig. 3.2A, p < 0.05). Likewise, a reduction in CYP2C11 
expression was also demonstrated in moderate (41%) and severe (68%) kidney disease  
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Table 3.1 Physical and biochemical characteristics of control, moderate and severe 
kidney disease rats. 
 Control Moderate CKD Severe CKD 
Number of Rats 6 7 4 
Body Weight (g) 478 ± 20 448 ± 17 419 ± 10 
Serum Creatinine (µM) 23 ± 1 38 ± 1* 110 ± 10***,††† 
Serum Urea (mM) 6.1 ± 0.5 9.1 ± 0.6 23.35 ± 3.1***,††† 
Data are presented as means ± SEM. 
*p < 0.05 compared to control. 
***p < 0.001compared to control. 
†††p < 0.001 compared to moderate CKD. 
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Figure 3.1 mRNA expression of hepatic P450s in control, moderate and severe kidney 
disease rats.  
mRNA expression of hepatic CYP3A2 (A) and CYP2C11 (B) in control, moderate and 
severe kidney disease rats. Correlation between hepatic CYP3A2 (p < 0.001) (C) and 
CYP2C11 (p < 0.001) (D) mRNA expression with serum creatinine levels of control (○), 
moderate (□) and severe (Δ) kidney disease rats. Expression of CYP3A2 and CYP2C11 
was normalized to expression of the housekeeping gene β-actin. Analysis was performed 
in triplicate and results are presented as mean ± SEM, n ≥ 4 (A, B) or means of triplicates 
(C, D), **p < 0.01 compared to control.  
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Figure 3.2 Protein expression of hepatic P450s in control, moderate and severe kidney 
disease rats. 
Protein expression of hepatic CYP3A2 (A) and CYP2C11 (B) in control, moderate and 
severe kidney disease rats. Correlation between hepatic CYP3A2 (p < 0.001) (C) and 
CYP2C11 (p < 0.01) (D) protein expression with serum creatinine of control (○), 
moderate (□) and severe (Δ) kidney disease rats. Protein bands are expressed in 
densitometry units (%) and are standardized to actin. Control bands were arbitrarily 
defined as 100%. Experiments were performed in duplicate and results are presented as 
mean ± SEM, n ≥ 4 (A, B) or means of duplicates (C, D), *p < 0.05, **p < 0.01, ***p < 
0.001 compared to control. Representative blots are shown. 
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compared to controls (Fig. 3.2B, p < 0.05). Both CYP3A2 and CYP2C11 protein 
expression showed a significant inverse exponential relationship with serum creatinine 
levels. (Fig. 3.2C rs = -0.820 and Fig. 3.2D rs= -0.665, respectively; p < 0.05). 
3.3.3 Hepatic CYP3A and CYP2C Mediated Drug Metabolism 
To determine the effect of varying degrees of kidney disease on hepatic CYP3A function, 
we evaluated the metabolism of CYP3A probe drugs, midazolam and testosterone, using 
rat liver microsomes. Both 1’-OH midazolam and 4’-OH midazolam are produced by 
CYP3A (Chovan et al., 2007) and full enzyme kinetics of these metabolites were 
determined in this study. Vmax values for 1’-OH midazolam production was significantly 
reduced by 62% and 72%, respectively, in moderate and severe kidney disease groups 
compared to control (Fig. 3.3A; p < 0.05). 4’OH-midazolam production was reduced by 
63% and 75%, respectively, in moderate and severe CKD compared to controls (Fig. 
3.3B; p < 0.05). The formation of 6βOH-testosterone is also specifically catalyzed by 
CYP3A dependent mechanisms (Chovan et al., 2007). A 66% and 68% decrease in 
6βOH-testosterone Vmax was demonstrated in moderate and severe kidney disease groups, 
respectively, compared to controls (Fig. 3.3C). Michaelis-Menten kinetic parameters for 
1’-OH midazolam, 4’-OH midazolam and 6βOH-testosterone are summarized in Table 
3.2. A significant inverse correlation was found between Vmax values for 1’-OH 
midazolam, 4’-OH midazolam and 6βOH-testosterone formation and serum creatinine 
levels (Fig. 3.3D rs = -0.818, Fig. 3.3E rs = -0.750 and Fig 3.3F rs = -0.742, respectively; 
p < 0.05). Hepatic CYP2C enzyme activity was evaluated using the probe drugs 
testosterone and tolbutamide. Testosterone is specifically metabolized to 16αOH-
testosterone by CYP2C11. CYP2C11 Vmax was significantly decreased by 67% and 82% 
in moderate and severe kidney disease rats, respectively (Fig. 3.4A). An inverse 
correlation was also demonstrated between Vmax values for 16αOH-testosterone 
production and serum creatinine (Fig. 3.4C rs = -0.742, p < 0.05). Hepatic CYP2C 
function was also characterized by evaluating tolbutamide metabolism. Formation of OH-
tolbutamide was unchanged between control, moderate and severe kidney disease groups 
(Fig. 3.4B) and there was no correlation between OH-tolbutamide Vmax and serum 
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creatinine (Fig. 3.4D). Michaelis-Menten kinetic parameters for 16αOH-testosterone and 
OH-tolbutamide are presented in Table 3.3. 
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Figure 3.3 Michaelis-Menten kinetics of CYP3A enzyme function in rat liver 
microsomes from control, moderate and severe kidney disease groups. 
Michaelis-Menten plots of 1’OH-midazolam (A), 4’OH-midazolam (B) and 6β-OH 
testosterone (C) after incubation of rat liver microsomes with 1 mM NADPH and various 
concentrations of midazolam (A and B) or testosterone (C). Correlation between 1’OH-
midazolam Vmax (D) (p < 0.001), 4’OH-midazolam Vmax (E) (p < 0.01) and 6β-OH 
testosterone Vmax (F) (p < 0.001) with serum creatinine of control (○), moderate (□) and 
severe (Δ) kidney disease rats. Experiments were performed in duplicate and results are 
presented as mean ± SEM, n ≥ 4 (A, B, C) or means of duplicates (D, E, F).  
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Table 3.2 Michaelis-Menten kinetic values for CYP3A probe substrates in control, 
moderate and severe kidney disease rat liver microsomes. 
 
1’OH-midazolam 4’OH-midazolam  6β-OH Testosterone 
Km  
(µM) 
Vmax 
(pmol min-1 
mg protein-1) 
Km  
(µM) 
Vmax 
(pmol min-1 
mg protein-1) 
Km  
(µM) 
Vmax 
(pmol min-1 
mg protein-1) 
Control 
39.98 ± 
7.33 
19.64 ± 2.38 
29.11 ± 
2.78 
20.80 ± 5.07 
178.7 ± 
26.9 
186.10 ± 17.76 
Moderate 
CKD 
16.63 ± 
2.18* 
7.41 ± 1.04*** 
16.18 ± 
4.00 
7.61 ± 2.38* 
329.8 ± 
60.4 
62.38 ± 13.30*** 
Severe  
CKD 
28.66 ± 
9.94 
5.57 ± 0.32*** 
20.41 ± 
9.06 
5.12 ± 1.14* 
411.4 ± 
125.9 
58.80 ± 11.90*** 
Data are presented as means ± SEM. 
*p < 0.05 compared to control. 
**p < 0.01 compared to control. 
***p < 0.001 compared to control. 
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Figure 3.4 Michaelis-Menten kinetics of CYP2C enzyme function in rat liver 
microsomes from control, moderate and severe kidney disease groups. 
Michaelis-Menten plots of 16αOH-testosterone (A) and OH-tolbutamide (B) after 
incubation of rat liver microsomes with 1 mM NADPH and various concentrations of 
testosterone and tolbutamide, respectively. Relationship between 16αOH-testosterone 
Vmax (C) (p < 0.001) and OH-tolbutamide Vmax (D) with serum creatinine of control (○), 
moderate (□) and severe (Δ) kidney disease rats. Experiments were performed in 
duplicate and results are presented as mean ± SEM, n ≥ 4 (A, B) or means of duplicates 
(C, D). 
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Table 3.3 Michaelis-Menten kinetic values for CYP2C probe substrates in control, 
moderate and severe kidney disease rat liver microsomes. 
 
16α-OH Testosterone OH-Tolbutamide 
Km  
(µM) 
Vmax 
(pmol min-1mg 
protein-1) 
Km  
(µM) 
Vmax 
(pmol min-1 mg 
protein-1) 
Control 215.1 ± 64.6 432.6 ± 75.7 674.4 ± 72.1 1408 ± 115 
Moderate CKD 257.8 ± 37.3 144.4 ± 38.3** 565.7± 68.3 1239 ± 103  
Severe  
CKD 
233.3 ± 81.8 76.83 ± 20.9** 626.5 ± 49.2 1384 ± 197 
Data are presented as means ± SEM. 
**p < 0.01 compared to control. 
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3.4 Discussion 
A number of studies have shown altered hepatic CYP expression in severe CKD (Uchida 
et al., 1995; Leblond et al., 2000; Leblond et al., 2001). Major rat drug metabolizing 
isoforms investigated have included CYP1A2, CYP2C6, CYP2C11, CYP2D, CYP2E1 
and CYP3A1/2. Of these isoforms, CYP2C11 and CYP3A1/2 continually appear 
downregulated in severe CKD (Uchida et al., 1995; Leblond et al., 2001; Guevin et al., 
2002; Rege et al., 2003). Our results indicate that CYP3A2 and CYP2C11 protein 
expression are decreased by 75% and 40% in moderate kidney disease, respectively. This 
profound decrease in protein expression is similar to the decrease seen in severe kidney 
disease. Clinically, this suggests that patients with earlier stages of CKD are likely to 
experience variable and unpredictable pharmacokinetics and drug response when taking 
standard doses of drugs that are substrates for CYP3A and CYP2C. These results may 
help explain the increased incidence of medication related adverse events in patients with 
CKD (Manley et al., 2005). 
Previous studies have suggested that protein downregulation is the result of a reduction in 
mRNA for hepatic CYP3A2 and CYP2C11 (Leblond et al., 2001). Our study provides 
further evidence of this notion as both moderate and severe kidney disease resulted in 
reduced CYP3A2 and CYP2C11 protein expression that is secondary to decreased 
mRNA. A possible cause for this decrease may be due to uremic toxin accumulation in 
moderate and severe CKD. Recent studies have shown that uremic toxins can cause direct 
inhibition or down-regulation of drug metabolizing enzymes and drug transporters 
(Tsujimoto et al., 2010; Reyes and Benet, 2011). In this study, it appears that uremic 
toxins are interfering with the regulation of drug metabolizing enzyme transcription. 
Indeed, rat hepatocytes treated with pre-dialysis serum from human ESRD patients 
exhibit down-regulation of CYP3A and CYP2C. This affect was alleviated by the 
addition of an NF-κB inhibitor suggesting that uremic toxins may be activating the NF-
κB pathway (Michaud et al., 2005). The uremic toxin, indoxyl sulfate, has been shown to 
activate NF-κB in proximal tubule cells and enhance the infiltration of monocytes to 
uremic kidneys (Miyazaki et al., 1997). Furthermore, down-regulation of hepatic CYP 
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expression has been noted in inflammation-associated pathological states occurring in 
other organs (Renton and Nicholson, 2000). 
The majority of studies demonstrating decreased hepatic CYP3A function in severe CKD 
have used erythromycin as a CYP3A probe (Leblond et al., 2000; Leblond et al., 2001; 
Sun et al., 2004). Although erythromycin is metabolized by CYP3A, its disposition is 
determined by the interplay between transport and metabolism (Sun et al., 2010). This 
confounds its use as a specific CYP3A probe for whole cell and in vivo studies (Sun et 
al., 2004). Pharmacokinetic studies in patients with varying degrees of kidney function 
have also used a variety of non-selective probe substrates for P450 enzymes (Ahmed et 
al., 1991; De et al., 2006). Although these studies clearly highlight that drug metabolism 
is differentially affected as kidney function declines, it is impossible to draw mechanistic 
conclusions about which specific P450 isozymes are affected. An alternate approach is to 
use midazolam, a selective phenotypic probe for CYP3A, which is not a substrate for 
uptake or efflux drug transporters (Nolin et al., 2009). In the present study, we evaluated 
the function of CYP3A using the well-established probe substrates, midazolam and 
testosterone (Guengerich, 1999; Dostalek et al., 2011). Our results demonstrate that as 
kidney function declines, there is a rapid decrease in CYP3A enzymatic activity. 
CYP2C function has been assessed in severe CKD using the aminopyrine breath test 
(Leblond et al., 2000). Although aminopyrine is metabolized by CYP2C enzymes, it is 
also metabolized by many other P450 isoforms, such as CYP1A2 and CYP3A (Tanaka 
and Breimer, 1997). In our study, CYP2C mediated metabolism of tolbutamide to OH-
tolbutamide was unchanged in CKD. Tolbutamide is a CYP2C family drug probe but is 
not specific for CYP2C11 (Cribb et al., 1995; Brown et al., 2007; Dostalek et al., 2007). 
Therefore, other CYP2C isoforms that are unaffected by CKD may have accounted for 
the lack of effect observed with regard to tolbutamide metabolism. This theory is 
supported by studies which show no effect of severe CKD on CYP2C6 protein 
expression (Leblond et al., 2001). To characterize the effect of progressive decline in 
kidney function on CYP2C11 activity, we analyzed the formation of 16αOH-testosterone, 
a specific metabolite of CYP2C11. The formation of 16αOH-testosterone was decreased 
in hepatic microsomes of both moderate and severe CKD. These data support other 
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studies, which demonstrate that CYP2C11 function is diminished in severe kidney 
disease (Uchida et al., 1995; Leblond et al., 2000). This also suggests that earlier stages 
of kidney disease result in a significant decrease in CYP2C11 function, similar to the 
outcome seen in severe kidney disease. 
Few studies have evaluated the correlation between the progression of kidney disease and 
extent of drug metabolism. After demonstrating that CYP3A and CYP2C11 enzyme 
function and expression were decreased in moderate CKD, we examined the correlation 
of this affect with the degree of kidney function. Our study shows a significant inverse 
exponential correlation between kidney function and CYP3A2 and CYP2C11 protein and 
mRNA expression. A similar inverse correlation was also demonstrated between kidney 
function and CYP3A and CYP2C11 enzyme function. Surprisingly, these correlations are 
not linear as our data clearly demonstrates that a small decrease in kidney function during 
earlier stages of CKD produces a pronounced decrease in enzyme function and 
expression. The mechanism by which this occurs is unknown but may be due to the 
exponential increase in serum uremic mediators as CKD progresses. For example, the 
uremic toxin indoxyl sulfate increases exponentially as kidney disease progresses (Niwa 
and Ise, 1994; Barreto et al., 2009). A similar trend has also been demonstrated for the 
uremic toxin p-cresyl sulfate (Liabeuf et al., 2010). Our results suggest that the rapid 
decrease in kidney function may coincide with the exponential increase in uremic toxins 
that occurs in earlier stages of CKD. 
Altered non-renal drug clearance has been studied in patients with varying levels of 
kidney disease including ESRD (Nolin et al., 2006; Nolin et al., 2009; Sun et al., 2010). 
A recent study by Nolin et al. (2009) administered oral midazolam to ESRD patients on 
hemodialysis. Surprisingly, the metabolism of midazolam was unchanged in ESRD 
patients compared to healthy controls. The authors suggest that as ESRD patients 
undergo routine hemodialysis, it is possible that uremic toxins modulating the expression 
and/or direct inhibition of CYP3A4 are removed and restore drug metabolism to levels 
observed in healthy controls (Nolin et al., 2009). This is supported by other clinical 
studies that show no change in nicardipine metabolism in ESRD patients on dialysis, yet 
significant reductions in patients with CKD not requiring dialysis (Ahmed et al., 1991). 
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In conclusion, this study demonstrates that changes in drug metabolism are not restricted 
to severe CKD and that, in fact, milder forms of CKD significantly decrease the 
expression and activity of CYP3A and CYP2C enzymes. To our knowledge this is the 
first study to systematically evaluate the effect of varying degrees of CKD on hepatic 
drug metabolism using variations of the commonly used remnant kidney model.  In 
addition, this is the first study to evaluate CYP3A and CYP2C activity in CKD by 
performing full enzyme kinetics of substrate drugs.  The results of our study suggest that 
metabolism and disposition of drugs that are substrates of CYP3A or CYP2C may be 
altered in earlier stages of kidney disease.  This may have profound implications in the 
variable pharmacokinetics of medications in kidney disease. A recent assessment by the 
US Food and Drug Administration highlights the importance of evaluating the impact of 
kidney impairment on the pharmacokinetics of drugs (Zhang et al., 2009).  Our data are 
in agreement with this assessment and suggest that the pharmacokinetics of drugs in all 
stages of kidney impairment should be investigated, not just ESRD.  
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4 DECREASED NUCLEAR RECEPTOR ACTIVITY AND 
EPIGENETIC MODULATION ASSOCIATES WITH 
DOWNREGULATION OF HEPATIC DRUG 
METABOLIZING ENZYMES IN CHRONIC KIDNEY 
DISEASE.3 
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4.1  Introduction 
Patients with CKD take many medications to manage their CKD and co-morbidities 
(Talbert, 1994). Sub-therapeutic dosing and overdosing result in adverse drug events 
commonly associated with CKD, which translates into therapeutic ineffectiveness or 
drug-induced toxicity. It is estimated that 1 medication related problem occurs with every 
2.7 medication exposures in dialysis patients (Manley et al., 2005). Several reports 
suggest that altered pharmacokinetics in CKD at least partially mediates this increase in 
adverse drug events (Leblond et al., 2000; Nolin et al., 2009; Sun et al., 2010b). Although 
it is well known that the renal clearance of drugs is altered in CKD, the effect on non-
renal drug clearance is not well understood.  
Hepatic drug metabolism is the major route of drug elimination and is mediated 
predominantly by the P450 superfamily of oxidizing enzymes. The P450 isoforms, 
CYP2C and CYP3A, metabolize the majority (43%) of clinically used drugs (Zanger and 
Schwab, 2013). Several studies have reported downregulation of CYP2C and CYP3A 
enzymes in CKD (Leblond et al., 2000; Leblond et al., 2001; Leblond et al., 2002; 
Michaud et al., 2005). In addition, in vitro studies incubating rat primary hepatocytes 
with uremic serum demonstrate a decrease in CYP2C11 and CYP3A2 expression, which 
are rat orthologs for human CYP2C9 and CYP3A4, respectively (Michaud et al., 2008). 
Consistent with these studies, surgical induction of CKD in rats results in a pronounced 
decrease of hepatic CYP2C and CYP3A function and expression (Leblond et al., 2000; 
Leblond et al., 2001; Velenosi et al., 2012). Although decreased CYP2C and CYP3A 
function and protein expression appear to be secondary to decreased mRNA expression, 
the molecular mechanism(s) by which this occurs in CKD is unclear.  
Hepatic P450 enzymes are transcriptionally regulated by nuclear receptors. These 
xenosensing and hormonal regulators of gene expression include PXR and HNF-4α 
(Tirona et al., 2003; Urquhart et al., 2007). PXR contains a promiscuous ligand-binding 
domain that can be activated by chemically diverse compounds to regulate CYP3A 
expression. When activated, PXR translocates into the nucleus and heterodimerizes with 
RXR. This heterodimer binds to regulatory regions on DNA to modulate transcription. 
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HNF-4α is an essential transcriptional regulator of CYP3A and CYP2C expression 
(Ibeanu and Goldstein, 1995; Tirona et al., 2003). In contrast to PXR, HNF-4α binds to 
the promoter of these enzymes as a homodimer to activate transcription (Ibeanu and 
Goldstein, 1995; Tirona et al., 2003). In addition to altered CYP expression, numerous 
clinical and animal studies suggest that adverse drug events occur due to altered 
pharmacokinetics in patients with CKD (Ahmed et al., 1991; Leblond et al., 2000; 
Leblond et al., 2001; Leblond et al., 2002; Nolin et al., 2009; Sun et al., 2010b). Although 
the mechanism(s) remain controversial, several reports indicate that altered drug 
pharmacokinetics in CKD is mediated by accumulation of uremic waste products (Nolin 
et al., 2008; Naud et al., 2012; Velenosi and Urquhart, 2014). These uremic waste 
products become toxins at high levels and include amino acid metabolites, hormones, 
cytokines and other metabolic waste products. Many of these toxins are cleared in 
dialysis; however, some circulate bound to plasma proteins and are poorly cleared 
(Duranton et al., 2012). 
Altered transcriptional regulation of several genes has also been associated with 
epigenetic modifications in the setting of CKD (Noh et al., 2009; Sun et al., 2010a). 
Previous studies have suggested that the uremic environment of CKD produces 
epimutations including DNA methylation and histone posttranslational modifications, 
which result in altered gene expression (Dwivedi et al., 2011). In the context of 
regulating CYP enzymes, transcriptional activation occurs in tandem with the binding of 
PXR and HNF-4α as well as post-translational histone modifications leading to a 
permissive chromatin environment (Barrero and Malik, 2006; Xie et al., 2009; Cui et al., 
2010). Therefore, it is possible that alterations in histone modifications play an important 
role in the mechanism of CKD-induced changes in hepatic CYP2C and CYP3A 
expression. 
The objective of this study was to identify possible mechanisms by which hepatic drug 
metabolizing enzyme function and expression are altered in CKD. We hypothesize that 
altered drug metabolism in CKD is secondary to decreased nuclear receptor binding to 
the promoters of CYP2C and CYP3A as a result of histone modulation. In this study, we 
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investigate the nuclear receptor and epigenetic regulation of hepatic drug metabolizing 
enzymes in a well-characterized rat model of CKD. 
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4.2 Methods 
4.2.1 Experimental Rat Model 
Male Sprague-Dawley rats, weighing 150 g, were obtained from Charles River 
Laboratories, Inc. (Wilmington, MA, USA). Twelve rats were randomly separated into 
two groups, which simulated normal kidney function and CKD. CKD was surgically 
induced by a two-stage 5/6 subtotal nephrectomy (Leblond et al., 2000). Control rats 
were pair-fed the same amount of standard rat chow that was ingested by CKD rats on the 
previous day. Six weeks after initial surgery, rats were sacrificed by isoflurane anesthesia 
followed by decapitation. Liver tissue was harvested, snap frozen in liquid nitrogen and 
stored at -80°C prior to analysis.  Serum creatinine and urea were determined by the 
London Laboratory Services Group by standard methods (London, Ontario, Canada).  
The animal protocols were approved by the University of Western Ontario Animal Care 
Committee (Appendix A). 
4.2.2 Testosterone Metabolism and Analyte Quantification 
Liver microsomal fractions were isolated by differential centrifugation as previously 
published (Velenosi et al., 2012). Testosterone was selected as a probe substrate to 
determine hepatic CYP2C11 and CYP3A enzyme function as described previously 
(Velenosi et al., 2012).  
4.2.3 RNA Extraction and Real-time PCR Analysis 
RNA was extracted from rat livers using TRIzol according to the manufacturers protocol. 
cDNA was synthesized from 1 µg of total RNA according to  manufacturers protocol 
with qScript cDNA Supermix (Quanta BioSciences, Inc., Gaithersburg, MD, USA) and 
relative mRNA expression quantified by real-time PCR with PerfeCta SYBR Green 
Fastmix (Quanta BioSciences, Inc., Gaithersburg, MD, USA). Primer sets for CYP1A1, 
CYP1A2, CYP2C11, CYP3A2, PXR, HNF-4α, CAR, and RXR were generated using 
NCBI Primer-Blast (Table 4.1). Gene expression was normalized to β-actin using the 
∆∆CT method.  
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Table 4.1 Real-time PCR Primers 
 Gene/Promoter Primer (5′-3′)  
Drug 
Metabolizing 
Enzymes 
Rat CYP1A1 
Forward 
ATGTCCAGCTCTCAGATGATAAGGTC   
Reverse ATCCCTGCCAATCACTGTGTCTAAC   
 
Rat CYP1A2 
Forward 
CAACCCAGCCCTCAAGAGGTTTAAG   
Reverse GCGCCTGTGATGTCCTGGATAC   
 
Rat CYP2C11 Forward CCCTGAGGACTTTTGGGATGGGC Reverse AGGGGCACCTTTGCTCTTCCTC  
Rat CYP3A2 
Forward 
GCTCTTGATGCATGGTTAAAGATTTG 
Reverse ATCACAGACCTTGCCAACTCCTT 
 
Nuclear 
Receptors 
Rat PXR Forward TGCACACAGGTTCCTGTTCCTGA   Reverse GGGGTGCGTGTCCTGGATGC    
Rat HNF-4α Forward GGGATCGGATCAGCACGCGG   Reverse GGGGGAGGTGATCTGCTGAGACA    
Rat CAR Forward CCTTTTCCGTTCCCTGACCA Reverse AGGCAGAACGTAGTGTTGAGT  
Rat RXR Forward AACCCCCTCTAGGCCTCAAT Reverse TAGTGTTTGCCTGAGGAGCG  
Nuclear 
Receptor and 
RNA Pol II 
Binding Sites 
-292 to -172 Rat 
CYP3A2 
Promoter 
Forward GGCTCACCTGGACTTTGGTACTCT   
Reverse CCCATGTAGCACTGCTGTTTACTGA 
 
-793 to -692 Rat 
CYP2C11 
Promoter 
Forward CCTTCACTGCTAAAACTCAGTC 
Reverse CCCCAGAGAGTTTCAACATACA 
-145 to -22 Rat 
CYP2C11 
Promoter 
Forward 
ACAGGTCAGGGTCCACAAAGAAGAA 
Reverse CTGTGAGCTTGCTGTCCAGGACTT 
Rat RNA Pol II 
GAPDH 
Binding Site 
Forward CGTAGCTCAGGCCTCTGCGCCCTT   
Reverse 
CTGGCACTGCACAAGAAGATGCGGCTG   
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4.2.4 Western Blot Analysis 
Protein expression of CYP2C11 and CYP3A2 was assessed in hepatic microsomal 
fractions using western blot analysis as previously described (Chapter 3). HNF-4α and 
PXR western blots were performed in hepatic lysates. Immunoblots were performed 
according to antibody manufacturer’s recommendation for CYP2C11 (Detroit R&D Inc., 
Detroit, MI, USA), CYP3A2 (Millipore, Billerica, MA, USA), HNF-4α (GeneTex, 
Irvine, CA, USA) and PXR (Abcam, Cambridge, MA, USA). Secondary HRP-linked 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, Dallas, TX, USA). 
Immune complexes were revealed by horseradish peroxidase (Millipore, Billerica, MA, 
USA) and band intensity determined by densitometry (Quantity One 1-D Analysis 
Software on a VersaDoc Imaging System, Bio-Rad, Hercules, CA, USA).  
4.2.5 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed on rat liver tissue using a previously 
published method with slight modification (Sohi et al., 2011). Briefly, DNA was cross-
linked to protein with 1% formaldehyde and subsequently sheared by sonication. 
Chromatin samples were pre-cleared with protein A/G agarose then incubated with 
antibodies to RNA polymerase II (RNA Pol II, 1 µg per aliquot, 17-620, Millipore, 
Billerica, MA, USA), PXR (5 µg per aliquot, sc-25381, Santa Cruz, Dallas, TX, USA), 
HNF-4α (5 µg per aliquot, sc-8987, Santa Cruz, Dallas, TX, USA), acetyl histone H3 (5 
µg per aliquot, K9, K14, #06-559, Millipore, Billerica, MA, USA), acetyl histone H4 (5 
µg per aliquot, K5, K8, K12, K16, #06-886, Millipore, Billerica, MA, USA), H3K27me3 
(5 µg per aliquot, #07-449, Millipore, Billerica, MA, USA), H3K9me3 (Billerica, MA, 
USA), H4R3me2 (5 µg per aliquot, #39705, ActivMotif, Carlsbad, CA, USA) or 
H3K4me2 (5 µg per aliquot, #07-030, Millipore, Billerica, MA, USA) overnight at 4°C. 
Separate aliquots were treated with the same amount of non-immune IgG from the same 
host species to determine non-specific binding (Santa Cruz Biotechnology or Millipore). 
The binding of RNA Pol II, PXR (-217 to -208) and HNF-4α (-190 to -180) to the rat 
CYP3A2 promoter (Huss et al., 1999) was quantified by real-time PCR using primers to 
amplify -292 to -172 (Table 4.1). This primer set was also used to determine histone 
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modifications in the CYP3A2 promoter. GeneInspector™ was used to identify putative rat 
HNF-4α binding sites in the CYP2C11 promoter (-1 to -10,000 bp). A proximal putative 
HNF-4α binding site was identified from -755 to -751 bp and was evaluated using 
forward and reverse primers amplifying -793 to -692 bp (Table 4.1). A site upstream of 
the CYP2C11 HNF-4α binding site binding site (-4438 to -4296 bp) was also amplified 
as a negative control. -793 to -692bp was also amplified to determine histone H4 
acetylation and H4R3me2 in the CYP2C11 promoter. PCR primers were also used to 
amplify -145 to -22 to assess CYP2C11 promoter binding of RNA Pol II as well as 
H3K4me2, H3K9me3 and H3K27me3 epigenetic markers (Table 4.1).  
4.2.6 Statistical Analysis 
Statistical differences between control and CKD rats were assessed using the unpaired 
Student’s t-test. Results are expressed as mean ± SEM and p < 0.05 was considered 
statistically significant. 
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4.3 Results 
4.3.1 Serum Biochemistry and Body Weight 
Serum levels of creatinine and urea in rats with surgically induced CKD were 2.74-fold 
and 1.97-fold higher, respectively, compared to control (p < 0.05, Table 4.2). There was 
no difference in body weight between CKD and control rats. 
4.3.2 Hepatic CYP3A and CYP2C Mediated Drug Metabolism 
To confirm decreased CYP2C and CYP3A mediated metabolism in CKD, we evaluated 
metabolism of testosterone, using rat liver microsomes. A 68% decrease in the CYP2C11 
mediated production of 16α-OH testosterone was demonstrated in rats with CKD 
compared to controls (Fig. 4.1A, p < 0.05). CYP3A activity assessed by measuring 6β-
OH testosterone formation was also significantly decreased by 78% in CKD rats, 
compared to controls (Fig. 4.1B, p < 0.05).  
4.3.3 Protein and mRNA expression of Drug Metabolizing 
Enzymes 
Microsomal protein expression of CYP2C11 and CYP3A2 was decreased by 65.6% and 
88.8%, respectively, in CKD rats compared to controls (Fig. 4.1C, p < 0.05). Real-time 
PCR indicated a 70.5% and 97.8% decrease in hepatic CYP2C11 and CYP3A2 mRNA 
expression in CKD rats, respectively, compared to controls (Fig. 4.1D, p < 0.05).  
4.3.4 RNA Pol II Recruitment to the CYP3A2 and CYP2C11 
Promoters 
A potential transcriptional mechanism of CYP2C11 and CYP3A2 downregulation was 
investigated by measuring the binding of RNA Pol II to the promoters of CYP2C11 and 
CYP3A2 using ChIP. Rats with CKD had greater than a 76% and 71% decrease in 
recruitment of RNA Pol II to the CYP2C11 and CYP3A2 promoters, respectively (p < 
0.05, Fig. 4.2). Non-immune IgG ChIP resulted in negligible binding to the CYP2C11 
and CYP3A2 promoters. 
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Table 4.2 Characteristics of control and CKD rats.  
Data are represented as mean ± SEM, n = 6.  
 Control Chronic Kidney Disease 
Body Weight (g) 478 ± 20 451 ± 12 
Serum Creatinine (µM) 23 ± 1 63 ± 12* 
Serum Urea (µM) 6.1 ± 0.5 12.0 ± 0.3* 
* p < 0.05 compared to control. 
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Figure 4.1 Hepatic P450 enzyme function and expression in control and chronic kidney 
disease (CKD) rats. 
Hepatic CYP2C (A) and CYP3A (B) enzyme activity in control and CKD rats. 
Production of 16α-OH testosterone (CYP2C11) and 6β-OH testosterone (CYP3A2) was 
measured after incubation of rat liver microsomes with 1 mM NADPH and 200 µM 
testosterone. Hepatic protein (C) and mRNA (D) expression of drug metabolizing 
enzymes in control and CKD rats. Protein and mRNA are standardized to β-actin. 
Controls were arbitrarily defined as 100%. Results are presented as mean ± SEM, n = 6, 
*p < 0.05 compared to control. Representative western blots are shown. 
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Figure 4.2 RNA Pol II chromatin immunoprecipitation 
RNA Polymerase II (RNA Pol II) binding to the initiation site of hepatic CYP2C11 (A) 
and CYP3A2 (B) in control and chronic kidney disease (CKD) rats. Chromatin 
Immunoprecipitation (ChIP) was carried out on rat liver tissue using an RNA Pol II 
specific antibody.  All target genes were normalized to RNA Pol II binding to GAPDH. 
Relative binding of RNA Pol II is expressed as a percentage of control binding. Controls 
were arbitrarily defined as 100%. Results are presented as mean ± SEM, n = 6, *p < 0.05 
compared to control. 
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4.3.5 Hepatic Nuclear Receptor Expression and Recruitment to 
the CYP2C11 and CYP3A2 Promoters in CKD 
To determine the effect of nuclear receptors on transcriptional regulation of CYP2C11 
and CYP3A2 in CKD, we assessed the steady-state levels of nuclear receptor mRNA and 
protein along with promoter recruitment. CKD did not significantly alter the hepatic 
mRNA expression of PXR, HNF-4α, CAR or RXRα (Fig. 4.3A). Protein expression of 
PXR and HNF-4α was also unchanged (Fig. 4.3B and Fig. 4.3C). While a previously 
described binding site for HNF-4α in the CYP3A2 promoter has been established (Huss et 
al., 1999), we used GeneInspector™ to identify a novel putative binding site at -757 of 
the CYP2C11 promoter. ChIP was used to assess the binding of HNF-4α to the promoter 
of both CYP2C11 and CYP3A2 in control and CKD rats. Binding of HNF-4α to its 
binding sites in the CYP2C11 and CYP3A2 promoters was significantly decreased by 
57% and 77%, respectively in CKD rats compared to controls (p < 0.05, Fig. 4.4A,B). 
Recruitment of PXR to the CYP3A2 promoter was also significantly decreased greater 
than 57% in CKD rats compared to controls (p < 0.05, Fig. 4.4C).  
4.3.6 Decreased Histone Acetylation in the CYP2C11 and 
CYP3A2 Promoters of Rats with CKD. 
Epigenetic modulation can cause gene silencing through decreased histone acetylation 
(Jenuwein and Allis, 2001). To assess the possibility that altered histone acetylation in 
the promoters of CYP2C11 and CYP3A2 occurs in tandem with decreased nuclear 
receptor binding in CKD, ChIP was employed using antibodies against acetyl histone H3 
and acetyl histone H4 in control and CKD liver tissue. Interestingly, histone H3 
acetylation was decreased in both the CYP2C11 (-145 to -22) and CYP3A2 (-292 to -172) 
promoter regions by 77% (p < 0.05, Fig. 4.5A, B). Histone H4 acetylation was also 
decreased in the CYP3A2 promoter (p < 0.05, Fig. 4.5D); however, there was no change 
in H4 acetylation of the putative HNF-4α binding site in the CYP2C11 promoter (-793 to 
-751, Fig. 4.5C). Given alterations in histone methylation can also influence gene 
expression (Shilatifard, 2006), we next assessed if activating and/or inhibiting histone 
methylation modifications occurred in hepatic CYP2C11 and CYP3A2 promoters. 
H3K4me2 and H4R3me2 activating modifications were examined by ChIP in the  
104 
 
 
 
Figure 4.3 Nuclear receptor expression in control and chronic kidney disease (CKD) rats. 
(A) mRNA expression of nuclear receptors regulating drug metabolizing enzymes in 
control and CKD rats. Pregnane X Receptor (PXR) (B) and Hepatocyte Nuclear Factor 4 
α (HNF-4α) (C) protein expression in control and CKD rats. Protein is standardized to β-
actin and controls were arbitrarily defined as 100%. Results are presented as mean ± 
SEM, n = 6. Representative western blots are shown. 
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Figure 4.4 Nuclear receptor binding to the CYP2C11 and CYP3A2 promoter in control 
and chronic kidney disease (CKD) rats. 
Hepatocyte Nuclear Factor 4 α binding to the promoter regions of CYP2C11 (A) and 
CYP3A2 (B) drug metabolizing enzymes in control and CKD rats. Pregnane X Receptor 
(PXR) binding to the promoter of hepatic CYP3A2 in control and CKD rats (C). 
Chromatin Immunoprecipitation (ChIP) was carried out on rat liver tissue using a PXR or 
HNF-4α specific antibody. The relative level of immunoprecipitated genomic DNA was 
normalized to total genomic DNA. Relative binding of PXR and HNF-4α are expressed 
as a percentage of control binding. Results are presented as mean ± SEM, n = 6, *p < 
0.05 compared to control.  
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Figure 4.5 Histone acetylation at the initiation site of hepatic CYP2C11 and CYP3A2. 
Histone 3 acetylation at the initiation sites of hepatic CYP2C11 (A) and CYP3A2 (B) in 
control and chronic kidney disease rats (CKD). Histone 4 acetylation at the nuclear 
receptor binding sites of CYP2C11 (C) and CYP3A2 (D) in control vs. CKD rats. 
Chromatin Immunoprecipitation (ChIP) was carried out on rat liver tissue using an 
Acetyl-H3 (AcH3) or Acetyl-H4 (AcH4) specific antibody. The relative level of 
immunoprecipitated genomic DNA was normalized to total genomic DNA. Relative 
levels of AcH3 and AcH4 are expressed as a percentage of control. Results are presented 
as mean ± SEM, n = 6, *p < 0.05 compared to control.  
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CYP2C11 and CYP3A2 promoters of control and CKD rat livers. ChIP revealed no 
significant change in H3K4me2 and H4R3me2 in promoters of these enzymes for rats 
with CKD (Fig. 4.6A, C).  Histone methylation silencing modifications assessed included 
H3K9me3 and H3K27me3. No significant differences in silencing methylation 
modifications were found in the promoters of hepatic CYP2C11 and CYP3A2 for rats 
with CKD compared to controls (Fig. 4.6B, D). 
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Figure 4.6 Histone methylation at the initiation site of hepatic CYP2C11 and CYP3A2. 
Histone 3 lysine 4 dimethylation (H3K4me2, A), histone 3 lysine 9 trimethylation 
(H3K9me3, B) and histone 3 lysine 27 trimethylation (H3K27me3, D) at the initiation 
site of hepatic CYP2C11 and CYP3A2 in control rats and rats with chronic kidney 
disease (CKD). Asymmetric histone 4 arginine 3 dimethylation (H4R3me2, C) at the 
nuclear receptor binding sites of CYP2C11 and CYP3A2 in control and CKD rats. 
Chromatin Immunoprecipitation (ChIP) was carried out on rat liver tissue using an 
H3K4me2, H3K9me3, H3K27me3 or H4R3me2 specific antibody. The relative level of 
immunoprecipitated genomic DNA was normalized to total genomic DNA. Relative 
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levels of H3K4me2, H3K9me3, H3K27me3 and H4R3me2 are expressed as a percentage 
of control. Results are presented as mean ± SEM, n = 6, *p < 0.05 compared to control.  
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4.4 Discussion 
In this study, we explored the possible underlying transcriptional factor (e.g. nuclear 
receptor activity) and epigenetic (e.g. posttranslational histone modifications) alterations 
that accompany downregulation of the important drug metabolizing enzymes CYP2C and 
CYP3A in CKD. Hepatic CYP2C11 and CYP3A2 function and expression are decreased 
in CKD similar to levels observed in previous studies. Decreased protein expression and 
function of these drug metabolizing enzymes have been consistently supported as 
secondary to the decrease in mRNA expression (Leblond et al., 2000; Okabe et al., 2003; 
Velenosi et al., 2012).  
Activity of PXR and HNF-4α nuclear receptors commonly occurs through post-
translational modifications and protein interactions; however, some studies have 
indicated that changes in the expression of these nuclear receptors can alter CYP3A 
mRNA expression (Souidi et al., 2005; Ni et al., 2009). For example, rats exposed to 
depleted uranium exhibited increased hepatic PXR expression, which occurred 
concomitantly with increased CYP3A2 expression (Souidi et al., 2005). Moreover, 
inflammatory animal models, such as intraperitoneal lipopolysaccharide injection in 
mice, have demonstrated decreased PXR and RXRα expression, which leads to impaired 
CYP3A11 expression (Xu et al., 2006). CKD can be considered an inflammation-
associated pathological state and although there was a slight trend towards decreased 
nuclear receptor expression, there was no significant change in the expression of nuclear 
receptors that regulate CYP2C11 and CYP3A2 in CKD compared to controls.  
While the expression of these nuclear receptors was not altered in our study, we 
demonstrated that the recruitment of hepatic PXR and HNF-4α to the CYP3A promoter 
was substantially decreased in CKD. To our knowledge, this is the first study in an in 
vivo disease model to implicate alterations in PXR and HNF-4α binding along with 
changes in the chromatin environment associated with recruitment of these nuclear 
receptors. Previous in vitro studies suggest that decreased PXR binding may be a result of 
protein-protein interactions, epigenetic changes, reduced recruitment of co-activators or a 
combination of these mechanisms (Tian, 2013). Protein-protein interactions with NF-κB 
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and PXR have been demonstrated through direct binding with the RXRα DNA binding 
domain to inhibit transcriptional activity (Gu et al., 2006). Moreover, NF-κB has been 
shown to play a role in mediating uremic toxin induced downregulation of CYP2C and 
CYP3A expression. In a previous study, NF-κB inhibitors mitigated the downregulation 
of these enzymes in rat hepatocytes treated with pre-dialysis serum. However, post-
dialysis serum had no effect on drug metabolizing enzyme expression suggesting the 
toxins involved may be cleared in dialysis (Michaud et al., 2008).  
Basal expression of rat CYP2C11 is regulated by growth hormone in a complex 
interaction between signal transducer and activator of transcription-5b (STAT5b), HNF-
1α, HNF-3β, HNF-4α and HNF-6 (Park and Waxman, 2001; Wauthier and Waxman, 
2008). In humans, the major regulators of CYP2C9 are PXR, CAR and HNF-4α (Zanger 
and Schwab, 2013). Therefore, although this study demonstrates a decrease in binding of 
a common nuclear receptor regulating both CYP2C11 and CYP2C9, these enzymes 
display distinct species differences in regulation. 
The focus of our study was to also examine the associated epigenetic changes in the 
promoter region of these enzymes as a result of CKD. In vitro studies have shown that 
both PXR and HNF-4α activation occurs through the activity of PRMT1, which 
asymmetrically dimethylates histone H4R3 causing subsequent H4 acetylation and 
transcriptional activation (Barrero and Malik, 2006; Xie et al., 2009). This pathway is 
thought to be unidirectional as acetylation of histone H4 has been shown to inhibit 
H4R3me2 (Tian, 2009; Tian, 2013). Our study demonstrated that histone H4R3me2 was 
not significantly altered in the promoters of hepatic CYP2C11 (-793 to -751) and 
CYP3A2 (-292 to -172) in CKD (Fig. 4.6C). Further, PRMT1 mRNA was unchanged in 
CKD rats compared to control (Supplementary Fig. C2, Appendix C). Our results 
indicate that histone H4 acetylation is significantly decreased alongside RNA Pol II 
recruitment in the promoter region of hepatic CYP3A2 in rats with CKD suggesting 
decreased transcriptional activation (Fig. 4.5D). Tian categorized chromatin remodeling 
by PRMT1 in a three state cycle: “transcriptionally silent” with no chromatin markers, 
“ready state” which occurs after asymmetric dimethylation of H4R3 by PRMT1 and 
“active state” which occurs during H4 acetylation and the removal of H4R3me2 markers 
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(Tian, 2009). Therefore, it is possible that the percentage of CYP3A2 promoter in 
H4R3me2 “ready state” (Fig. 4.6C) is unaffected by CKD while the percentage of histone 
H4 acetylation is significantly decreased (Fig 4.5D) resulting in a higher percentage in 
the transcriptionally silent state. The mechanism by which H4 acetylation is decreased 
may be a result of NF-κB activation and histone deacetylases (HDACs) causing 
deacetylation to the transcriptionally silent state (Tian, 2009; Tian, 2013). A previous 
study demonstrated reduced HDAC1 binding to the CYP3A4 promoter in the presence of 
the CYP3A4 inducer, carbamazepine (Wu et al., 2012). However, HDAC1 was not 
enriched in the rat CYP3A2 promoter for control or CKD rats (data not shown). 
Decreased recruitment of RNA Pol II is associated with increased H3K9 methylation 
silencing modifications and decreased H3K9 acetylation activating modifications (Sohi et 
al., 2011).  A maternal protein restriction model of intrauterine growth restriction has 
shown long term gene silencing of hepatic CYP7A1. CYP7A1 gene silencing occurred as 
a result of decreased RNA Pol II binding in rats (Sohi et al., 2011). This study also 
showed decreased H3 acetylation and increased H3K9me3 in the CYP7A1 promoter. 
Other studies have associated these histone modifications with decreased RNA Pol II 
recruitment (Lorincz et al., 2004; Shilatifard, 2006).  In our study, H3K9me3 was 
unaltered in rat hepatic CYP2C11 and CYP3A2 promoters; however, H3 acetylation was 
decreased further suggesting the possibility of increased HDAC activity in the promoter 
of these enzymes.  Studies examining the epigenetic changes associated with 
phenobarbital-induced CAR induction of CYP2B1 have also noted increases in H3 
acetylation as well as methylation modifications including increased H3K4me2 and 
decreased H3K27me3 (Lempiainen et al., 2011). H3K4me2 is associated with activation 
of transcription while H3K27me3 is a marker of silencing heterochromatin (Lorincz et 
al., 2004; Shilatifard, 2006). In our study, no significant changes in H3K4me2 and 
H3K27me3 were found in the promoters of CYP2C11 or CYP3A2 in CKD. Another 
potential silencing mechanism that could explain our results is silencing via direct DNA 
methylation. Although direct DNA methylation silencing modifications have been 
associated with PXR binding sites in mice (Cui et al., 2010), our in silico screen did not 
identify any CpG islands in the rat CYP2C11 or CYP3A2 promoters as predicted by CpG 
island searcher software (Takai and Jones, 2002). 
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Emerging evidence strongly suggests that alterations in non-renal clearance pathways in 
CKD impact the pharmacokinetics of drugs. Our study describes a possible mechanism 
by which these enzymes are downregulated. We therefore propose a mechanistic 
hypothesis to explain how uremia induces altered nuclear receptor binding and epigenetic 
modifications to downregulate drug disposition genes (Fig. 4.7). We show for the first 
time that hepatic CYP2C11 and CYP3A2 downregulation in CKD are associated with 
both decreased nuclear receptor binding and decreased acetylation in the promoter region 
of these enzymes. Future studies should address the temporal and severity relationships 
between changes in nuclear receptor binding and histone acetylation in CKD. Given the 
complex nature of uremia and the several putative uremic toxins that likely contribute to 
this effect, future studies are also needed to elucidate the role of specific uremic toxins in 
regulation of drug metabolism 
In summary, CYP2C and CYP3A enzymes are involved in the oxidative metabolism of 
almost half of all prescribed medications (Zanger and Schwab, 2013). They also play 
essential roles in cholesterol, steroid, and lipid homeostasis (Luoma, 2008). Our study 
provides evidence for an association between decreased transcription factor binding and 
histone acetylation and downregulation of these important genes in the setting of CKD. 
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Figure 4.7 Schematic of mechanistic hypothesis describing the downregulation of drug 
metabolizing enzymes in chronic kidney disease (CKD).  
In the absence of CKD (left), PXR, HNF-4α and RNA polymerase II bind to the promoter 
region of CYP2C11 and CYP3A2 to drive transcription.  In CKD (right), we propose that 
uremic toxins accumulate in the blood and impact transcriptional processes in the 
hepatocyte. This results in decreased PXR, HNF-4α and RNA Pol II binding to the 
promoter of CYP2C11 and CYP3A2. In addition, histone acetylation in the promoters of 
CYP2C11 and CYP3A2 is decreased promoting a transcriptionally silent state. 
Collectively, changes in nuclear receptor binding and epigenetic histone acetylation 
mediate decreased transcription. Images used to generate Fig. 4.7 were modified from 
Servier Medical Art (http://www.servier.co.uk/medical-art-gallery). 
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5.1 Introduction 
The National Kidney Foundation defines CKD as the presence of kidney damage or a 
progressive decline in renal function lasting for three or more months (National Kidney 
Foundation, 2002). The prevalence of CKD is estimated to be upwards of 14% in the 
United States (KEEP, 2011; McCullough et al., 2011; Stevens et al., 2011). CKD is 
divided into 5 stages, which are classified based on glomerular filtration rate. In end stage 
renal disease, patients experience fatigue, impaired vascular reactivity, hypothermia, 
malnutrition and psychological disturbances associated with being on dialysis, known as 
the “residual syndrome” (Depner, 2001). Many of these signs and symptoms can develop 
in early stages of CKD but are not specific to the disease and therefore, are difficult to 
identify (Meyer and Hostetter, 2007). Although biochemical mechanisms of the residual 
syndrome are not completely understood, uremia is considered a major cause of this 
condition (Depner, 2001). 
Uremia is the accumulation of solutes that are normally cleared by the kidneys in CKD 
(Meyer and Hostetter, 2007). At high concentrations, the accumulating solutes are 
considered uremic toxins as they begin to induce the residual syndrome. Many of these 
highly concentrated toxins are gut-derived metabolites generated via protein fermentation 
by bacteria in the colon (Meyer and Hostetter, 2012). The majority of gut-derived uremic 
toxins are also protein-bound solutes that are less efficiently dialyzed and therefore, 
remain highly concentrated in patients on dialysis (Niwa and Ise, 1994; Lesaffer et al., 
2000). Gut-derived aromatic amino acid metabolites, such as indoxyl sulfate and p-cresyl 
sulfate, have been extensively studied in CKD (Vanholder et al., 2003; Duranton et al., 
2012). Indoxyl sulfate and p-cresyl sulfate play a significant role in cardiovascular 
disease, which is the leading cause of death in patients with CKD accounting for 45% of 
mortalities (Collins et al., 2010; Cao et al., 2015; Wang et al., 2015). Indoxyl sulfate 
concentration is correlated with aortic calcification and vascular stiffness in patients with 
CKD (Barreto et al., 2009). High plasma levels of unbound p-cresyl sulfate increases the 
risk of cardiovascular and all-cause mortality in hemodialysis patients (Wu et al., 2012). 
Other gut-derived metabolites identified in animals have also been shown to contribute to 
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cardiovascular disease and through the generation of pro-atherosclerotic metabolites 
(Wang et al., 2011; Meyer and Hostetter, 2012). 
AST-120 is a spherical carbon adsorbent that has been used in Japanese CKD patients 
since 1991 to remove the precursors of uremic toxins produced in the gut. This 
compound is formulated to bind small molecules (100 to 10,000 Da) while larger 
molecules such as digestive enzymes and hormones are left unbound (Schulman et al., 
2015). Adsorption of gut-derived uremic precursors to AST-120 decreases circulating 
levels of these toxins. In clinical trials, AST-120 has been shown to mitigate symptoms of 
uremia in CKD (Akizawa et al., 1998; Schulman et al., 2015). 
A number of studies have quantified individual uremic toxin levels in patients with CKD. 
In 2003, the EuTox compiled mean and median serum or blood levels of 90 uremic toxins 
using meta-analysis (Vanholder et al., 2003). Subsequent updates were published in 2007 
and 2012, adding 14 and 56 uremic toxins, respectively (Vanholder et al., 2007; Duranton 
et al., 2012). This is an effective method for determining mean patient uremic toxin 
levels; however, the uremic toxins reported are a result of targeted analysis, which can 
limit the identification of novel toxins. Recent advances in mass spectrometry allow for 
identification of novel uremic toxins using an untargeted metabolomics approach. 
Metabolomics is the study of all metabolites generated in a biological system. Thousands 
of metabolites can be detected using untargeted metabolomics without prior knowledge 
of their composition (Beger, 2013). In the setting of CKD, metabolomics can provide 
uremic signatures directly associated with decreased renal function through plasma 
analysis (Rhee, 2015). Recently, clinical and animal studies have begun to identify 
plasma uremic toxins using untargeted metabolomics (Rhee et al., 2010; Sharma et al., 
2013; Niewczas et al., 2014).  
Plasma uremic toxin levels have been correlated with CKD complications, most notable 
are the cardiovascular effects including endothelial dysfunction and heart failure 
(Shibahara and Shibahara, 2010; Cao et al., 2015). Metabolic changes in the kidney are 
known to occur as a result of kidney damage, and the accumulation of uremic toxins has 
been shown to further kidney injury (Zhao et al., 2012; Zhao et al., 2014). However, 
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effects of accumulating toxins on metabolic changes in other major organs such as the 
heart and liver, have not been assessed. Therefore, the purpose of this study was to 
determine the metabolic changes in plasma, liver, heart and kidney tissue as well as the 
metabolic axis between these matrices in rats with CKD. We also assessed the plasma 
and tissue metabolic effects of removing gut-derived uremic toxins using AST-120 to 
further understand the gut contribution to the uremic condition in both plasma and tissues 
in CKD. 
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5.2 Methods 
5.2.1 Chemicals and Reagents 
Harlan 8640 Teklad 22/5 rodent diets were used for both control and 0.7% adenine 
supplemented diets (Madison, WI). Indoxyl sulfate was obtained from Gold 
Biotechnology (Olivette, MO). P-cresyl glucuronide and equol 7-glucuronide were 
purchased from Toronto Research Chemicals (Toronto, ON, Canada) and β-
glucuronidase from Helix pomatia (G-7051), pyrocatechol, p-cresol and 4-ethylphenol 
were obtained from Sigma-Aldrich (St. Louis, MO). Flurazepam was purchased from 
Cerilliant (Round Rock, TX). Isatin was purchased from Alfa Aesar (Ward Hill, MA). P-
cresyl sulfate, phenyl sulfate and 4-ethyl phenyl sulfate were synthesized as previously 
described (Feigenbaum and Neuberg, 1941). AST-120 was a kind gift from the Kureha 
Corporation (Tokyo, Japan). 
5.2.2 Animal Models 
A total of 30 male Wistar rats were obtained from Charles River Laboratories, Inc. 
(Wilmington, MA) for this study. Animal care and experimental protocols and 
procedures were approved by the Western University Animal Care Committee and 
conducted in accordance with the Canadian Council on Animal Care (Appendix A). Rats 
initially weighed 150 g and after 5 days of acclimatization were divided into two groups: 
control (n=10) and CKD (n=20). The CKD group received 0.7% adenine supplemented 
into rat chow ad libitum for 5 weeks to induce kidney disease. Food was weighed daily 
for the CKD group and pair-fed as standard chow to control animals. After 5 weeks, the 
CKD group was equally divided and the diet was changed to standard chow (CKD, n=10) 
or standard rat chow supplemented with 8% AST-120 (CKD+AST-120, n=10) for an 
additional 3 weeks. All animals were weighed daily throughout the study. Three rats from 
the CKD and CKD+AST-120 groups experienced significant weight loss and were 
euthanized prior to the end of the study. At the conclusion of the study, control (n=10), 
CKD (n=7) and CKD+AST-120 (n=7) rats were sacrificed and blood was obtained in 
heparinized tubes to acquire plasma. Liver, heart and left kidneys were removed, snap-
frozen in liquid nitrogen and stored at -80°C. Plasma creatinine and urea were determined 
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by the London Laboratory Services Group (London, ON, Canada) using standard 
methods. 
5.2.3 Sample Preparation  
Plasma samples were thawed to room temperature and protein was precipitated with the 
addition of ice-cold acetonitrile (3:1, acetonitrile:plasma). Liver, heart and kidney tissue 
(100 mg) were homogenized in 250 µL of ice-cold acetonitrile. All samples were placed 
on ice for 20 minutes and centrifuged at 14,000 g for 5 minutes. The supernatant from 
tissue samples was diluted to 80% acetonitrile. Quality control samples were generated 
for each matrix by creating a pooled sample. Acetonitrile used for protein precipitation 
contained isatin (5 µg/mL) and flurazepam (25 ng/mL) as internal standards.  
5.2.4 Chromatographic Separation and Mass Spectrometry 
Samples were transferred to vials and 1 µL was injected in triplicate for each vial. 
Injections were randomized to reduce error associated with instrument drift and quality 
control samples were run every 6 injections. Metabolites were separated using a Waters 
ACQUITY UPLC HSS T3 column (1.8 µm particle size, 100 mm X 2.1 mm). The 
column was maintained at 45°C in a Waters ACQUITY UPLC I-Class system (Waters, 
Milford, MA). The mobile phase flow was set to 0.45 ml/min and consisted of water (A) 
and acetonitrile (B), both containing 0.1% formic acid. The UPLC conditions were as 
follows: 0-2 mins, 1-60%B; 2-6 mins 60-85%B; 6-8 mins 85-99%B; 8-10 mins 99-1%B. 
Mass spectrometry was performed using a Waters XevoTM G2S-QToFMS. Metabolites 
were measured separately in positive and negative ESI modes. Capillary voltage and cone 
voltage were set at 2 kV and 40 V, respectively. The source temperature was 150°C.  The 
desolvation gas flow was set to 1200 L/h at 600°C and the cone gas flow was 50 L/h. The 
data was acquired in centroid mode using an MSE method, which allows for both MS and 
MS/MS fragmentation in a single run. Functions 1 and 2 of the MSE method acquired 
data with a 0.1 s scan time in the range of 50-1200 m/z. Collision energy was set to 0V 
and ramped from 15-50V for functions 1 and 2, respectively.  Function 3 acquired 
lockspray to ensure mass accuracy. Leucine-enkephalin (500 ng/mL) was used as the 
lockmass set at a flow rate of 10 µL/min, measured every 10 s and averaged over 3 scans. 
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5.2.5 Data Analysis 
5.2.5.1 Mutlivariate Data Analysis 
Mutlivariate analysis of LC-MS data was achieved by Waters Markerlynx with EZinfo 
2.0 (Umetrics, Umeå, Sweden) software packages. Peak intensities were normalized to 
total marker intensity in Markerlynx and subsequently transferred to EZinfo. Pareto 
scaling was used to dampen the selection of features with the highest variance. EZinfo 
was used for principal component analysis (PCA) of plasma, liver, heart and kidney, as 
well as orthogonal partial least squares discriminant analysis (OPLS-DA) between 
control and CKD rats for each matrix.  
5.2.5.2 Univariate Data Analysis 
XCMS Online (Tautenhahn et al., 2012) (https://xcmsonline.scripps.edu) was used for 
univariate data analysis. Raw data files were initially converted to mzData files and the 
lockmass was removed using massWolf 4.3.1 and the chemhelper package in R version 
3.2.0. Function 1 MS data was uploaded to XCMS Online and the data were processed as 
a multigroup experiment using the default UPLC with G2S MS parameters. Briefly, the 
centWave method was used for feature detection (m/z tolerance = 15 ppm, min peak 
width = 2 s, max peak width = 25 s). The Obiwarp method was used for retention time 
correction (profStep = 0.5) and chromatograms were aligned using the following 
parameters: mzwid = 0.1, minfrac = 0.5, bw = 2. Metabolite features were statistically 
analyzed using one-way ANOVA with Tukey’s post-hoc test. Isotopes and adducts were 
annotated using CAMERA (m/z absolute error = 0.015, ppm = 5) and arranged into 
feature groups. Features for each biological matrix were filtered for isotopes. The feature 
with the maximum intensity in each feature group and present in at least 80% of pooled 
sample injections was chosen for statistical analysis. Highly significant metabolites were 
selected to assess differences between biological matrices in control, CKD, and 
CKD+AST-120 rats (p < 0.01, q < 0.001, maximum intensity > 1500).  
Pairwise metabolite differences between control and CKD rats that were common across 
all biological matrices were determined using metaXCMS (Patti et al., 2012). Highly 
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significant metabolites for each tissue were aligned using a 20 second retention time 
tolerance and a 0.01 m/z tolerance.  
5.2.6 Metabolite Identification 
Metabolites that were considered highly significant between control and CKD rats from 
multivariate and univariate analysis were searched in METLIN and Human Metabolome 
Database (HMDB) metabolomics databases. Fragmentation patterns for each metabolite 
were compared to putative database compound fragmentation using MassFragment®. 
Compound standards were purchased or synthesized, and retention time and 
fragmentation pattern were compared to confirm the metabolite identity. Pyrocatechol 
sulfate was identified by incubation of plasma with β-glucuronidase from Helix pomatia, 
which has ≥10,000 units/g sulfatase activity. The sulfatase product fragmentation pattern 
was confirmed as pyrocatechol to a purchased standard. 
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5.3 Results 
5.3.1 Validation of Experimental Model 
The extent of CKD was assessed by plasma creatinine and urea levels (Table 5.1). 
Creatinine levels were 8.0-fold and 5.8-fold higher in CKD and CKD+AST-120 groups, 
respectively, compared to controls (p < 0.05). CKD and CKD+AST-120 rats had a 6.8 
and 5.1-fold increase in plasma urea levels compared to controls. There were no 
significant differences in weights between each group. 
5.3.2 Principal Component Analysis and the Removal of 
Metabolites by AST-120 in Biological Matrices 
To determine the metabolic changes in CKD with and without the administration of AST-
120, samples were analyzed by ultra performance liquid chromatography with 
quadropole time-of-flight mass spectrometry (UPLC-QToFMS) in positive and negative 
ESI modes. All samples, including pooled samples, were evaluated by multivariate 
analysis. Pooled sample injections demonstrated reproducibility and were clustered in the 
center of principal component analysis plots (Supplementary Figure C3 and C4, 
Appendix C). The first component in plasma negative mode PCA did not show clustering 
of experimental groups. When using second and third components, CKD rat plasma 
samples appeared as a separate cluster compared to control and CKD+AST-120 groups 
(Fig. 5.1A). The control and CKD+AST-120 samples were also grouped together in this 
analysis. The majority of metabolites were increased in CKD relative to control and 
CKD+AST-120 groups. Using XCMS Online multigroup experiment, 26 metabolites 
were significantly increased in CKD plasma samples compared to control. Of those 26 
metabolites, 24 were significantly reduced by the administration of AST-120 to rats with 
CKD (Fig. 5.1C). The PCA for liver metabolites in negative mode also demonstrated 
clustering of CKD samples; however, CKD+AST-120 showed some separation from 
control samples (Fig. 5.1B). Further analysis revealed that AST-120 removed 60.7% of 
metabolites that were significantly increased in CKD rat livers (Fig. 5.1D). Positive ESI 
did not show marked differences between groups for plasma and liver samples. The   
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Table 5.1. Physical and biochemical characteristics of control, CKD and CKD+AST-120 
rats. 
 Control CKD CKD+AST-120 
Body Weight (g) 277 ± 12 297 ± 18 258 ± 23 
Serum Creatinine 
(µM) 
23 ± 1 181 ± 22* 130 ± 17* 
Serum Urea (mM) 6.6 ± 0.5 44.9 ± 5.6* 33.6 ± 5.8* 
Data are presented as means ± SEM. 
*p < 0.05 compared to control. 
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Figure 5.1 Plasma and liver tissue principal component analysis and metabolites 
increased in CKD and decreased by AST-120 in negative ESI mode.  
Control (n), CKD (l) and CKD+AST-120 (▲) negative ESI mode principal component 
analysis of plasma (A) and liver (B) tissue in rats. Triplicate injections are shown. 
Metabolites significantly increased in CKD compared to control (represented as whole 
pie) and significantly decreased in CKD+AST-120 compared to CKD (represented as 
shaded pie) for plasma (C) and liver (D) tissue. Metabolites were considered significantly 
altered using one-way ANOVA (p < 0.01, q < 0.001, and maximum intensity > 1500) and 
Tukey’s post-hoc test. 
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Figure 5.2 Heart and kidney tissue principal component analysis and metabolites 
increased in CKD and decreased by AST-120 in negative ESI mode.  
Control (n), CKD (l) and CKD+AST-120 (▲) negative ESI mode principal component 
analysis of heart (A) and kidney (B) tissue in rats. Triplicate injections are shown. 
Metabolites significantly increased in CKD compared to control (represented as whole 
pie) and significantly decreased in CKD+AST-120 compared to CKD (represented as 
shaded pie) for heart (C) and kidney (D) tissue. Metabolites were considered significantly 
altered using one-way ANOVA (p < 0.01, q < 0.001, and maximum intensity > 1500) and 
Tukey’s post-hoc test. 
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metabolic profile in heart tissue was distinctly different between control and CKD rats 
with complete separation of samples in the PCA for both negative and positive ESI 
modes (Fig. 5.2A and 5.3A). CKD+AST-120 rat samples were clustered between control 
and CKD groups. AST-120 significantly decreased 58 of 92 metabolites in heart tissue 
that were increased in CKD (Fig. 5.2C and 5.3C). Metabolites between control, CKD and 
CKD+AST-120 kidney tissue were mutually exclusive in the PCA for negative ESI mode 
showing the greatest separation between all matrices analyzed (Fig 5.2B). In positive ESI 
mode, control and CKD components were well separated with slight overlap between 
CKD and CKD+AST-120 groups. Kidney tissue had the largest number of significantly 
increased metabolites in CKD compared to control. However, AST-120 reduced less than 
40% (90 of 233) of metabolites that were significantly increased in CKD compared to 
control kidneys (Fig. 5.2D and 5.3D).   
5.3.3 Orthogonal Partial Least Squares Discriminant Analysis of 
Control and CKD Biological Matrices. 
The metabolites responsible for the differences between control and CKD rats were 
assessed by OPLS-DA in plasma, liver, heart and kidney. Plasma metabolites in control 
and CKD samples were well described by OPLS-DA (R2(Y) = 0.92) with high predictive 
ability (Q2(Y) = 0.75). The majority of metabolites in plasma samples were increased in 
CKD relative to control. Many of these metabolites were aromatic amino acid derivatives 
including phenyl sulfate, indoxyl sulfate, p-cresyl sulfate, 4-ethylphenyl sulfate, hippuric 
acid and p-cresol glucuronide (Fig. 5.4E and Table 5.2). Tissue samples from rats with 
CKD also had high levels of aromatic amino acid derivatives. Few metabolites were 
significantly higher in control plasma samples compared to CKD. However, many fatty 
acids including palmitic acid, oleic acid, linoleic acid, arachidonic acid, eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) were present at higher levels in control 
livers. CKD rat livers were described by increases in equol sulfate and taurocholic acid 
compared to control livers along with a similar aromatic amino acid derivative profile as 
CKD plasma in OPLS-DA (Fig. 5.4F, R2(Y) = 0.98, Q2(Y) = 0.87). In negative ESI 
mode, heart metabolites in the control group were defined by lysophosphatidylcholines 
and lysophosphoethanolamines (Fig 5.4G, R2(Y) = 0.97, Q2(Y) = 0.89). Heart   
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Figure 5.3 Principal component analysis and metabolites increased in CKD and 
decreased by AST-120 in positive ESI mode.  
Control (n), CKD (l) and CKD+AST-120 (▲) positive ESI mode principal component 
analysis of heart (A) and kidney (B) tissue in rats. Triplicate injections are shown. 
Metabolites significantly increased in CKD compared to control (represented as whole 
pie) and significantly decreased in CKD+AST-120 compared to CKD (represented as 
shaded pie) for heart (C), kidney (D). Metabolites were considered significantly altered 
using one-way ANOVA (p < 0.01, q < 0.001, and maximum intensity > 1500) and 
Tukey’s post-hoc test. 
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Figure 5.4 Orthogonal partial least squares discriminant analysis (OPLS-DA) and S-plots 
of control and CKD biological matrices in negative ESI mode.  
Control (n) and CKD (l) negative ESI mode OPLS-DA of plasma (A) (R2(Y) = 0.92, 
Q2(Y) = 0.75), liver (B) (R2(Y) = 0.98, Q2(Y) = 0.87), heart (C) (R2(Y) = 0.97, 
Q2(Y)=0.89), and kidney (D) (R2(Y) = 1.00, Q2(Y) = 0.95) tissue in rats. Triplicate 
injections are shown. S-plots showing ions that define the CKD group in the upper right 
quadrant and ions that define control group in the lower left quadrant for plasma (E), liver 
(F), heart (G) and kidney (H) tissue. Ions with the greatest contribution in separating 
control and CKD groups are labeled and defined in Table 5.2 and Supplementary Table 
C2, Appendix C. Gut-derived metabolites that are increased in CKD and shared by all 
tissues are labeled 1 to 8 (n). 
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Table 5.2 Summary of metabolites altered in plasma, liver, heart and kidney tissue in rats 
with CKD compared to control and CKD+AST-120. 
 
aone plasma CKD outlier with a value of 14351% of control for p-cresyl sulfate was 
removed in the correlation analysis. 
 
Ion tR (min) 
Mass 
(m/z) 
Empirical 
Formula 
Mass  
Error  
(ppm) 
Identity Tissue 
Change compared to Control Change compared to CKD+AST-120 Metabolite 
ID Level 
Correlation 
with Plasma 
Levels (R2) 
 
S-plot 
VIP Fold P-value  Fold P-value 
1 2.28 201.0223 C8H10O4S[H-] 0.5 4-Phenylethyl  Sulfate 
Plasma ↑ 12.26 27.84 2.08E-10 ↑ 17.33 2.08E-10 
1 
 
Liver ↑ 15.01 35.88 4.89E-10 ↑ 23.42 4.89E-10 0.74 
Heart ↑ 16.96 44.31 4.89E-10 ↑ 19.40 4.89E-10 0.93 
Kidney ↑ 14.17 5.81 4.89E-10 ↑ 12.61 4.89E-10 0.58 
2 1.63 172.9908 C6H5O4S[H-] 0.6 Phenyl  Sulfate 
Plasma ↑ 9.55 29.41 2.08E-10 ↑ 3.43 2.12E-10 
1 
 
Liver ↑ 12.16 28.02 4.89E-10 ↑ 4.25 4.89E-10 0.91 
Heart ↑ 13.26 39.22 4.89E-10 ↑ 3.12 2.06E-09 0.86 
Kidney ↑ 11.06 5.46 4.89E-10 ↑ 3.35 4.91E-10 0.81 
3 1.71 212.0018 C8H6NO4S[H-] 0 Indoxyl Sulfate 
Plasma ↑ 8.12 39.07 2.08E-10 ↑ 4.41 1.20E-09 
1 
 
Liver ↑ 13.12 31.58 4.89E-10 ↑ 5.12 4.89E-10 0.78 
Heart ↑ 16.24 42.60 4.89E-10 ↑ 4.38 4.89E-10 0.76 
Kidney ↑ 11.22 3.62 4.89E-10 ↑ 3.14 4.91E-10 0.69 
4 1.93 187.0065 C7H7O4S[H-] 0 P-Cresyl Sulfate 
Plasma ↑ 7.09 40.84 1.43E-07 ↑ 26.36 1.56E-06 
1 
 
Liver ↑ 7.46 19.01 4.94E-10 ↑ 19.62 5.83E-10 0.82a 
Heart ↑ 7.87 40.03 4.90E-10 ↑ 15.58 5.53E-10 0.84a 
Kidney ↑ 5.31 4.17 4.16E-08 ↑ 12.29 1.90E-09 0.68a 
5 1.60 178.0503 C9H8NO3[H-] 0.6 Hippuric Acid 
Plasma ↑ 4.73 32.13 2.08E-10 ↑ 6.32 2.75E-10 
1 
 
Liver ↑ 7.09 12.42 4.89E-10 ↑ 4.50 4.91E-10 0.96 
Heart ↑ 8.37 27.02 4.89E-10 ↑ 3.50 6.57E-08 0.98 
Kidney ↑ 7.58 2.43 5.40E-10 ↑ 2.34 2.74E-09 0.73 
6 1.82 417.1186 C21H21O9[H-] 0 Equol 7-Glucoronide 
Plasma ↑ 5.18 21.65 2.08E-10 ↑ 4.24 8.55E-05 
1 
 
Liver ↑ 10.65 11.54 4.89E-10 ↑ 79.24 4.89E-10 0.88 
Heart ↑ 8.14 34.49 4.89E-10 ↑ 214.44 4.89E-10 0.92 
Kidney ↑ 7.89 5.04 4.89E-10 ↑ 70.97 4.89E-10 0.81 
7 1.59 188.9862 C6H5O5S[H-] 2.1 Pyrocatechol Sulfate 
Plasma ↑ 2.56 33.91 2.08E-10 ↑ 7.14 2.08E-10 
1 
 
Liver ↑ 6.21 39.39 4.89E-10 ↑ 7.62 4.89E-10 0.87 
Heart ↑ 6.15 55.45 4.89E-10 ↑ 6.40 4.89E-10 0.88 
Kidney ↑ 6.07 5.84 4.89E-10 ↑ 5.37 4.89E-10 0.75 
8 1.67 283.0822 C13H15O7[H-] 1.4 P-Cresyl Glucuronide 
Plasma ↑ 2.28 16.80 2.14E-10 ↑ 21.57 2.83E-10 
1 
 
Liver ↑ 2.35 4.60 5.27E-10 ↑ 10.71 3.68E-09 0.81 
Heart ↑ 4.03 28.26 4.90E-10 ↑ 25.45 4.97E-10 0.99 
Kidney ↑ 3.54 2.87 6.27E-08 ↑ 14.61 4.94E-10 0.85 
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metabolites that were increased in CKD included aromatic amino acid derivatives as well 
as pantothenic acid and glutathione, which also appeared in positive ESI mode (Fig. 5.4G 
and 5.5C). Positive ESI OPLS-DA demonstrated increased levels of L-carnitine and L-
carnitine derivatives in heart tissue of control rats compared to CKD. Rat kidneys had the 
greatest separation in negative and positive ESI mode OPLS-DA plots, and showed the 
best fit and predictive ability compared to all other biological matrices (Fig. 5.4D, R2(Y) 
= 1.0, Q2(Y) = 0.95, Fig. 5.5B, R2(Y) = 0.99, Q2(Y) = 0.92). CKD kidneys had higher 
levels of aromatic amino acid derivatives and adrenic acid. Both positive and negative 
ESI mode demonstrated increased levels of lysophosphatidylcholines and 
lysophosphoethanolamines in CKD. Control kidneys had higher levels of similar fatty 
acids seen in control livers including linoleic acid and arachidonic acid. DHA 
glychocholic acid, L-carnitine and L-carnitine derivatives were also increased in control 
kidneys compared to CKD.  
5.3.4 Common Significant Metabolites  
A second order analysis in metaXCMS was used to determine common metabolic 
differences in plasma, liver, heart and kidney tissue between control and CKD rats. All 
tissues shared 8 common metabolites, which were significantly increased in CKD 
compared to control rats (Fig. 5.6A).  All 8 metabolites were gut derived uremic toxins 
and included the aromatic amino acid derivatives: phenyl sulfate, indoxyl sulfate, p-
cresyl sulfate, hippuric acid, pyrocatechol sulfate and p-cresol glucuronide as well as 4-
ethylphenyl sulfate and equol 7-glucuronide (Fig. 5.7, Table 5.2). These 8 metabolites 
were significantly decreased in CKD+AST-120 rats compared to CKD. Plasma levels of 
these metabolites also showed a significant correlation with liver, heart and kidney levels 
(Table 5.2, Supplementary Fig. C5, Appendix C). In positive ESI mode, L-carnitine and 
many of the L-carnitine derivatives found to be significantly different between control 
and CKD rats in pairwise comparisons were shared between heart and kidney tissue (Fig. 
5.6B). 
 
138 
 
 
Figure 5.5 Orthogonal partial least squares discriminant analysis (OPLS-DA) and S-plots 
of control and CKD biological matrices in positive ESI mode. 
Control (n) and CKD (l) positive ESI mode OPLS-DA of heart (A) (R2(Y) = 0.98, 
Q2(Y)=0.86), and kidney (B) (R2(Y) = 0.99, Q2(Y) = 0.92) tissue in rats. Triplicate 
injections are shown. S-plots showing ions that define the CKD group in the upper right 
quadrant and ions that define control group in the lower left quadrant for plasma (E), liver 
(F), heart (G) and kidney (H) tissue. Ions with the greatest contribution in separating 
control and CKD groups are labeled and defined in Supplementary Table C2, Appendix 
C.  
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Figure 5.6 Meta-analysis of significantly different metabolites between control and CKD 
in biological matrices.  
A second-order analysis of significantly different metabolites in negative ESI mode for 
plasma, heart, liver and kidney tissue (A) and positive ESI mode for heart and kidney 
tissue (B). Highly significant metabolites (p < 0.01, q < 0.001, and maximum intensity > 
1500) were used for second-order analysis. Second-order analysis parameters included 
fold-changes ≥ 1.5 and p < 0.05 for Tukey’s post-hoc test. Common metabolites between 
biological matrices were aligned using a m/z = 0.01 and a retention time = 20 s tolerance. 
Information about the 8 common metabolites between all biological matrices in negative 
ESI mode is listed in Table 5.2.  
140 
 
 
 
Figure 5.7 Common significantly different metabolites found in all biological matrices.  
Plasma, liver, heart and kidney levels of the 8 gut-derived metabolites found to be 
significantly different in Fig. 5.5A: 4-ethylphenyl sulfate (A), phenyl sulfate (B), indoxyl 
sulfate (C), p-cresyl sulfate (D), hippuric acid (E), equol 7-glucuronide (F), pyrocatechol 
suflate (G) and p-cresyl glucuronide (H). Controls were arbitrarily defined as 100%. 
Results are means ± SEM; n = 10 (control) and n = 7 (CKD and CKD+AST-120). * p < 
0.05 vs control and CKD+AST-120. 
 
 
141 
 
5.4 Discussion 
In this study, rat plasma, liver, heart and kidney metabolic signatures were evaluated in 
CKD with and without the administration of AST-120. Rat plasma metabolic changes in 
CKD have been assessed in previous studies with the use of AST-120 (Kikuchi et al., 
2010; Akiyama et al., 2012). Renal metabolic profiles in negative ESI mode have also 
been evaluated in rats with CKD (Zhao et al., 2013); however, this study is the first to 
assess tissue metabolic signatures in heart, liver and kidney including the metabolic axis 
between plasma and tissues. We demonstrate that the uremic condition causes a number 
of metabolic changes in both plasma and tissues in CKD and that many of these can be 
mitigated with AST-120. 
The accumulation of uremic toxins in plasma and their contribution to the residual 
syndrome can be deleterious to patients with CKD (Depner, 2001). Non-invasive plasma 
sampling is crucial for evaluating the uremic condition in patients; however, to further 
our understanding of the metabolic interaction between plasma and tissues in CKD, tissue 
metabolic signatures must be directly assessed. A total of 29, 149, 72 and 236 metabolites 
were significantly altered between control and CKD rats for plasma, liver, heart and 
kidney, respectively (Fig. 5.6). Only 10 of the 29 metabolites in plasma were also 
significantly altered in other tissues. This accounted for less than 14% of metabolites that 
were significantly different between control and CKD rats in liver, heart and kidney 
tissues. Therefore, tissue metabolic signatures of CKD were weakly represented in 
plasma samples. 
Rats with CKD had reduced kidney function that was not significantly affected by AST-
120. The majority of plasma metabolites increased in CKD were reduced by 
administration of AST-120, suggesting that a number of these metabolites are derived 
from the gut or produced from the effects of gut-derived uremic toxins on in vivo 
metabolic processes (Fig. 5.1C).  Surprisingly, more than 50% of metabolites were 
reduced by administration of AST-120 in both liver and heart tissue metabolic profiles 
(Fig. 5.1D, 5.2C). Therefore, although kidney function was not altered by AST-120, a 
number of tissue metabolic processes are affected by gut-derived metabolites.  
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The 8 metabolites that were significantly increased in all biological matrices were also 
significantly reduced by AST-120 (Fig. 5.6A, 5.7). P-cresyl sulfate, p-cresyl glucuronide, 
indoxyl sulfate, hippuric acid and phenyl sulfate are known gut-derived uremic toxins 
(Meyer and Hostetter, 2012). Gut precursors of p-cresyl sulfate, indoxyl sulfate, p-cresyl 
glucuronide and phenyl sulfate undergo sulfation or glucuronidation, which occurs 
through phase II drug metabolizing enzymes (Banoglu and King, 2002; Kikuchi et al., 
2010). The major site of phase II drug metabolism is in the liver and therefore, hepatic 
metabolism of gut precursors plays a major role in the accumulation of these toxins. Gut-
derived toxins can also affect hepatic drug metabolizing enzymes. Cytochrome P450 3A4 
metabolizes approximately 40% of drugs on the market and indoxyl sulfate levels have 
been correlated with decreased levels of the CYP3A4 endogenous metabolite, 4β-
hydroxycholesterol (Zanger and Schwab, 2013; Suzuki et al., 2014). Once in the blood 
stream, these uremic toxins are also highly protein bound and both p-cresyl sulfate and 
indoxyl sulfate renal clearance is mediated by organic anion transporters (OAT) 1 and 3 
in the kidney (Miyamoto et al., 2011; Wikoff et al., 2011). Only the free fraction of these 
uremic toxins can exhibit biological effects or undergo transport into cells. In OAT1 
knock-out mice, indoxyl sulfate, p-cresyl sulfate, phenyl sulfate and pantothenic acid 
accumulate in plasma (Wikoff et al., 2011). Therefore, increased levels of these toxins in 
both plasma and tissues are likely a result of decreased OAT1 function in the kidneys of 
rats with CKD.  
In this study, we demonstrate for the first time that both p-cresyl sulfate and indoxyl 
sulfate accumulate in heart tissue and can be mitigated by AST-120 in vivo. P-cresyl 
sulfate is a gut-derived bacterial metabolite produced from tyrosine. In a prospective 
clinical study, free p-cresyl sulfate levels predicted cardiovascular mortality and all-cause 
mortality in dialysis patients (Wu et al., 2012). The effect of p-cresyl sulfate on cardiac 
toxicity and dysfunction were recently published in rats with CKD suggesting NADPH 
oxidase activation and ROS as possible mechanisms in p-cresyl sulfate mediated cardiac 
apoptosis (Han et al., 2015). Indoxyl sulfate is formed from tryptophan and has been 
shown to cause pro-fibrotic, pro-inflammatory and pro-hypertrophic affects through p38 
MAPK, p42/44 MAPK, and NF-κB pathways in both rat cardiac myocytes and 
fibroblasts in vitro (Lekawanvijit et al., 2010). In patients, indoxyl sulfate has been 
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associated with the first heart failure event, and removal of indoxyl sulfate by AST-120 
has been shown to improve cardiac function (Shibahara and Shibahara, 2010; Cao et al., 
2015). Prevention of cardiovascular disease in CKD is essential as these patients are more 
likely to die of cardiovascular disease than progress to requiring dialysis (Sarnak et al., 
2003). P-cresyl sulfate and indoxyl sulfate are increased 361-fold and 438-fold, 
respectively, in CKD heart tissue compared to control (Fig. 5.7A, B). Therefore, 
accumulation of these uremic toxins in the heart may provide evidence for potential 
mechanisms of cardiovascular disease development in CKD.  
Pyrocatechol sulfate is a dietary phenolic metabolite that has not been previously 
described as a uremic toxin (Hanhineva et al., 2015). Equol 7-glucoronide and 4-ethyl 
phenyl sulfate are also produced from gut bacteria but are specifically derived from soy 
protein. Standard rat chow includes soy as the main source of protein and the diet used in 
this study contained daidzein and genistein aglycone equivalents between 350 and 650 
mg/kg, which are metabolized by gut bacteria into precursors of equol 7-glucuronide and 
4-ethylphenyl sulfate, respectively (Setchell and Clerici, 2010; Yang et al., 2012). These 
uremic toxins have not been identified in patients with CKD. Intestinal bacteria produce 
equol in 20-30% of Western populations and 40-60% of Asian populations (Setchell and 
Clerici, 2010; Rafii, 2015). Consequently, equol may only accumulate in patients who 
both consume soy protein and have the gut bacteria to convert daidzein to equol. 
Although all patients with CKD will have high aromatic amino acid derived uremic 
toxins levels, accumulation of equol 7-glucuronide and 4-ethyl phenyl sulfate 
demonstrate the importance of diet on the production of uremic toxins in CKD. The 8 
common metabolites identified had the highest variable importance in projection (VIP) 
values defining CKD in plasma and tissue S-plots (Fig. 5.4 and Table 5.2). Therefore, 
gut-derived uremic toxins provide the most definitive metabolic signatures of both 
plasma and tissue in CKD. Tissue accumulation of these gut-derived uremic toxins in 
patients is unknown; however, in this study, we demonstrate that plasma levels of the 8 
gut-derived metabolites were highly correlated with tissue levels (Supplementary Figure 
C5, Appendix C). This suggests that the non-invasive measurement of these 8 gut-derived 
uremic toxins in plasma may be used as a surrogate for tissue levels in CKD. 
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In control animals, higher levels of free fatty acids were observed in liver tissue, which 
were decreased in animals with CKD. These included palmitic acid, oleic acid, linoleic 
acid, arachidonic acid, EPA and DHA (Fig. 5.4 and Supplementary Table C2, Appendix 
C). All of these fatty acids are provided in the rat diet. A previous study identified 
increased palmitic acid levels in feces of rats with adenine induced CKD (Zhao et al., 
2012). Therefore, it is possible that absorption of palmitic acid is compromised in rats 
with CKD. The depletion of both EPA and DHA in kidney tissue of rats with CKD is 
demonstrated in this study and others (Zhao et al., 2013; Zhao et al., 2014). Although 
plasma levels of these fatty acids were not detected, patients on dialysis have lower 
plasma levels of EPA and DHA, which are unaltered in non-dialysis CKD patients 
(Nakamura et al., 2008). A recent clinical study supplementing CKD patients with 
omega-3 fatty acids showed increases in specialized pro-resolving lipid mediators, which 
can inhibit pro-inflammatory cytokine production and potentially decrease low grade 
inflammation in CKD (Mas et al., 2015). AST-120 recovered free fatty acid levels in 
animals with CKD (see Supplementary Table C2, Appendix C).  
Fatty acids are an important energy source for cardiac tissue, which can be utilized via β-
oxidation (Rebouche, 1992). L-carnitine mediated transport of long chain fatty acids into 
the mitochondria is the rate-limiting step in fatty acid oxidation (Flanagan et al., 2010). In 
this study, we demonstrate decreased levels of L-carnitine and L-carnitine derivatives in 
heart tissue from rats with CKD. Cardiac tissue cannot synthesize L-carnitine, which 
must be obtained through plasma from dietary sources or production in the liver and 
kidney. L-carnitine is cleared through the dialysis membrane resulting in decreased levels 
for dialysis patients; however, levels in CKD patients are not correlated with kidney 
function (Fouque et al., 2006). In humans, 75% of L-carnitine is obtained from the diet 
(De Vivo and Tein, 1990; Flanagan et al., 2010). The standard rat diet used in this study 
was not supplemented with L-carnitine. As a result, it is possible that synthesis of L-
carnitine is decreased in rats with CKD; however, this effect is not seen in patients due to 
substantial dietary L-carnitine consumption. AST-120 recovered levels of L-carnitine in 
CKD rats and therefore gut-derived uremic toxins may affect the synthesis of L-carnitine 
(see Supplementary Table C2, Appendix C). 
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In summary, gut-derived metabolic signatures most prominently defined plasma, liver, 
heart and kidney tissues in rats with CKD. The majority of these compounds were 
aromatic amino acid metabolites. Increased levels of soy protein metabolites 4-ethyl 
phenyl sulfate and equol-glucuronide, which have not been described in patients with 
CKD, emphasize the potential for dietary effects on individual uremic toxin profiles. This 
study also highlights the gut-plasma-tissue metabolic axis, directly demonstrating the 
accumulation of gut-derived uremic toxins in multiple major organs of rats with CKD. 
146 
 
5.5 References 
Akiyama Y, Takeuchi Y, Kikuchi K, Mishima E, Yamamoto Y, Suzuki C, Toyohara T, 
Suzuki T, Hozawa A, Ito S, Soga T, and Abe T (2012) A metabolomic approach 
to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary 
electrophoresis with mass spectrometry (CE-MS). Toxins (Basel) 4:1309-1322. 
Akizawa T, Koide K, and Koshikawa S (1998) Effects of Kremezin® on patients with 
chronic renal failure: Results of a nationwide clinical study. Kidney Dial 45:373-
388. 
Banoglu E and King RS (2002) Sulfation of indoxyl by human and rat aryl (phenol) 
sulfotransferases to form indoxyl sulfate. Eur J Drug Metab Pharmacokinet 
27:135-140. 
Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, 
Vanholder R, Massy ZA, and European Uremic Toxin Work G (2009) Serum 
indoxyl sulfate is associated with vascular disease and mortality in chronic kidney 
disease patients. Clin J Am Soc Nephrol 4:1551-1558. 
Beger RD (2013) A review of applications of metabolomics in cancer. Metabolites 
3:552-574. 
Cao XS, Chen J, Zou JZ, Zhong YH, Teng J, Ji J, Chen ZW, Liu ZH, Shen B, Nie YX, 
Lv WL, Xiang FF, Tan X, and Ding XQ (2015) Association of indoxyl sulfate 
with heart failure among patients on hemodialysis. Clin J Am Soc Nephrol 
10:111-119. 
Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu 
J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Li S, Peng Y, 
Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, 
Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik 
C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers 
PW, and Agodoa L (2010) Excerpts from the US Renal Data System 2009 Annual 
Data Report. Am J Kidney Dis 55:S1-420, A426-427. 
De Vivo D and Tein I (1990) Primary and secondary disorders of carnitine metabolism. 
Int Pediatr 5:134-141. 
Depner TA (2001) Uremic toxicity: urea and beyond. Semin Dial 14:246-251. 
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A, 
and European Uremic Toxin Work G (2012) Normal and pathologic 
concentrations of uremic toxins. J Am Soc Nephrol 23:1258-1270. 
147 
 
Feigenbaum J and Neuberg CA (1941) Simplified Method for the Preparation of 
Aromatic Sulfuric Acid Esters. Journal of the American Chemical Society 
63:3529-3530. 
Flanagan JL, Simmons PA, Vehige J, Willcox MD, and Garrett Q (2010) Role of 
carnitine in disease. Nutr Metab (Lond) 7:30. 
Fouque D, Holt S, Guebre-Egziabher F, Nakamura K, Vianey-Saban C, Hadj-Aissa A, 
Hoppel CL, and Kopple JD (2006) Relationship between serum carnitine, 
acylcarnitines, and renal function in patients with chronic renal disease. J Ren 
Nutr 16:125-131. 
Han H, Zhu J, Zhu Z, Ni J, Du R, Dai Y, Chen Y, Wu Z, Lu L, and Zhang R (2015) p-
Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney 
disease by enhancing apoptosis of cardiomyocytes. J Am Heart Assoc 4:e001852. 
Hanhineva K, Lankinen MA, Pedret A, Schwab U, Kolehmainen M, Paananen J, de 
Mello V, Sola R, Lehtonen M, Poutanen K, Uusitupa M, and Mykkanen H (2015) 
Nontargeted metabolite profiling discriminates diet-specific biomarkers for 
consumption of whole grains, fatty fish, and bilberries in a randomized controlled 
trial. J Nutr 145:7-17. 
KEEP (2011) KEEP 2010 Summary Figures, Reference Tables, and Analytical Methods. 
Am J Kidney Dis 57:S32-S166. 
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, and Niwa T (2010) Metabolomic 
search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by 
liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci 878:2997-3002. 
Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, and Krum H (2010) Does 
indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and 
myocytes? Eur Heart J 31:1771-1779. 
Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, and Vanholder R (2000) 
Intradialytic removal of protein-bound uraemic toxins: role of solute 
characteristics and of dialyser membrane. Nephrol Dial Transplant 15:50-57. 
Mas E, Barden A, Burke V, Beilin LJ, Watts GF, Huang RC, Puddey IB, Irish AB, and 
Mori TA (2015) A randomized controlled trial of the effects of n-3 fatty acids on 
resolvins in chronic kidney disease. Clin Nutr. 
McCullough PA, Vassalotti JA, Collins AJ, Chen SC, Bakris GL, and Whaley-Connell 
AT (2011) National Kidney Foundation's Kidney Early Evaluation Program 
(KEEP) annual data report 2010: executive summary. Am J Kidney Dis 57:S1-3. 
Meyer TW and Hostetter TH (2007) Uremia. N Engl J Med 357:1316-1325. 
148 
 
Meyer TW and Hostetter TH (2012) Uremic solutes from colon microbes. Kidney Int 
81:949-954. 
Miyamoto Y, Watanabe H, Noguchi T, Kotani S, Nakajima M, Kadowaki D, Otagiri M, 
and Maruyama T (2011) Organic anion transporters play an important role in the 
uptake of p-cresyl sulfate, a uremic toxin, in the kidney. Nephrol Dial Transplant 
26:2498-2502. 
Nakamura N, Fujita T, Kumasaka R, Murakami R, Shimada M, Shimaya Y, Osawa H, 
Yamabe H, and Okumura K (2008) Serum lipid profile and plasma fatty acid 
composition in hemodialysis patients--comparison with chronic kidney disease 
patients. In Vivo 22:609-611. 
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 
39:S1-266. 
Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, 
Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, 
Pennathur S, Meyer TW, and Krolewski AS (2014) Uremic solutes and risk of 
end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 
85:1214-1224. 
Niwa T and Ise M (1994) Indoxyl sulfate, a circulating uremic toxin, stimulates the 
progression of glomerular sclerosis. J Lab Clin Med 124:96-104. 
Patti GJ, Tautenhahn R, and Siuzdak G (2012) Meta-analysis of untargeted metabolomic 
data from multiple profiling experiments. Nat Protoc 7:508-516. 
Rafii F (2015) The role of colonic bacteria in the metabolism of the natural isoflavone 
daidzin to equol. Metabolites 5:56-73. 
Rebouche CJ (1992) Carnitine function and requirements during the life cycle. FASEB J 
6:3379-3386. 
Rhee EP (2015) Metabolomics and renal disease. Curr Opin Nephrol Hypertens 24:371-
379. 
Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, Steele DJ, Thadhani R, Clish CB, 
Greka A, and Gerszten RE (2010) Metabolite profiling identifies markers of 
uremia. J Am Soc Nephrol 21:1041-1051. 
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough 
PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa 
DJ, Wilson PW, American Heart Association Councils on Kidney in 
Cardiovascular Disease HBPRCC, Epidemiology, and Prevention (2003) Kidney 
disease as a risk factor for development of cardiovascular disease: a statement 
from the American Heart Association Councils on Kidney in Cardiovascular 
149 
 
Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology 
and Prevention. Hypertension 42:1050-1065. 
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, and Shimizu M 
(2015) Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am 
Soc Nephrol 26:1732-1746. 
Setchell KD and Clerici C (2010) Equol: history, chemistry, and formation. J Nutr 
140:1355S-1362S. 
Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, Pu M, Sharma S, You 
YH, Wang L, Diamond-Stanic M, Lindenmeyer MT, Forsblom C, Wu W, Ix JH, 
Ideker T, Kopp JB, Nigam SK, Cohen CD, Groop PH, Barshop BA, Natarajan L, 
Nyhan WL, and Naviaux RK (2013) Metabolomics reveals signature of 
mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 24:1901-
1912. 
Shibahara H and Shibahara N (2010) Cardiorenal protective effect of the oral uremic 
toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J 
Nephrol 23:535-540. 
Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, Whaley-
Connell AT, Bakris GL, and McCullough PA (2011) Comparison of the CKD 
Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal 
Disease (MDRD) study equations: risk factors for and complications of CKD and 
mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 
57:S9-16. 
Suzuki Y, Itoh H, Fujioka T, Sato F, Kawasaki K, Sato Y, Sato Y, Ohno K, Mimata H, 
and Kishino S (2014) Association of plasma concentration of 4beta-
hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of 
indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos 42:105-
110. 
Tautenhahn R, Cho K, Uritboonthai W, Zhu Z, Patti GJ, and Siuzdak G (2012) An 
accelerated workflow for untargeted metabolomics using the METLIN database. 
Nat Biotechnol 30:826-828. 
Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, 
Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, 
Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel 
P, Tetta C, Wanner C, Zidek W, and European Uremic Toxin Work G (2003) 
Review on uremic toxins: classification, concentration, and interindividual 
variability. Kidney Int 63:1934-1943. 
Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke 
T, Mischak H, Spasovski G, Massy Z, Jankowski J, and European Uremic Toxin 
Work G (2007) Review on uraemic solutes II--variability in reported 
150 
 
concentrations: causes and consequences. Nephrol Dial Transplant 22:3115-
3121. 
Wang CH, Cheng ML, Liu MH, Shiao MS, Hsu KH, Huang YY, Lin CC, and Lin JF 
(2015) Increased p-cresyl sulfate level is independently associated with poor 
outcomes in patients with heart failure. Heart Vessels. 
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, 
Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato 
JA, Lusis AJ, and Hazen SL (2011) Gut flora metabolism of phosphatidylcholine 
promotes cardiovascular disease. Nature 472:57-63. 
Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, and Nigam SK (2011) Untargeted 
metabolomics identifies enterobiome metabolites and putative uremic toxins as 
substrates of organic anion transporter 1 (Oat1). J Proteome Res 10:2842-2851. 
Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, and Wu MS (2012) Serum free p-
cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly 
hemodialysis patients--a prospective cohort study. Nephrol Dial Transplant 
27:1169-1175. 
Yang Z, Kulkarni K, Zhu W, and Hu M (2012) Bioavailability and pharmacokinetics of 
genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem 
12:1264-1280. 
Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic variation. 
Pharmacol Ther 138:103-141. 
Zhao YY, Chen H, Tian T, Chen DQ, Bai X, and Wei F (2014) A pharmaco-
metabonomic study on chronic kidney disease and therapeutic effect of ergone by 
UPLC-QTOF/HDMS. PLoS One 9:e115467. 
Zhao YY, Cheng XL, Wei F, Bai X, and Lin RC (2012) Application of faecal 
metabonomics on an experimental model of tubulointerstitial fibrosis by ultra 
performance liquid chromatography/high-sensitivity mass spectrometry with 
MS(E) data collection technique. Biomarkers 17:721-729. 
Zhao YY, Lei P, Chen DQ, Feng YL, and Bai X (2013) Renal metabolic profiling of 
early renal injury and renoprotective effects of Poria cocos epidermis using UPLC 
Q-TOF/HSMS/MSE. J Pharm Biomed Anal 81-82:202-209. 
 
151 
4The material in this chapter is based on a manuscript in preparation: Velenosi TJ, Tieu 
A, Kucey A, Urquhart BL. (2015) 2. The effects of gut-derived uremic toxins on hepatic 
drug metabolism in chronic kidney disease. In preparation 
 
 
 
 
 
 
6 THE EFFECT OF GUT-DERIVED UREMIC TOXINS 
ON THE EXPRESSION OF HEPATIC DRUG 
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6.1 Introduction 
CKD is the result of a progressive decline in renal function over time. According to the 
Kidney Early Evaluation Program (KEEP, 2000 to 2010) and the National Health and 
Nutritional Examination Survey (NHANES, 1996 to 2006), the prevalence of renal 
failure is estimated to be upwards of 14% in the United States (Saran et al., 2015). The 
leading causes of CKD are diabetes and vascular disease (primarily hypertension), which 
are prevalent in 40% and 31% of adults with CKD, respectively (National Kidney 
Foundation, 2002). Other comorbidities include cardiovascular disease and obesity. 
According to the United States Renal Data System (USRDS), there has been a 30% 
increase in diabetic related ESRD from 1994 to 2008 (Collins et al., 2012).  
Kidney function is determined based on estimated glomerular filtration rate (eGFR). The 
National Kidney Foundation divides CKD into 5 distinct stages classified by eGFR 
(National Kidney Foundation, 2002). Complications generally begin when eGFR is < 60 
ml/min per 1.73 m2 in stage 3, which contains more than half of all CKD patients and is 
the fastest growing stage of the disease (Coresh et al., 2007; Saran et al., 2015). CKD 
progresses when eGFR continues to decline until stage 5 (< 15 ml/min per 1.73m2) or 
end-stage renal disease (ESRD), where patients require renal replacement strategies such 
as dialysis or transplantation to sustain life. 
As renal function declines, organic waste products begin to accumulate in the blood. 
Uremia is the condition of increased organic waste products that are retained in CKD 
(Meyer and Hostetter, 2007; Meyer and Hostetter, 2014). A number of these organic 
waste products are derived from metabolites produced by bacteria in the colon. These 
include aromatic amino acid metabolites such as indoxyl sulfate, phenyl sulfate, hippuric 
acid, p-cresyl sulfate and p-cresyl glucuronide. We have previously identified these gut-
derived uremic toxins as the most definitive metabolic signatures of CKD in both plasma 
and liver, using untargeted metabolomics (Chapter 5). Plasma levels of indoxyl sulfate 
and p-cresyl sulfate have been correlated with cardiovascular events and implicated in the 
progression of CKD (Niwa and Ise, 1994; Watanabe et al., 2013; Cao et al., 2015; Wang 
et al., 2015). Unlike metabolic waste products that are produced by various organs in the 
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body, gut-derived uremic toxins are produced in an external environment in the colon 
lumen. Therefore, these metabolites can be targeted for removal through oral dosing of 
AST-120, a spherical carbon adsorbent. AST-120 has been used in a number of animal 
and clinical studies to limit the absorption of gut-derived uremic toxins (Inami et al., 
2014; Schulman et al., 2015; Yamamoto et al., 2015). Its large surface area and spherical 
shape allow it to bind small molecules, leaving large molecules such as digestive 
enzymes unaffected (Niwa et al., 1991; Schulman et al., 2015).  
End stage renal disease patients on dialysis have a daily median pill burden of 19, which 
is considered the highest of any chronic disease (Chiu et al., 2009). The incidence of 
adverse drug reactions (ADRs) is more prevalent in patients with CKD (Manley et al., 
2005). According to the Institute of Medicine, ADRs have become the 4th leading cause 
of death among hospitalized patients and approximately 2 million ADRs occur each year 
(Lazarou et al., 1998). In CKD patients, it is estimated that 1 medication problem occurs 
per 2.7 medication exposures (Manley et al., 2005). Inhibition and downregulation of 
drug metabolizing enzymes often lead to ADRs through increased systemic drug levels 
and subsequent toxicity. It is well understood that the renal clearance of drugs is 
compromised in renal failure; however, a number of studies have demonstrated that 
kidney disease can also affect non-renal clearance (Leblond et al., 2001; Naud et al., 
2008; Nolin et al., 2009; Thomson et al., 2015). 
Hepatic drug metabolism is the major route of drug elimination and is primarily mediated 
by the cytochrome P450 superfamily of oxidizing enzymes. Two major P450 isoforms, 
CYP3A4 and CYP2C9, metabolize 43% of clinically used drugs (Zanger and Schwab, 
2013). Many of these P450 enzymes are tightly regulated by nuclear receptors; 
specifically, PXR and HNF-4α regulate CYP3A drug metabolizing enzymes (Tirona et 
al., 2003). We have previously shown that CYP3A and CYP2C drug metabolizing 
enzyme function and expression are downregulated in rats with moderate and severe 
CKD (Chapter 3). We have also demonstrated that PXR and HNF-4α nuclear receptor 
binding and histone H3 and H4 acetylation are decreased in the promoter of CYP3A and   
that HNF-4α and histone H3 acetylation are decreased in the promoter of CYP2C 
(Chapter 4).  
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A number of literature reviews have suggested that uremic toxins cause downregulation 
of drug metabolizing enzymes in CKD; however, it is unknown which uremic toxin(s) 
mediate this effect (Nolin et al., 2008; Velenosi and Urquhart, 2014; Yeung et al., 2014). 
A previous study demonstrated downregulation of CYP2C and CYP3A when treating 
primary rat hepatocytes with uremic serum from ESRD patients (Michaud et al., 2005). 
Therefore, the first aim of this study was to identify which uremic toxin(s) cause the 
down-regulation of hepatic CYP3A in vitro. Gut-derived uremic toxins have been shown 
to cause a number of deleterious effects in CKD (Meyer and Hostetter, 2012). For this 
reason, the second aim of this study was to determine if gut-derived uremic toxins down 
regulate hepatic drug metabolizing enzymes in CKD. We hypothesize that the removal of 
gut-derived uremic toxins, using AST-120, would recover expression and function of 
hepatic CYP2C and CYP3A in rats with CKD. 
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6.2 Methods 
6.2.1 In vitro Assessment of Uremic Toxins on CYP3A4 
Expression 
Human hepatoma Huh7 cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin and 2 
mM L-glutamine. Cells were grown at confluence for 4 weeks prior to treatment to 
ensure adequate CYP3A4 expression levels (Sivertsson et al., 2010). Huh7 cells were 
treated with creatinine (2121.6 µM), p-cresyl sulfate (186.1 µM), CMPF (391.7 µM), 
guanidinosuccinic acid (268.6 µM), hippuric acid (2631.3 µM), indole-3-acetic acid (51.9 
µM), indoxyl sulfate (1113.2 µM), methylguanidine (24.9 µM), urea (76.6 mM) and a 
cocktail of the above uremic toxins at their listed concentration in the above maintenance 
media without FBS for 24 hours (Vanholder et al., 2003). Indoxyl sulfate and CMPF 
were obtained from Gold Biotechnology (Olivette, MO) and Cayman Chemical Company 
(Ann Arbor, MI), respectively. All other toxins were obtained from Sigma-Aldrich (St. 
Louis, MO). An indoxyl sulfate concentration-response effect on CYP3A4 mRNA 
expression was generated using a concentration range of indoxyl sulfate found in normal 
and CKD patients (0 to 1000 µM) with 40 g/L human serum albumin (HSA, Lee 
Biosolutions, St. Louis, MO)(Duranton et al., 2012). Indoxyl sulfate was incubated in 
media containing 40 g/L HSA for 3 hours at 37°C to allow for plasma protein binding 
equilibration prior to cell treatment. Cell viability was assessed using the TACS 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously 
described (Arp et al., 2005).  
6.2.2 Animal Model 
Studies were performed in 40 male Wistar rats initially divided into two groups. Each 
group received a control diet or 0.5% adenine supplemented into rat chow for 5 weeks to 
induce CKD. After 5 weeks, groups were equally divided and rats received either a 
control diet or 8% AST-120 supplemented into rat chow for 3 weeks. Control rats in the 
study were pair-fed the same amount of rat chow that was ingested by CKD rats on the 
previous day. Upon completion of the study, control, control+AST-120, CKD and 
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CKD+AST-120 groups each contained 10 animals (Fig. 6.1). Rats were sacrificed 8 
weeks after the initiation of the study and liver tissue was harvested, flash frozen in liquid 
nitrogen and stored at -80°C prior to analysis.  Plasma creatinine and urea were 
determined by the London Laboratory Services Group by standard methods.  
6.2.3 Plasma Quantification of Gut-derived Uremic Toxins 
Plasma protein was precipitated with ice-cold acetonitrile containing isatin as internal 
standard in a 3:1 acetonitrile:plasma ratio. Samples were placed on ice for 20 minutes and 
centrifuged at 14,000 g for 5 minutes. The supernatant was injected onto a Waters 
Acquity UPLCTM BEH C18 column (1.7 µm, 50 X 2.1 mm) maintained at 40°C in a 
Waters Acquity UPLC I-Class system. The mobile phase flow was set to 0.5 ml/min and 
consisted of water (A) and acetonitrile (B), both containing 0.1% formic acid. The UPLC 
conditions were as follows: 0-0.5 mins, 0%B; 0.5-2.5 mins 0-60%B; 2.5-3.5 mins 80%B; 
3.5-4.5 mins 0%B. The total run time was 4.5 minutes. Indoxyl sulfate, p-cresyl sulfate 
and hippuric acid were detected using a Waters XevoTM G2S-QToFMS operated in 
negative electrospray ionization mode. Capillary voltage and cone voltage were set at 0.5 
kV and 40 V, respectively. The source temperature was 150°C.  The desolvation gas flow 
was set to 1200 L/h at 600°C and the cone gas flow was 50 L/h. Lockspray was used to 
ensure mass accuracy. Leucine-enkephalin (500 ng/mL) was used as the lockmass set at a 
flow rate of 10 µL/min, measured every 10 s and averaged over 3 scans. 
6.2.4 RNA Extraction and Real-time PCR Analysis 
RNA was extracted from rat livers using TRIzol and cDNA was synthesized from 1 µg of 
total RNA using qScript cDNA Supermix (Quanta BioSciences, Inc., Gaithersburg, MD). 
Relative mRNA expression was quantified by real-time PCR using primer sets for 
CYP2C11 (forward) 5′-CCCTGAGGACTTTTGGGATGGGC-3′ and (reverse) 5′- 
AGGGGCACCTTTGCTCTTCCTC-3′, CYP3A2 (forward) 5′- 
GCTCTTGATGCATGGTTAAAGATTTG-3′ and (reverse) 5′- 
ATCACAGACCTTGCCAACTCCTT-3′,  
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Figure 6.1 Study diet schedule for rats with CKD given AST-120, n = 10. 
Weeks
Control+
5 6 7 80 1 2 3 4
Control+++8%+AST:120
0.5%+Adenine
Control+++8%+AST:120Control+
0.5%+Adenine
Control+
Control+
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β-actin (forward) 5′- ACGAGGCCCAGAGCAAGA-3′ and (reverse) 5′-
TTGGTTACAATGCCGTGTTCA-3′, CYP3A4 (forward) 5′-
CAGGAGGAAATTGATGCAGTTTT-3′ and (reverse) 5′-
GTCAAGATACTCCATCTGTAGCACAGT-3′, and 18S (forward) 5′-
GTAACCCGTTGAACCCATT-3′ and (reverse) 5′-CCATCCAATCGGTAGTAGCG-3′. 
PerfeCta SYBR Green Fastmix (Quanta BioSciences, Inc., Gaithersburg, MD) was used 
to amplify and quantify cDNA. Gene expression was normalized to β-actin or 18S rRNA 
by the ∆∆CT method.  
6.2.5 Western Blot Analysis  
Hepatic microsomal fractions were isolated and used to assess protein expression of 
CYP2C11 and CYP3A2 by Western blot analysis as previously described (Chapter 3). 
Briefly, 20 µg of microsomal protein was resolved by 10% SDS-PAGE and transferred to 
nitrocellulose membranes.  Immunoblots were performed for CYP2C11 (Detroit R&D 
Inc., Detroit, MI) and CYP3A2 (Millipore, Billerica, MA). Secondary HRP-linked 
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). β-actin 
HRP-linked primary antibody was used as an internal control (Sigma, St. Louis, MO). 
Immune complexes were revealed by horseradish peroxidase (Millipore, Billerica, MA) 
and band intensity determined by densitometry (Quantity One 1-D Analysis Software on 
a VersaDoc Imaging System, Bio-Rad, Hercules, CA).  
6.2.6 Hepatic CYP3A and CYP2C Microsomal Metabolism  
Midazolam and testosterone were used as probe drugs to determine CYP2C11 and 
CYP3A hepatic microsomal activity, respectively, as previously described with some 
modifications (Chapter 3). CYP3A metabolizes midazolam to 1’OH-midazolam and 
4’OH-midazolam. CYP2C11 metabolizes testosterone to 16α-OH testosterone. Increasing 
concentrations of midazolam or testosterone were incubated with 0.2 mg/mL microsomal 
protein at 37°C to generate Michalis-Menten kinetic curves. Reactions were initiated with 
the addition of 1 mM NADPH.  Ice-cold acetonitrile, containing flurazepam as internal 
standard, was added at 10 and 20 minutes for midazolam and testosterone reactions, 
respectively, in a 3:1 ratio to stop metabolic activity. Formation of 1’OH-midazolam and 
159 
 
4’OH-midazolam occurs through CYP3A metabolism and formation of 16α-OH 
testosterone occurs through CYP2C11 metabolism. Linear enzyme activity at these time 
points was validated prior to Michaelis-Menten experiments. Samples were incubated on 
ice for 20 minutes, centrifuged at maximum speed, diluted in mobile phase and analyzed 
by UPLC-QToFMS analysis. Mobile phase consisted of water (A) and acetonitrile (B), 
both containing 0.1% formic acid, and flow was set to 0.6 ml/min on a Waters Acquity 
UPLCTM BEH C18 column (1.7 µm, 50 X 2.1 mm) at 40°C. For midazolam metabolites, 
mobile phase gradient of 0-2.5 mins 20-35%B, 2.5-3.5 mins 80%B and 3.5-4.5 mins 
20%B was used. Testosterone metabolites were separated with the following mobile 
phase parameters: 0-2 mins 20-80%B, 2-3 mins 80%B and 3-4 mins 20%B. Metabolites 
were quantified by Waters XevoTM G2S-QTofMS in positive electrospray ionization 
mode, using the same settings as described above. 
6.2.7 Data and Statistical Analysis 
One-way ANOVA with Tukey’s multiple comparison tests were used to determine 
statistical differences between control, control+AST-120, CKD and CKD+AST-120 
groups. Dunnet’s post-hoc test was used to compare indoxyl sulfate treatments to 
baseline in Huh7 cells. Enzyme kinetic data was fitted with a Michaelis-Menten model to 
define the maximum enzyme velocity (Vmax) and Michaelis constant (Km) for midazolam 
and testosterone probe substrates. 
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6.3 Results 
6.3.1 Indoxyl Sulfate Downregulates Hepatic CYP3A4 Expression 
in vitro    
To investigate the mechanism of CYP3A downregulation in CKD, human hepatoma 
Huh7 cells were treated with selected uremic toxins as well as a combination of these 
toxins. As an initial proof-of-concept screen, concentrations of uremic toxins used were 
the highest found in patients with CKD (Table 6.1) (Vanholder et al., 2003; Duranton et 
al., 2012). A 24 hour indoxyl sulfate treatment decreased CYP3A4 mRNA expression by 
70% in Huh7 cells, which was equivalent to the effect demonstrated by the combination 
of toxins  (Fig. 6.1). Other individual uremic toxins did not affect CYP3A4 mRNA 
expression. Indoxyl sulfate is a protein bound uremic toxin; therefore, the concentration 
dependence of this effect was evaluated in the presence of 40 g/L HSA in the culture 
medium. Treatment with indoxyl sulfate for 48 hours produced a concentration-
dependent decrease in CYP3A4 mRNA expression as the concentration was increased 
from those measured in healthy controls to concentrations in patients with CKD (IC50 = 
113.0 ± 3.5 µM). A significant decrease in the steady-state levels of CYP3A4 mRNA was 
demonstrated when Huh7 cells were treated with ≥ 300 µM indoxyl sulfate in the 
presence of 40 g/L HSA supplemented media (Fig. 6.2A, p < 0.05). Huh7 cells treated 
with indoxyl sulfate in the uremic range resulted in a 21% to 95% decrease in CYP3A4 
mRNA expression. Cell viability was unaffected by indoxyl sulfate in media containing 
HSA after 48 hour treatment at clinically relevant concentrations  (Fig. 6.2B).  
6.3.2 Plasma Biochemistry and Body Weight 
Plasma creatinine was used as a measurement of kidney function. The CKD and 
CKD+AST-120 group had a ~3.3-fold and ~2.3-fold increase in plasma creatinine and 
urea levels, respectively, compared to control and control+AST-120 groups (Table 6.2, p 
< 0.05). There were no significant differences in weight between all four groups (Table 
6.2). Indoxyl sulfate, p-cresyl sulfate and hippuric acid plasma concentrations were 
significantly increased in CKD rats compared to control; however, plasma levels of these  
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Table 6.1 Normal and uremic serum concentrations of selected uremic toxins.  
Data are represented as mean ± SD (Duranton et al., 2012; Vanholder et al., 2003).  
Uremic Toxin 
Normal 
Concentration 
(µM) 
Mean Uremic 
Concentration 
(µM) 
Fold 
Increase 
Highest Uremic 
Concentration 
(µM) 
Creatinine <106.2 1203.5 ± 407.1 11.3 2121.6 
p-Cresyl Sulfate 10.1 ± 6.9 111.1 ± 64.8 11.0 186.1 
CMPF 32.08 ± 13.8 254.2 ± 68.8 7.9 391.7 
Guanidinosuccinic 
acid 0.17 ± 0.06 37.14 ± 19.40 217.2 268.6 
Hippuric acid <27.9 1379.9 ± 625.7 49.4 2631.3 
Indole-3-acetic 
acid 0.1 ± 0.1 5000 ± 3200 50.0 51.9 
Indoxyl Sulfate 2.4 ± 1.37 210.9 ± 72.1 88.6 1113.2 
Methylguanidine <0.1 10.6 ± 6.97 106.0 24.9 
Urea <6666.7 38333 ± 18333 5.7 76666.7 
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Figure 6.2 CYP3A4 mRNA expression in Huh7 cells treated with uremic toxins. 
CYP3A4 mRNA expression in Huh7 cells treated with 0.1% DMSO, creatinine (2121.6 
µM), p-cresyl sulfate (PCS, 186.1 µM), 3-carboxy-4-methyl-5-propyl-2-furanpropanoic 
acid (CMPF, 391.7 µM), guanidinosuccinic acid (GSA, 268.6 µM), hippuric acid (HA, 
2631.3 µM), indole-3-acetic acid (I3AA, 51.9 µM), indoxyl sulfate (IS, 1113.2 µM), 
methylguanidine (MG, 24.9 µM), urea (76.6 mM) and a cocktail of the above uremic 
toxins at their listed concentration in the absence of serum albumin for 24 hours. 
CYP3A4 mRNA expression was standardized to 18S rRNA and controls were arbitrarily 
defined as 100%. Results are presented as mean ± SEM, n = 3. 
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Figure 6.3 Huh7 CYP3A4 mRNA expression and cell viability in the presence of 
increasing indoxyl sulfate (IS) concentrations. 
Indoxyl sulfate (IS) concentration-dependent (0-1000 µM) effect on CYP3A4 mRNA 
expression in Huh7 cells (A). MTT assay for Huh7 cell viability in the presence of 0-
5000 µM IS (B). All treatments were performed in media supplemented with 40 g/L HSA 
for 48 hours. The grey solid area represent normal plasma IS concentrations mean 
(dashed line) ± 2SD. The grey-checkered area represents mean uremic concentration 
(dashed line) minus 2SD to the highest individual measured uremic concentration 
(Duranton et al., 2012). CYP3A4 mRNA expression was standardized to 18S rRNA and 
controls were arbitrarily defined as 100%. Results are presented as mean ± SEM, n ≥ 3, 
*p < 0.05 compared to control.  
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Table 6.2 Rat body weight and plasma biochemistry of 8 weeks after study initiation.  
Data are represented as mean ± SEM, n = 10.  
 
Control Control +AST-120 CKD 
CKD + AST-
120 
Body Weight (g) 277 ± 12 265 ± 13 280 ± 6 277 ± 5 
Creatinine (µM) 22.8 ± 0.6 23.3 ± 0.7 77.2 ± 8.1* 73.7 ± 6.7* 
Urea (mM) 6.59 ± 0.47 6.55 ± 0.35 14.6 ± 1.61* 15.74 ± 3.46* 
*p < 0.05 compared to control 
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Figure 6.4. Plasma indoxyl sulfate (A), p-cresyl sulfate (B), and hippuric acid (C) levels 
in control, control +AST-120, CKD, and CKD+AST-120 groups. 
Plasma levels were measured at the end of the 8-week study. Results are presented as 
mean ± SEM, n = 10, *p < 0.05 compared to control. 
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toxins were not significantly increased in CKD rats given AST-120 compared to controls 
(p < 0.05, Fig. 6.4). 
6.3.3 Hepatic CYP2C and CYP3A Enzyme Function 
To evaluate hepatic CYP2C and CYP3A enzyme function, microsomal metabolism of the 
probe drugs, midazolam and testosterone, were used as previously described (Velenosi et 
al., 2012). Midazolam is converted to 1’OH and 4’OH-midazolam by CYP3A and 
testosterone is converted to 16αOH-testosterone by CYP2C11. Enzyme kinetics revealed 
a 65.8% and 60.8% decrease in 1’OH-midazolam Vmax for CKD and CKD+AST-120 
groups, respectively, compared to control (p < 0.05, Fig. 6.5, Table 6.3).  Similarly, 
4’OH-midazolam Vmax was also significantly reduced by 86.7% and 84.6% for CKD 
and CKD+AST-120 groups, respectively, compared to control (p < 0.05, Fig. 6.5, Table 
6.3). There were no significant differences in Vmax values between control and 
control+AST-120 groups or CKD and CKD+AST-120 groups. The Vmax values for 
testosterone metabolism to 16αOH-testosterone were significantly decreased by 67% and 
62.5% for CKD and CKD+AST-120 groups, respectively, compared to control (p < 0.05, 
Fig. 6.5, Table 6.3). The Km values were unchanged between all groups for 4’OH-
midazolam and 16αOH-testosterone; however, the Km for 1’OH-midazolam was 
significantly reduced in CKD and CKD+AST-120.  
6.3.4 Hepatic CYP2C11 and CYP3A2 Protein and mRNA 
Expression 
CYP3A2 protein expression was decreased 88.7% and 81.7% in CKD and CKD+AST-
120 groups, respectively, compared to control (Fig. 6.6). CKD and CKD+AST-120 
groups also had a 62.3% and 73.7% decrease in CYP2C11 protein expression 
respectively, compared to control (Fig. 6.6). CYP3A2 mRNA expression was 
significantly decreased in CKD rats by 91.4% compared to control; however, AST-120 
recovered CYP3A2 mRNA expression by 25% in the CKD+AST-120 group which was 
not significantly different than control rats (Fig. 6.7). Hepatic CYP2C11 mRNA 
expression followed protein expression with a 71.6% and 61.7% decrease in CKD and 
CKD+AST-120 rats, respectively, compared to control (Fig. 6.7). 
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Figure 6.5 Michaelis-Menten kinetics of hepatic CYP3A and CYP2C drug metabolizing 
enzymes in control, control +AST-120, CKD and CKD+AST-120 rats. 
Michaelis-Menten plots of 1’OH midazolam (A), 4’OH midazolam (B) and 16αOH-
testosterone (C) in control (○), control +AST-120 (□), CKD (Δ) and CKD+AST-120 (▽) 
rats. Analysis was performed in duplicate and data is presented as mean ± SEM, n = 10.  
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Table 6.3 Michaelis-Menten kinetic values for P450 probe substrates in control, 
control+AST-120, CKD and CKD+AST-120 rat liver microsomes. 
Data are presented as means ± SEM. 
*p < 0.05 compared to control. 
 
  
 
1’OH-midazolam 4’OH-midazolam  16α-OH Testosterone 
Km  
(µM) 
Vmax 
(pmol min-1 
mg protein-1) 
Km  
(µM) 
Vmax 
(pmol min-1 
mg protein-1) 
Km  
(µM) 
Vmax 
(pmol min-
1mg protein-1) 
Control 7.62 ± 
0.61 68.52 ± 9.66 
4.828 ± 
2.78 109.2 ± 22.70 
9.834 ± 
0.98 2937 ± 393.5 
Control+ 
AST-120  7.10 ± 0.94  56.75 ± 6.37 
5.20 ± 
0.73 94.97± 16.74 
9.43 ± 
1.36 2223 ± 240.6 
CKD 2.97 ± 
0.59* 23.40 ± 3.02* 
4.71 ± 
0.43 14.58 ± 3.19* 
46.07 ± 
20.43 969.1 ± 285.3
* 
CKD+ 
AST-120 3.01 ± 0.82* 26.85 ± 2.45* 
4.51 ± 
0.62 16.80 ± 2.86* 
20.62 ± 
2.28 1099 ± 144.2
* 
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Figure 6.6 Protein expression of hepatic CYP2C11 (A) and CYP3A2 (B) in control, 
control +AST-120, CKD and CKD+AST-120 rats.  
Control bands were arbitrarily defined as 100% and results are presented as mean ± SEM, 
n = 10, *p < 0.05 compared to control. Representative blots are shown. 
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Figure 6.7 mRNA expression of hepatic CYP2C11 (A) and CYP3A2 (B) in control, 
control +AST-120, CKD and CKD+AST-120 rats.  
Control expression was defined as 100% and results are presented as mean ± SEM, n = 
10, *p < 0.05 compared to control. 
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6.4 Discussion 
In this report, we present an in vitro to in vivo study design to investigate uremic toxin 
downregulation of hepatic drug metabolizing enzymes in CKD. A screen of selected 
uremic toxins provided evidence for indoxyl sulfate downregulation of CYP3A4 in Huh7 
cells. Further characterization of this effect was demonstrated with a concentration-
dependent decrease in CYP3A4 mRNA expression using indoxyl sulfate concentrations 
found in patients with CKD. In vivo, removal of indoxyl sulfate and other gut-derived 
uremic toxins in rats with CKD provided a modest recovery of CYP3A2 mRNA 
expression. However, enzyme function and protein expression of CYP2C11 and CYP3A2 
drug metabolizing enzymes were unaffected by administration of AST-120 to rats with 
CKD.  
Uremic toxins screened in this study were chosen from meta-analysis reviews based on 
high plasma concentrations in CKD and fold change relative to normal kidney function 
(Table 6.1). These included the aromatic amino acid metabolites indoxyl sulfate, p-cresyl 
sulfate, and hippuric acid, which are increased in patient plasma as well as both plasma 
and liver tissue of animals with CKD. Although indoxyl sulfate, p-cresyl sulfate, and 
hippuric acid are protein-bound, in the absence of HSA, our initial screen demonstrated 
no effect of p-cresyl sulfate and hippuric acid on CYP3A4 mRNA expression in Huh7 
cells. Indoxyl sulfate, however, caused a pronounced downregulation of CYP3A4 
mRNA, which was similar to mRNA levels observed in the treatment combining all 
toxins. Consequently, this suggests that indoxyl sulfate caused downregulation of 
CYP3A4 both individually, and in the combined treatment. In the indoxyl sulfate 
concentration-dependent response, the range of indoxyl sulfate concentrations in normal 
plasma was defined within two standard deviations of the mean (0-5.09 µM). The range 
of indoxyl sulfate levels in patients with CKD was described as two standard deviations 
below the mean and the highest concentration published in a CKD patient (65.6-1113.2 
µM). These concentration ranges are mutually exclusive and CYP3A4 mRNA expression 
was decreased only in the uremic range (Fig. 6.3). The IC50 (113.0 µM) was also below 
the average indoxyl sulfate concentration measured in patients with CKD (210.9 µM, 
Table 6.1), indicating a physiologically relevant effect. This study is supported by a 
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previous study in CKD patients, which demonstrated a correlation between plasma 
indoxyl sulfate concentration and CYP3A4 enzyme function using the endogenous 
biomarker 4β-hydroxycholesterol (Suzuki et al., 2014). This biomarker is produced from 
CYP3A4 mediated cholesterol metabolism and is not cleared by the kidney (Diczfalusy et 
al., 2009). 4β-Hydroxycholesterol also has a 17-day half-life and can assess steady-state 
CYP3A4 function regardless of dialysis frequency. Although indoxyl sulfate and indole-
3-acetic acid plasma concentrations are strongly correlated with eGFR in CKD, indole-3-
acetic acid was not correlated with 4β-hydroxycholesterol plasma levels (Niwa and Ise, 
1994; Suzuki et al., 2014). Taken together, our in vitro data and the previous clinical 
study suggest that indoxyl sulfate contributes to the down-regulation of human hepatic 
CYP3A4 in CKD. 
Although we demonstrate CYP3A down-regulation by a single uremic toxin, the in vivo 
condition of uremia is highly complex. Therefore, to assess the effect of gut-derived 
uremic toxins, such as indoxyl sulfate, on hepatic CYP3A and CYP2C enzyme function 
and expression in vivo, we used a rat model of adenine-induced kidney disease and 
subsequently administered AST-120. Both CKD and CKD+AST-120 groups had similar 
levels of plasma creatinine, suggesting that AST-120 did not affect renal function 
following the adenine-induction of CKD (Table 6.2). The use of AST-120 in rodent 
models of CKD has been previously shown to reduce levels of indoxyl sulfate, p-cresyl 
sulfate and hippuric compared to CKD rats that do not receive the compound (Shimoishi 
et al., 2007; Inami et al., 2014). However, in many of these studies, the severe nature of 
the CKD results in significantly higher levels of indoxyl sulfate, p-cresyl sulfate and 
hippuric in CKD+AST-120 rats when compared to controls. Therefore, in this study, we 
developed a model of adenine-induced CKD with less severe kidney dysfunction. Using 
this model in combination with AST-120, we were able to decrease plasma gut-derived 
uremic toxin levels similar to those measured in control animals. 
Altered hepatic drug metabolism has been described in a number of studies in CKD 
(Leblond et al., 2000; Leblond et al., 2001; Michaud et al., 2005). Initial studies 
identified decreased hepatic CYP3A enzyme function using the erythromycin breath test 
(Leblond et al., 2000; Leblond et al., 2001). More recently, using both midazolam and 
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testosterone probe drugs, our group demonstrated an inverse exponential correlation 
between kidney function and CYP2C11 as well as CYP3A2 enzyme activity in rats with 
CKD (Chapter 3). In the current study, rats with a similar degree of CKD had decreased 
CYP2C11 and CYP3A2 enzyme function that was unaffected by the administration of 
AST-120. Protein expression of CYP2C11 and CYP3A2 were also unaffected by AST-
120 in rats with CKD; however mRNA levels of CYP3A2 were increased 25% in the 
CKD+AST-120 group compared to CKD. CYP3A2 mRNA expression is diminished to a 
greater degree than protein expression and enzyme function are in CKD. This is 
supported by previous studies, suggesting a transcriptional mechanism of downregulation 
(Leblond et al., 2001; Michaud et al., 2006; Velenosi et al., 2012; Velenosi et al., 2014). 
The mechanism of CYP3A2 downregulation has been attributed to decreased PXR, HNF-
4α recruitment and histone H3 and H4 acetylation in CKD (Chapter 4). Therefore, 
removal of gut-derived toxins using AST-120 may moderately recover CYP3A2 mRNA 
expression through nuclear receptor and epigenetic regulatory mechanisms; however, this 
effect did not translate into recovered protein expression and enzyme function. 
Although many of the same nuclear receptors regulate human and rat CYP3A drug 
metabolizing enzymes, there are distinct differences in nuclear receptor homology and 
promoter binding sites between species. CYP3A4 has both proximal and distal nuclear 
receptor binding regions, unlike CYP3A2, which is only regulated at a proximal binding 
region (Huss et al., 1999; Tirona et al., 2003). The HNF-4α homodimer is highly 
conserved and essential for basal transcription of both CYP3A2 and CYP3A4 (Miyata et 
al., 1995; Tirona et al., 2003). Contrary to rat CYP3A2, which has a proximal HNF-4α 
binding site, HNF-4α enhances PXR binding to the distal CYP3A4 promoter in humans 
(Tirona et al., 2003). The DNA binding domain of PXR is also well conserved between 
rats and humans (95.5% identical); in contrast, the ligand-binding domain amino acid 
sequence is only 75.9% identical (Jones et al., 2000). As a result, the prototypical human 
PXR ligand, rifampicin, only moderately activates rat PXR. Conversely, pregnenolone-
16α-carbonitrile is a potent activator of rodent PXR and not human PXR (Tirona et al., 
2004). Despite the broad substrate specificity of the PXR ligand-binding domain, 
antagonists have been identified and include polychlorinated biphenyls and azoles (Tabb 
et al., 2004; Ekins et al., 2007). Accordingly, it is possible that indoxyl sulfate is an 
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antagonist for human PXR and not for rat PXR. Therefore, CYP3A transcriptional 
regulation and PXR ligand-binding domain differences may account for the disparity in 
results between species; however, further study is necessary to support these claims. 
Hepatic CYP enzyme expression is also altered during infection and inflammation. 
Adenovirus infection downregulates hepatic CYP2C11 and CYP3A2 resulting in 
decreased enzyme activity (Callahan et al., 2005). Lipopolysaccharide treated rats in 
acute models of inflammation demonstrate decreased function and activity of these 
enzymes (Cheng et al., 2003). CYP2C11 and CYP3A2 expression are also downregulated 
as a result of secondary inflammation in ulcerative colitis (Masubuchi et al., 2008). 
Systemic inflammation occurs secondary to CKD. ESRD patients have increased plasma 
levels of CRP as well as pro-inflammatory cytokines including TNFα and IL-6, which 
have been shown to downregulate rat CYP2C11 and CYP3A2 in vitro and in vivo 
(Morgan et al., 1994; Morgan, 1997; Duranton et al., 2012; Hsu et al., 2014). In ESRD 
patients, CRP is correlated with alprazolam 4-hydroxylation, which is marker of 
CYP3A4 activity (Molanaei et al., 2012). Pro-inflammatory cytokines can activate NF-
kB, which binds and inhibits the PXR/RXR nuclear receptor heterodimer from 
transcriptional activation (Gu et al., 2006). Treatment of primary rat hepatocytes with 
uremic serum results in NF-κB-mediated downregulation of CYP2C11 and CYP3A2 
(Michaud et al., 2008). AST-120 has been shown to attenuate systemic inflammation and 
reduce plasma levels of CRP, TNFα, and IL-6 in rats with CKD (Vaziri et al., 2013). 
Therefore, elevated circulating levels of other pro-inflammatory cytokines or other 
pathways activating NF-κB may be the cause of CYP2C11 and CYP3A2 downregulation. 
In summary, indoxyl sulfate caused downregulation of CYP3A4 at uremic concentrations 
in a human hepatoma cell line. Our experiments in Huh7 cells are supported by clinical 
evidence correlating decreased CYP3A4 function with plasma indoxyl sulfate levels 
(Suzuki et al., 2014). However, there is more evidence in the literature to suggest that 
indoxyl sulfate may be one of many factors in the complex uremic milieu that cause 
downregulation of hepatic CYP2C and CYP3A in CKD. In contrast, removal of gut-
derived uremic toxins, including indoxyl sulfate, did not recover function and expression 
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of CYP2C11 and CYP3A2 in rats with CKD. Therefore, gut-derived uremic toxins do not 
cause downregulation of hepatic CYP2C11 and CYP3A2 in rats with CKD. 
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7 DISCUSSION AND CONCLUSIONS 
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7.1 Summary and Discussion 
7.1.1 Chapter 3 
Expression and activity of drug metabolizing enzymes are decreased in severe kidney 
disease, however, only a small percentage of patients with CKD are at the final stage of 
the disease. The aim of Chapter 3 was to determine the changes in drug metabolizing 
enzyme function and expression in rats with varying degrees of kidney disease. Sprague-
Dawley rats were subjected to surgical procedures that allowed the generation of three 
distinct models of kidney function: normal kidney function, moderate and severe kidney 
disease. CKD was developed over 6 weeks and hepatic CYP3A and CYP2C mRNA and 
protein expression was determined.  In addition, enzymatic activity was determined in 
liver microsomes by evaluating midazolam (CYP3A), testosterone (CYP3A and CYP2C) 
and tolbutamide (CYP2C) enzyme kinetics. I hypothesized that induction of moderate 
and severe kidney disease will produce a corresponding decrease in liver CYP2C11 and 
CYP3A2 function and expression using rat partial nephrectomy models. Both moderate 
and severe kidney disease were associated with a reduction in CYP3A2 and CYP2C11 
expression (p < 0.05). Similarly, moderate kidney disease resulted in more than a 60% 
decrease in enzyme activity (Vmax) for CYP2C11 and CYP3A compared to controls (p < 
0.05). Our results demonstrate that CYP3A and CYP2C expression and activity are 
decreased in both moderate and severe CKD. When the degree of kidney disease was 
correlated with metabolic activity, an exponential decline in CYP2C and CYP3A 
mediated metabolism was observed. Our hypothesis was supported by the negative 
correlation between the degree of CKD and hepatic CYP2C and CYP3A function and 
expression; however, surprisingly, the negative association was exponential. Therefore, 
this Chapter suggests that drug metabolism is significantly decreased in earlier stages of 
CKD, which supports the overall hypothesis of this thesis. The data also imply that 
patients with moderate CKD may be subject to unpredictable pharmacokinetics.   
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7.1.2 Chapter 4 
Patients with CKD require many medications and CYP2C and CYP3A drug metabolizing 
enzymes play a critical role in determining the pharmacokinetics of almost half of all 
prescribed medications. These enzymes are transcriptionally regulated by the nuclear 
receptors PXR and HNF-4α. In Chapter 4, we aimed to determine the transcriptional 
mechanism of hepatic CYP2C11 and CYP3A2 downregulation in CKD. CKD was 
induced in rats by 5/6 nephrectomy and we used chromatin immunoprecipitation to 
determine nuclear receptor and epigenetic mediated differences in the promoter region of 
the CYP2C and CYP3A genes. Transcriptional activation of PXR is associated with 
PRMT1 H4R3 asymmetric dimethylation. In this reaction, s-adenosyl methionine is used 
as a methyl donor to produce H4R3me2 and s-adenosyl homocysteine (SAH) is released 
(Osborne et al., 2007). SAH is subsequently converted to homocysteine. Both SAH and 
homocysteine can inhibit PRMT1 methyltransferase activity (Osborne et al., 2007). 
Homocysteine levels are increased in CKD, which suggested that PRMT1 
methyltransferase inhibition may be responsible for decreased P450 transcriptional 
activation in CKD.  I hypothesized that altered drug metabolism in CKD is secondary to 
decreased nuclear receptor binding to the promoters of CYP3A as a result of histone 
modulation. RNA Pol II and HNF-4α binding was decreased 76% and 57% in the 
CYP2C11 and 71% and 77% in the CYP3A2 promoter, respectively (p < 0.05). ChIP also 
revealed a 57% decrease in PXR binding to the CYP3A2 promoter in CKD rats (p < 
0.05). The decrease in PXR and HNF-4α binding was accompanied by diminished 
histone 4 acetylation in the CYP3A2 promoter (48%) and histone 3 acetylation in the 
CYP2C11 (77%) and CYP3A2 (77%) promoter loci for nuclear receptor activation (p < 
0.05). However, markers of histone methylation, including H4R3me2, were unaltered in 
the CYP3A promoter. Therefore, PRMT1 methyltransferase inhibition in CKD does not 
mediate decreased transcriptional activation of CYP3A. Conversely, it is possible that 
PXR and HNF-4α nuclear receptor binding is inhibited in CKD or that histone 
deacetylation may be increased in CKD resulting in a transcriptionally silent state of 
CYP2C11 and CYP3A2. This study suggests decreased nuclear receptor binding and 
histone acetylation may contribute to the mechanism of drug metabolizing enzyme 
downregulation and altered pharmacokinetics in CKD. These results support the overall 
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hypothesis; however, the interplay between altered nuclear receptor binding and histone 
modulation in CKD remains to be determined. 
 
7.1.3 Chapter 5 
Uremia is the accumulation of metabolic waste products that are normally cleared by the 
kidney in CKD. Many of these waste products are derived from bacteria metabolites in 
the gut. Accumulation of uremic toxins in plasma and tissue, as well as the gut-plasma-
tissue metabolic axis is important for understanding pathophysiological mechanisms of 
comorbidities in CKD.  In Chapter 5, an untargeted metabolomics approach was used to 
determine uremic toxin accumulation in plasma, liver, heart and kidney tissue in rats with 
CKD. Rats with CKD were also given AST-120, a spherical carbon adsorbent, to assess 
metabolic changes in plasma and tissues with the removal of gut-derived uremic toxins. I 
hypothesized that gut-derived uremic toxins accumulate in both plasma and tissue in 
CKD. AST-120 decreased >55% of metabolites that were increased in plasma, liver and 
heart tissue of rats with CKD. CKD was primarily defined by 8 gut-derived uremic 
toxins, which were significantly increased in plasma and all tissues. These metabolites 
were derived from aromatic amino acids and soy protein including: indoxyl sulfate, p-
cresyl sulfate, hippuric acid, phenyl sulfate, pyrocatechol sulfate, 4-ethylphenyl sulfate, 
p-cresol glucuronide and equol 7-glucuronide. Gut-derived metabolites also represented 
the most significant metabolic signatures describing CKD in all tissues supporting the 
hypothesis. Patients with CKD have increased levels of aromatic amino acid metabolites; 
however, soy protein metabolites such as 4-ethylphenyl sulfate and equol 7-glucuronide 
have not been studied in these patients. In the Western world, soy protein is rarely the 
main protein source for the majority of the population. This suggests that enterotype may 
determine the accumulation of gut-derived metabolites in CKD. An enterotype is the 
classification of bacteria in the gut microbiome (Wu et al., 2011). The Bacterioides 
enterotype is associated with the “Western Diet” of animal protein and saturated fats. In 
contrast, the Prevotella enterotype is associated with high carbohydrates and agrarian 
societies (Wu et al., 2011). Therefore, accumulation of gut-derived uremic toxins may be 
dependent on patient enterotypes. This study highlights the importance of diet and gut-
186 
 
derived metabolites in the accumulation of uremic toxins and defines the gut-plasma-
tissue metabolic axis in CKD. 
 
7.1.4 Chapter 6 
The aim of Chapter 6 was to determine which uremic toxins(s) cause downregulation of 
hepatic CYP2C and CYP3A in CKD.  We utilized an in vitro to in vivo study design with 
human Huh7 cells and rats with adenine-induced CKD. Initially, uremic toxins that are 
highly increased in CKD were screened for the potential to cause CYP3A4 
downregulation. Indoxyl sulfate was shown to downregulate CYP3A4 at physiologically 
relevant plasma concentrations. In Chapter 5, we demonstrated that gut-derived uremic 
toxins accumulate in both plasma and liver of rats with adenine-induced CKD. Therefore, 
in this Chapter, I hypothesized that the removal of gut-derived uremic toxins would 
recover expression and function of hepatic CYP2C and CYP3A in rats with CKD. 
Administration of AST-120 to rats with CKD reduced indoxyl sulfate, p-cresyl sulfate 
and hippuric acid plasma levels similar to levels measured in control rats. Liver levels are 
well correlated with plasma levels of these toxins, suggesting that hepatic accumulation is 
also decreased by AST-120 (Chapter 5). AST-120 recovered CYP3A2 mRNA expression 
by 25% in rats with CKD; however, AST-120 did not affect CKD mediated decreases in 
CYP3A2 protein expression or function. CYP2C11 expression and function was also 
decreased in CKD and unaffected by AST-120 administration. This result was 
unexpected and not consistent with the in vitro data and other studies. Clearly, there are a 
number of potential uremic mediators that may influence expression of hepatic P450, 
which cannot be entirely assessed in vitro. There are also species differences in the 
regulation of hepatic P450s, which may account for altered regulation in CKD. 
Therefore, it is possible that only human CYP3A4 is downregulated by indoxyl sulfate in 
CKD; however, there is more evidence to suggest that other factors in the complex 
uremic milieu may be contributing to the downregulation of hepatic CYP2C and CYP3A 
in CKD. In conclusion, indoxyl sulfate caused CYP3A4 downregulation in Huh7 cells in 
vitro. Conversely, gut-derived uremic toxins do not affect CYP3A and CYP2C function 
and expression in rats with CKD. 
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7.2 Models of CKD 
In this thesis, a combination of partial nephrectomy and vessel ligation models as well as 
the adenine model were used to generate varying degrees of CKD. The 2/3 nephrectomy 
resulted in the most mild form of CKD with a 1.65-fold increase in plasma creatinine 
levels compared to control (Table 7.1). The 2/3 and 5/6 nephrectomy as well as the use of 
0.5% adenine resulted in similar decreases of hepatic CYP2C11 and CYP3A2 enzyme 
function and expression despite the plasma creatinine levels spanning a 2-fold range. 
Although the 0.5% adenine model resulted in more severe CKD than the 5/6 
nephrectomy according to plasma creatinine, the CYP3A2 mRNA expression levels were 
higher than 0.5% adenine model. The 2/3 nephrectomy with vessel ligation showed 
further progression of CKD severity and greater decreases in CYP2C11 and CYP3A2 
function and expression. The 0.7% adenine model was the most severe with the greatest 
increase in plasma creatinine levels. 
As mentioned in the introduction (1.9), the adenine model of CKD is more consistent 
than the use of partial nephrectomy models and does not require surgical expertise. The 
degree of CKD is also adenine dose-dependent, allowing for more control over the 
severity of CKD by varying the amount of adenine in the rat diet. Although different 
models of CKD were utilized, the degree of hepatic CYP2C11 and CYP3A2 
downregulation was consistent with the degree of CKD, regardless of the experimental 
model. 
188 
 
Table 7.1 Hepatic CYP2C11 and CYP3A2 enzyme function and expression in rats with 
CKD using various experimental models. 
 Plasma 
Creatinine 
(µM) 
Plasma 
Urea 
(mM) 
CYP2C11 Function and 
Expression (% of Control) 
CYP3A2 Function and 
Expression (% of Control) 
Vmax 
(16αOH-
testosterone) 
Protein 
Expression 
mRNA 
Expression 
Vmax 
(1-OH 
Midazolam) 
Protein 
Expression 
mRNA 
Expression 
Control 
(mean of all 
studies) 
23 6.35 100 100 100 100 100 100 
2/3 
nephrectomy 38   9.1
 33.4 59 23 37.7 25 12 
5/6 
nephrectomy 63  12.0  32 34.4 29.5 22 11.2 2.2 
0.5% 
Adenine 77.2  14.6  33 37.7 28.4 34.2 11.3 8.6 
2/3 
nephrectomy 
with vessel 
ligation 
110 23.35  28.4 32 5 17.8 9 0.4 
0.7% 
Adenine 181  44.9  N/A N/A 
Data are presented as means ± SEM. 
*p < 0.05 compared to control. 
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7.3 Therapeutic Implications 
Chronic kidney disease is a complex disorder that is associated with multiple co-
morbidities. The life expectancy of a hemodialysis patient has been estimated to be 
between 3-5 years. In order to treat co-morbidities and attempt to improve quality of life 
and life expectancy, patients with kidney disease are prescribed an average of 12 
medications, which increases the risk of drug-drug interactions. In addition, it is clear that 
significant drug accumulation occurs in dialysis patients, which also places patients at an 
increased risk for adverse medication reactions.  
Although it has long been appreciated that hemodialysis patients do not have renal drug 
excretion capacity, emerging studies have clearly documented that hepatic clearance of 
many drugs is decreased in kidney disease. Studies in both animal models of kidney 
disease and clinical pharmacokinetic studies in human dialysis patients have suggested 
that kidney disease decreases hepatic metabolism. In this thesis, we demonstrate that drug 
metabolism is decreased in moderate CKD likely as a result of decreased PXR and HNF-
4α binding as well as histone acetylation using a rat model. We also provide evidence of 
the uremic toxin, indoxyl sulfate, mediating downregulation of CYP3A4. Although these 
studies and others contribute to the possible mechanisms of decreased hepatic drug 
metabolism in CKD, the specific metabolic pathways that are uniformly altered in human 
patients with CKD are highly complex and unknown. This is best exemplified by a recent 
FDA review of new molecular entities, where only approximately 50% of approved 
molecules metabolized by CYP3A4 and CYP2C9 exhibit altered pharmacokinetics 
(Zhang et al., 2009). Therefore, pathway specific generalizations regarding the impact of 
kidney disease on drug metabolism should be avoided and all drugs that may be used in 
patients with kidney disease should undergo rigorous pharmacokinetic evaluation in this 
population. 
It is evident that regulatory bodies such as the FDA have begun to realize the important 
changes experienced in non-renal clearance pathways in dialysis patients. Indeed, the 
guidance document published in 1998 was updated in 2010 to reflect the progress in 
research investigating pharmacokinetics in kidney disease. Multiple studies have shown 
that the hemodialysis process itself can impact the inter-dialytic and intra-dialytic 
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pharmacokinetics of drugs (Osborne et al., 1986; Amin et al., 1999; Bezzaoucha et al., 
2014). Accordingly, clinical pharmacokinetic studies should be used to determine optimal 
dosing for patients across the spectrum of CKD and those in ESRD who require 
hemodialysis.  
When encountering a dialysis dependent or independent kidney disease patient, clinicians 
should first search for evidence of drug dosing recommendations in these populations. 
Indeed, dosage adjustments in renal failure may be found in the product monograph and 
have been the subject of several peer-reviewed articles (Lam et al., 1997; Gabardi and 
Abramson, 2005; Munar and Singh, 2007; Brater, 2009; Verbeeck and Musuamba, 2009; 
Matzke et al., 2011).  When specific pharmacokinetic data in kidney disease are not 
available, the clinician must evaluate all known information on the pharmacokinetics of 
the drug, what processes are likely to be altered in renal failure (e.g. renal excretion, 
hepatic clearance) and prescribe a dosage that is supported by available evidence. 
 
7.4 Future Directions 
In Chapters 3 and 4, we demonstrate downregulation of hepatic CYP2C and CYP3A drug 
metabolizing enzymes in moderate CKD and elucidate the possible mechanisms leading 
to downregulation of these enzymes using rat models of CKD. Rat models have been 
used in the majority of studies describing hepatic downregulation of CYP2C and CYP3A 
in CKD. However, there are differences in nuclear receptor homology and binding 
regions between rodents and humans that need to be addressed. In Chapter 6, indoxyl 
sulfate mediated CYP3A4 downregulation in human Huh7 cells but had a minimal effect 
on rat CYP3A2 in vivo suggesting that these enzymes may be regulated differently 
between species in CKD. Recently, the development of humanized PXR/CAR/CYP3A4 
mice facilitate assessment of PXR-mediated induction of CYP3A4 in vivo (Hasegawa et 
al., 2011). Future studies in humanized mice may be useful for evaluating changes in the 
CYP3A4 epigenetic environment that occur as a result of CKD. 
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The endogenous cholesterol metabolite, 4β-hydroxycholesterol, is a marker of CYP3A4 
function. A recent study demonstrated a negative correlation between plasma indoxyl 
sulfate concentrations and 4β-hydroxycholesterol levels (Suzuki et al., 2014). In Chapter 
6, we provide evidence of CYP3A4 downregulation when treating Huh7 cells with 
indoxyl sulfate concentrations found in patients with CKD.  Our preliminary work 
suggests the need to further assess the effects of indoxyl sulfate on hepatic CYP3A4 in a 
clinical study evaluating 4β-hydroxycholesterol plasma levels before and after 
prescribing AST-120 to patients with CKD. This study would be challenging to complete, 
as AST-120 is currently not approved for patient use in Canada. 
Finally, uremic toxins are likely responsible for altered function of hepatic CYP2C and 
CYP3A in CKD. In this thesis, we employed a top-down approach, beginning with the 
assessment of CYP2C and CYP3A function followed by protein and mRNA expression 
(Chapter 3). We then assessed changes in transcriptional activation by evaluating nuclear 
receptor binding as well as epigenetic modifications in the CYP2C and CYP3A promoters 
(Chapter 4). In Chapter 5, we present the metabolic changes and uremic toxin 
accumulation in the liver as a result of CKD using untargeted metabolomics. We also 
provide evidence of indoxyl sulfate mediated downregulation of CYP3A4 (Chapter 6). 
As a result, future studies are necessary to understand the possible signaling pathways 
involved in uremic toxin downregulation of CYP2C and CYP3A, including their 
influence on nuclear receptor activation and epigenetic mediators. The interplay between 
nuclear receptors and epigenetic mediators also requires further insight in order to 
understand the sequence of events that result in decreased transcriptional activation in 
CKD.  
 
7.5 Conclusions 
CKD and ESRD patients take many medications to manage the disease along with co-
morbidities. It is well known that renal clearance of drugs is compromised in CKD; 
however, altered non-renal clearance in CKD has more recently been recognized. The 
majority of drugs are eliminated by metabolism and the focus of this thesis was to 
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evaluate hepatic drug metabolism in CKD. The first section aimed to assess function, 
expression and regulation of hepatic drug metabolizing enzymes in CKD. We determined 
that hepatic CYP2C and CYP3A function and expression were decreased in moderate and 
severe CKD as a result of decreased nuclear receptor binding and histone acetylation in 
the promoter of these enzymes.  
The second part of this thesis focused on identifying which uremic toxin(s) mediate the 
downregulation of these CYP2C and CYP3A in CKD. We assessed the accumulation of 
uremic toxins as well as the metabolic changes that occur in both plasma and liver for rats 
with CKD using untargeted metabolomics. This resulted in the identification of gut-
derived uremic toxins as the most concentrated metabolites present in both plasma and 
tissues of rats with CKD. AST-120 administered to rats with CKD reduced plasma and 
liver levels of these toxins confirming that they were gut derived. Indoxyl sulfate, a gut-
derived uremic toxin, mediated downregulation of CYP3A4 at concentrations measured 
in CKD patient plasma; however, removal of gut-derived uremic toxins did not recover 
expression of CYP2C and CYP3A in rats with CKD. Taken together, these studies 
provide insight into the mechanisms of altered hepatic drug metabolism in CKD and 
support the pharmacokinetic evaluation of new drugs in this patient population. 
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Appendix C: Supplementary Information 
Supplementary Table C1. UPLC gradient conditions for drug metabolite quantification. 
Solvents are expressed as mobile phase percentage. 
Midazolam 
Time 
(min) 
10 mM 
KH2PO4  
(pH = 
3.0) 
Acetonitrile Methanol 
0.00 80 5 15 
3.00 68 5 27 
3.01 20 80 0 
4.00 20 80 0 
4.01 80 5 15 
Testosterone 
0.00 83 17 0 
2.00 83 17 0 
4.50 60 40 0 
4.51 20 80 0 
5.50 20 80 0 
5.51 83 17 0 
Tolbutamide 
0.00 80 20 0 
1.50 80 20 0 
3.00 40 60 0 
3.01 20 80 0 
4.00 20 80 0 
4.01 80 20 0 
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Supplementary Figure C1 Specificity of anti-rat P450 antibodies tested on recombinant 
cDNA-expressed P450 enzyme isoforms prepared from the baculovirus-infected insect 
cell system (BD SupersomesTM). Western blots were performed with 2 µg of each 
SupersomeTM preparation. 
202 
 
 
Supplementary Figure C2 Hepatic mRNA expression of protein arginine 
methyltransferase 1 (PRMT1) in control rats and rats with CKD. Results are presented as 
mean ± SEM, n = 6. 
203 
 
 
 
Supplementary Figure C3 Principal component analysis of Control (n), CKD (l), 
CKD+AST-120 (▲) and pooled samples in negative ESI mode for plasma (A), liver (B), 
heart (C) and kidney (D) tissue in rats. Triplicate injections are shown. 
204 
 
 
 
Supplementary Figure C4 Principal component analysis of Control (n), CKD (l), 
CKD+AST-120 (▲) and pooled samples in positive ESI mode for heart (A) and kidney 
(B) tissue in rats. Triplicate injections are shown. 
205 
 
Supplementary Figure C5. Correlations between plasma and tissues for 8 gut-derived 
uremic toxins. 
Plasma levels of 4-ethylphenyl sulfate (A), phenyl sulfate (B), indoxyl sulfate (C), p-
cresyl sulfate (D), hippuric acid (E), equol 7-glucuronide (F), pyrocatechol suflate (G) 
and p-cresyl glucuronide (H) were correlated to liver (¡), heart (o) and kidney (Δ) 
levels for control, CKD and CKD+AST-120 groups. Linear regressions (solid lines) are 
presented with 95% confidence intervals (dashed lines).
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